Novel amidine deirvatives,their preparation and applicantion as medicines and pharmaceutical compositions
Patent Information
- Application Number
- MYPI1999004114
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 1998-09-23
- Filing Date
- 1999-09-22
- Publication Date
- 2000-03-23
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for various pathologies involving excessive production or dysfunction of nitrogen monoxide (NO) and reactive oxygen species (ROS) lack effective inhibitors and traps, leading to inadequate management of conditions such as cardiovascular disorders, neurodegenerative diseases, inflammatory diseases, and cancer.
Development of new amidine derivatives that inhibit NO synthase enzymes and trap ROS, represented by specific compounds of general formula (I), which are prepared through condensation reactions and optimized for therapeutic use.
These amidine derivatives effectively inhibit NO synthase and trap ROS, offering potential therapeutic benefits in treating a wide range of pathologies characterized by excessive NO or ROS production, including cardiovascular, neurodegenerative, inflammatory, and cancerous conditions.
Abstract
Description
New derivatives of amidines. their preparation, their use as medicaments and the pharmaceutical compositions containing themA subject of the present invention is new derivatives of amidines which have an inhibitory activity on NO-synthase enzymes producing nitrogen monoxide NO and / or an activity which traps the reactive oxygen species (ROS). The invention relates in particular to the derivatives corresponding to general formula (I) defined below, their preparation methods, the pharmaceutical preparations containing them and their use for therapeutic purposes, in particular their use as NO-synthase inhibitors and selective or non selective traps for reactive oxygen species.Given the potential role of NO and the ROS's in physiopathology, the new derivatives described corresponding to general formula (I) may produce beneficial or favourable effects in the treatment of pathologies where these chemical species are involved. In particular:■ cardio-vascular and cerebrovascular disorders including for example atherosclerosis, migraine, arterial hypertension, septic shock, ischemic or hemorragic cardiac or cerebral infarctions, ischemias and thromboses;• disorders of the central or peripheral nervous system such as for example neurodegenerative diseases where there can in particular be mentioned cerebral infarctions, sub-arachnoid haemorrhaging, ageing, senile dementias including Alzheimer's disease, Huntington's chorea, Parkinson's disease, Creutzfeld Jacob disease and prion diseases, amyotrophic lateral sclerosis but also pain, cerebral ard bone marrow traumas, addiction to opiates, alcohol and addictive substances, erective and reproductive disorders, cognitive disorders, encephalopathies, encephalopathies of viral or toxic origin;• disorders of the skeletal muscle and neuromuscular joints (myopathy, myosis) as well as cutaneous diseases.• proliferative and inflammatory diseases such as for example artherosclerosis. pulmonary hypertension, respiratory distress, glomerulonephritis, portal hypertension, psoriasis, arthrosis and rheumatoid arthritis, fibroses, amvloidoses, inflammations of the gastro-intestinal system (colitis, Crohn's disease) or of the pulmonary system and airways (asthma, sinusitis, rhinitis).• organ transplants.• auto-immune and viral diseases such as for example lupus, AIDS, parasitic and viral infections, diabetes, multiple sclerosis.• cancer.• eye disorders like glaucoma and cataract.• neurological diseases associated with intoxications (Cadmium poisoning, inhalation of n-hexane, pesticides, herbicides), associated with treatments (radiotherapy) or disorders of genetic origin (Wilson's disease], -• all the pathologies characterized by an excessive production or dysfunction of NO and / or ROS's.^^ 'In all these pathologies, there is experimental evidence demonstrating the involvement of NO or ROS's ( / Med. Chem. (1995) 38, 4343-4362; Free Radic. Biol. Med. (1996) 20, 675-705; The Neuroscientist (1997) 3, 327-333).Moreover, in earlier patents, the inventors already described NO Synthase inhibitors and their use (Patents US 5,081,148; US 5,360,925), and more recently the combination of these inhibitors with products possessing antioxidant or antiradicular properties (Patent Application PCT WO 98 / 09653). In applications non yet published, they also described other derivatives of amidines or, more recently, derivatives of aminopyridines. These derivatives of amidines or aminopyridines have the characteristic of being both inhibitors of NO Synthases and inhibitors of ROS.A subject of the present invention is new derivatives of amidines, their preparation and their therapeutic use.The compounds of the invention correspond to genera] formula (I) characterized in that it comprises the compounds of general formula (!'):in which A represents: either aradical in which R|, R2 and Rj represent, independently, a halogen, the OH or SR<, group or a linear or branched alkyl, alkenyl or alkoxy radical having 1 to 6 carbon atoms, or a NR7R8 radicesR4 representing a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon aKSms,Rj represents a hydrogen atom, the OH or SR^ group or a linear or branched alkyl or alkoxy radical having 1 to 6 carbon atoms,R6 representing a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms,R7 and Rs independently representing a hydrogen atom, an OH group, a linear or branched alkyl radical having 1 to 6 carbon atoms or a -CO-R9 radical in which R9 represents a linear or branched alkyl radical having 1 to 6 carbon atoms;or aradical in which Rj, R2 and R3 represent, independently, a hydrogen atom, the OH or SRj group, a halogen or a linear or branched alkyl. alkenyl or alkoxy radical having 1 to 6 carbon atoms, or a NR7R8 radical,R4 represents a hydrogen atom or a linear or branched alkyl radical having 1 10 6 carbon atoms,Rf, representing a hydrogen atom or a linear or branched alkyl radical having I to 6 carbon atoms,R7 and Rg independently representing a hydrogen atom, an OH group, a linear or branched alkyl radical having 1 to 6 carbon atoms or a -CO-R9 radical in which R9 represents a linear or branched alkyl radical having 1 to 6 carbon atoms;or aradical in which Ri_ R2 and R3 represent, independently, a hydrogen atom, a halogen, the OH or SR$ group, a linear or branched alkyl, alkenyl or alkoxy radical having 1 to 6 carbon atoms, or an NR7R8 radical,R4 and R5 independently represent a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms,or R4 and R5 form together with the nitrogen atom an optionally substituted heterocycle having 4 to 7 members and 1 to 3 heteroatoms including the already present nitrogen atom, the additional heteroatoms being independently chosen from the group constituted by the O, N and S atoms,or furthermore R4 represents an alkylsulfonyl, alkylsulfoxide or alkylcarbonyl radical and then R5 represents H,Rs representing a hydrogen atom or a linear or branched alkyl radical having 1 lo 6 carbon atoms,R7 and Rg independently representing a hydrogen atom, an OH group, a linear or branched alkyl radical having 1 to 6 carbon atoms or a -CO-R9 radical in which R9 represents a linear or branched alkyl radical having 1 to 6 carbon atoms;or aradical in which T represents a -(CH2)k- radical, k representing 1 or 2, and R5 represents a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atomsor aradical in which R7 and Rg represent, independently, a hydrogen atom or an OH group, or aradical in which R9 represents a hydrogen atom, the OH group or a linear or branched alkyl or alkoxy radical having 1 to 6 carbon atoms,or aradical in which T represents a -(CH2)k- radical, k representing 1 or 2, and R17 represents a linear or branched alkyl radical having 1 10 6 carbon atoms, or an arylalkyl, diarylalkyl, bis-arylalkyl. aminoalkyl, alkvlaminoalkyl or dialkylaminoalkyl radical, or R17 further represents a (heterocyclo)alkyl radical in which the heterocycle is saturated or unsaturated, has 3 to 7 members and includes at least a nitrogen atom, said nitrogen atom being optionally substituted by a hydrogen atom or an alkyl radical.or aradical in which R]o and Rn represent, independently, a hydrogen atom or an OH group,or finally one of theradicals,B represents a linear or branched alkyl radical having 1 to 6 carbon atoms, carbocyclic or heterocyclic aryl with 5 or 6 members containing from 1 to 4 heteroatoms chosen from O, S, N and in particular the thiophene, furan, pyrrole orthiazole radicals, the aryl radical being optionally substituted by one or more groups chosen from the linear or branched alkyl, alkenyl or alkoxy radicals having 1 to 6 carbon atoms,or also B represents an NR|3RI4 radical, in which R13 and R]4 represent, independently, a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms, or R13 and R|4 form together with the nitrogen atom a non aromatic heterocycle with five to six members, the elements of the chain being chosen from a group comprising -CH;-, -NH-, -O- or -S-;X represents a bond or a -(CH2)m-. -(CH2)m-CO. -0-(CH2)m-, -S-(CH:)nl-. -NRi5-(CH2)m-, -CO-NR15-. -0-(CH2)m-C0-, -S-(CH:)m-CO-, -NR|,-(CH:)m-CO-. -(CH2)nrC(OH)(CH3)-CO-, -CH=CH- or -CH=N- radical;Y represents a bond or a -(CH2Jn- or -(CH2)r-Q-(CH2)s- radical,Q representing a piperazine, homopiperazine, 2-methylpiperazine, 2,5-dimethylpiperazine, piperidine, 1,2,3,6-tetrahydropyridine, pyrrolidine, azetidine or thiazolidine radical or a saturated carbon cycle having 3 to 7 members;O represents a bond or a -(CH2)p-O - ( C H 2)q-, -(CH2 )p-S - ( C H 2)q-, -(CH2)p-NR]6-(CH2)q-, -(CH2)p-CO-NR]6-(CH2)q- or -CO-(CH,)p-NRl6-(CH2)q-radical;R]2 represents a hydrogen atom or a linear or branched alkyl or alkoxy radical having 1 to 6 carbon atoms;R15 and R|g represent, independently, a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms or a -CO-R|g radical in which R]8 represents a linear or branched alkyl or alkoxy radical having 1 to 6 carbon atoms;m, n, p, q, r and s being integers from 0 to 6;it being understood that:- if A represents theradical then Y represents the piperidine radical; - if A represents theradical then Y represents a -(CHj)r-Q-(CH2V radical in which Q represents a saturated carbon cycle having 3 to 7 members;- and if A represents theradical with at least two of the R|, R2, Rj and R5 radicals representing H. then X represents a -CH=CH- or -CH=N- radical and the group X-Y-O- does not represent a -CH=CH-CO-co- radical in which 00 represents any radical;said general formula (I) also comprising the following compounds:- 2-hydroxy-5-methoxy-N-{2-[4-[(2-thienyi(imino)methyl)amino]phenyl]ethvl }-benzamide;- 2,5-dihydroxy-N-(2-[4[(2-thienyl(imino)methyl)amino]phenyl]ethyl -benzamide:- 2-hydroxy-3-isopropyl-N-{2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl}-benzamide;- 2,6-dihydroxy-N-12-[4-[(2-thienyl(imino)methyl)amino]phenyljethyl}-benzamide;- 2-hydroxy-4,6-dimethoxy-N-{2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl|-benzamide;- 2-hydroxy-3,5-di-tert-butyl-N-{2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl-benzamide;- 2-hydroxy-3,5-diisopropyl-N-(2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl)-benzamide;- 2-hydroxy-4-methoxy-N- {2-[4-[(2-thienyl( imino)me(hyl)amino]phenyl]ethyl) -benzamide;- 2-hydroxy-3-isopropyl-5-methoxy-N-{2-[4-[(2-thienyl(imino)methyl)amino] phenyljethyl)-benzamide;- N-(2-hydroxy-3-tert-butyl-5-methoxy)-4-([2-thienyl(imino)methyl]aminolbenzene-butan amide;- 3,4-dihydro-6-hydroxy-2,5,7.8-tetramethyl-N-{2-[4-[(2-thienyl(imino)methyl)amino] phenyl]ethyl}-2H-l-benzopyran-2-carboxamide;- 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-N-( l-[4-[(2-lhienyl(imino)methyl)amino] phenyljmethyl |-2H-l-benzopyran-2-carboxamide;- N-(2-hydroxyphenvl)-2-thiophenecarboximidamide;- N-(3-hydroxyphenyl)-2-thiophenecarboximidamide;- N-(3-hydroxy-4-methoxyphenyl)-2-thiophenecarboximidamide;- N-( 3-hydroxy-4-methylphenyl)-2-thiophenecarboximidamide;- N-(4-methoxyphenyl)-2-thiophenecarboximidamide;- N-(3,5-dimethyl-4-hydroxyphenyl)-2-thiophenecarboximidamide;- N-(3,5-dichloro-4-hydroxyphenyl)-2-thiophenecarboximidamide;- N-(2,6-bis-(l,l-dimethylelhyl)-4-hydroxyphenyl)-2-thiophenecarboximidamide:- N-(4-[4-[(3,4-djbydro-6-hydroxy-2,5,7,8-tetrametbyl-2H-l-benzopyran-2-yl)methyl]-l-piperazinyl]pheny]}-2-thiophenecarboximidamide;- l-(2-hydroxy-4,6-dimethoxybenzoyl)-3-(4-[(imino(2-thienyl)methyl)amino]phenoxy | azetidine;- N-(2-hydroxy-5-methoxy)-4-([2-thienyl(imino)methyl]amino}benzene-butanamide:- N-(2-hydroxy-5-methoxy)-4-([2-thienyl(imino)methyl] aminolbenzene-propanamide;- N-(4-([amino(2-thienyl)methylidene]aminolphenethyl)-2-hydroxy-5-methoxy-3-methy lbenzamide:(E)-N-(4-{[amino(2-thienyl)methylidene]amino)phenethyl)-3-(2-hydroxyphenyl)-2-propenamide;(E)-N-(4-{[amino(2-thienyl)methy]idene]amino)phenethyl)-3-(4-hydroxyphenyl)-2-propenamide;(E)-N-(4-)[amino(2-thienyl)methy]idene]amino|phenethyl)-3-(3,4-dihydroxyphenyl)-2-propenamide;- (E)-N-(4- ([amino(2-thienyl)methylidene]amino}phenethyl)-3-(4-hvdroxy-3,5-dimethoxyphenyl)-2-propenamide;- 3-[(3-([amino(2-thienyl)methylidene]amino)-benzyl)amino]-N-[3,5-di(tert-butyl)-4-hvdroxyphenyl]propanamide;N'-(4-{2-[(2-hydroxy-4,6-dimethoxybenzyl)amino]ethyl) phenyl) -2-thiophenecarboximidamide;- N'-[4-(2-{ [(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihvdro-2H-chromen-2-yl)methyl]amino}ethyl)phenyl]-2-thiophenecarboximidamide;or also the salts of the products of general formula (I).By alkyl, when no more precision is given, is understood a linear or branched alkyl radical having 1 to 6 carbon atoms. By cycloalkyl, when no more precision is given, is understood a carbonated monocyclic system having 3 to 7 carbon atoms. By alkenyl, when no more precision is given, is understood a linear or branched alkyl radical having 1 to 6 carbon atoms and presenting at least one unsaturation (double bond). By alkynyl. when no more precision is given, is understood a linear or branched alkyl radical having 1 to 6 carbon atoms and presenting at least one double unsaturation (triple bond). By carbocyclic or heterocyclic aryl is understood a carbocyclic or heterocyclic system comprising at least an aromatic ring, a system being said heterocyclic when at least one of the cycles that constitute it comprises a heteroatom (O, N or S). By heterocycle is understood a mono- or polycyclic system, said system comprising at least a heteroatom chosen from O, N and S and being saturated, partially or totally unsaturated or aromatic. By haloalkyl is understood an alkyl radical of which at least one of the hydrogen atoms (and optionally all of them) is replaced by a halogen atom.By alkylthio, alkoxy. haloalkyle, haloalkoxy, aminoalkyl, alkynyl, alkynyl and aralkyl radicals is understood respectively the alkylthio, alkoxy, haloalkyl, haloalkoxy, aminoalkyl, alkenyl, alkynyl and aralkyl radicals of which the alkyl radical has the meaning indicated previously.By heterocycle is notably understood the thiophene, piperidine, piperazine, quinoline, indoline and indole radicals. By linear or branched alkyl having 1 to 6 carbon atoms, is understood in particular the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl, pentyl, neopentyi, isopentyl. hexyl, isohexyl radicals. Finally, by halogen, is understood fluorine, chlorine, bromine or iodine atoms.Preferably, the compounds of general formula (I') are such that: A represents: either aradical in which Rj, R2 and R3 represent, independently, the OH or SRs group or a linear or branched alkyl or alkoxy radical having 1 to 6 carbon atoms, R4 representing a hydrogen atom or a linear or branched alkyl radical having I to 6 carbon atoms,R5 represents a hydrogen atom, the OH or SR^ group or a linear or branched alkyl or alkoxy radical having 1 to 6 carbon atoms,Rc representing a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms,or aradical in which R|, Rj and R3 represent, independently, a hydrogen atom, the OH group, a linear or branched alkyl or alkoxy radical having 1 to 6 carbon atoms, R4 and R5 represent independently a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms,or R4 and R5 form together with the nitrogen atom an optionally substituted heterocycle having 4 to 7 members and 1 to 3 heteroatoms including the already present nitrogen atom, the additional heteroatoms being independently chosen from the group constituted by the O, N and S atoms,or furthermore R4 represents an alkylsulfonyl or alkylcarbonyl radical and then R5 represents H,or aradical in which R|, Rj and Rj represent, independently, a hydrogen atom, the OH or SRg group, a halogen or linear or branched alkvl, alkenyl or alkoxy radical having 1 to 6 carbon atoms,R4 represents a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms,Rs representing a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms,or aradical in which T represents a -(CHjJt- radical, k representing 1 or 2, and R5 represents a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atomsor aradical in which R7 and Rg represent, independently, a hydrogen atom or an OH group, or aradical in which R9 represents a hydrogen atom, the OH group or a linear or branched alkyl or alkoxy radical having 1 to 6 carbon atoms.or aradical in which T represents a -(CH2)k- radical, k representing 1 or 2, and R| 7 represents a linear or branched alkyl radical having 1 to 6 carbon atoms, or an arylalkyl, diarylalkyl, bis-arylalkyl, aminoalkyl, alkylaminoalkyl or dialkylaminoalkyl radical, or Ri 7 further represents a (heterocyclo)alkyl radical in which the heterocycle is saturated or unsaturated, has 3 to 7 members and includes at least a nitrogen atom, said nitrogen atom being optionally substituted by a hydrogen atom or an alkyl radical,or aradical in which Rio and Rn represent, independently, a hydrogen atom or an OH group,or finally one of theradicalsB represents a linear or branched alkyl radical having 1 to 6 carbon atoms, carbocyclic or heterocyclic aryl with 5 or 6 members containing from 1 to 4 heteroatoms chosen from O, S, N and in particular the thiophene, furan, pyrrole or thiazole radicals, the aryl radical being optionally substituted by one or more groups chosen from the linear or branched alkyl, alkenyl or alkoxy radicals having 1 to 6 carbon atoms,X represents a bond or a -(CH2)ra-, -(CH2)m-CO, -0-(CH2)m-, -S-(CH2)m-, -NR15-(CH2)m-, -CO-NR,5-. -0-(CH2)m-C0-, -S-(CH2)m-CO-, -NR15-(CH2)m-CO-or -(CH2)m-C(OH)(CH3)-CO- radical;Y represents a bond or a -(CHi)n- or -(CH2)r-Q-(CH2)s- radical,Q representing a piperazine. piperidine, 1,2.3,6-tetrahydropyridine, azetidine or thiazolidine radical or a saturated carbon cycle having 3 to 7 members;O represents a bond or a -(CH2)p-0-(CH2)q- radical;R]2 represents a hydrogen atom or a linear or branched alkyl or alkoxy radical having I to 6 carbon atoms;R]5 and Rj^ represent, independently, a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms or a -CO-R^ radical in which R|g represents a linear or branched alkyl or alkoxy radical having 1 to 6 carbon atoms;m, n, p. q, r and s being integers from 0 to 6.Among the A radicals which can be used for the invention, the radicals of the typein which R| 7 represents a linear or branched alkyl radical having 1 to 6 carbon atoms, an aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, arylalkyl, diarylalkyl or bis-arylalkyl radical, and notably those in which Rn represents the methyl, benzyl ou naphtylmethvl radical, will be partticularly preferred.Preferably, the compounds according to the invention are one of the following compounds:- 2-hydroxy-5-methoxy-N-{2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl benzamide;- 2-hydroxy-5-methylthio-N-(2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl)-benzamide;- 2,5-dibydroxy-N-(2-[4[(2-thienyl(imino)methyl")amino]phenyl]ethyl -benzamide;- 2-hydroxy-3-isopropyl-N-{2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl )-benzamide;- 2,6-dihydroxy-N-(2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl)-benzamide;- 2-hydroxy-4,6-dimethoxy-N-(2-[4-[(2-thieny](imino)methyl)amino]phenyl]ethyl )-benzamide;- 2-hydroxy-4,5.6-tnmethoxy-N-{2-[4-[(2-thienyl(imino)methy])amino]phenyl]ethyl)-benzamide;- 2-hydroxy-3,5-di-tert-butyl-N-|2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl-benzamide;- 2-hydroxy-3,5-diisopropyl-N-(2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl |-benzamide;- 2,4-dihydroxy-3,6-dimethy]-N-(2-[4-[(2-thienyl(imino)me(hy])amino]phenyl]ethy]-benzamide;- 2,7-dihydroxy-N-{2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl }-2-naphthalenecarboxamide;- 2-hydroxy-4-methoxy-N-|2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl(-benzamide;- 2-hydroxy-3-isopropyl-5-methoxy-N-(2-[4-[(2-thienyl(imino)methyl)amino] phenyl]ethyl} -benzamide;- N-(2-hydroxy-3-tert-butyl-5-methoxy)-4-{[2-thienyl(imino)methyl]amino)benzene-butanamide;- 3,4-dihydro-6-hydroxy-2,5,7,8-le(ramethyl-N-(2-[4-[(2-thienyl(imino)methyl)amino] phenyl]ethyl (-2H- l-benzopyran-2-carboxamide;- 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-N-(1 -[4-[(2-thienyl(imino)methyl)amino] pheny]]methyl) -2H- J -benzopyran-2-carboxamide;- N-(4-hydroxyphenyl)-2-thiophenecarboximidamide;- N-(2-hydroxyphenyl)-2-thiophenecarboximidamide;- N-(3-hydroxyphenyl)-2-thiopheneearboximidamide;- N-(3-hydroxy-4-methoxypheny])-2-thiophenecarboximidamide;- N-(3-hydroxv-4-methylphenyl)-2-thiophenecarboximidamide;- N-(4-methoxyphen_vl)-2-thiophenecarboximidamide;- N-(3,5-dimethyl-4-hydroxyphenyl)-2-thiophenecarboximidamide;- N-(3,5-dichloro-4-hydroxyphenvl)-2-thiopheneearboximidamide;- N-(2,6-bis-( 1,1 -dimethylethyl )-4-hydroxyphenyl )-2-thiophenecarboximidamide;- N-|4-[4-[(3,4-dihydro-6-hydroxy-2,5 J,8-tetramethyl-2H-l-benzopvran-2-yl)methyl]-1 -piperazinyl]phenyl} -2-thiophenecarboximidamide;- l-(2-hydroxy-4,6-dimethoxybenzoyl)-3-(4-[(imino(2-thienyl)me(hyl)amino] phenoxy) azetidine;- N-(2-hydroxy-5-methoxyM-{[2-thienyl(imino)methy]]amino}benzene-butanamide;- N-(2-hvdroxy-5-raethoxy)-4-( [2-thienyl(imino)methyl] amino)benzene-propanamide;- tert-butyl 2-[[(4-([amino(2-thienyl)methylidene]amino}phenethyl)amino]-carbonyl}-4-methoxyphenylcarbaraate ;- 2-arruno-N-(4-|[amino(2-thienyl)methylidene]amino)phenethyl)-5-methoxybenzamide;- 5-amino-N-(4-{[arruno(2-thienyl)methylidene]amino}phenethyl)-2-hydroxybenzamide;- N-(4-{[araino(2-thienyl)methylidene]amino}phenethyl)-2-hydroxy-5-methoxy-3-methylbenzamide;- N-[2-(4-([amino(2-thienyl)methylidene]amino)aniIino)-2-oxoethyl]-3,5-di(;eri-butyl)-4-hydroxybenzamide;- N'-{4-[4-( l,2,3,4-tetrahydro-2-naphthalenyicarbonyl)-l-piperazinyl]phenyl J-2-thiophenecarboximidaraide;- 4-(4-{[amino(2-thienyl)methylidene]amino}pheny))-N-|4-[(methylsulfonyl)amino]phenyllbutan amide;- 4-(4-|[amino(2-thienyl)methylidene]amino}phenyl)-N-[4-(dimethylaraino)phenyl]butan amide;- 5-(4-{[amino(2-thienyl)methylidene]amino]phenyl)-N-[4-(dimethylamino)phenyl]pentanamide;- (E)-N-(4- ([amino(2-thienyl)methylidene]amino I phenethyl)-3-(2-hydroxyphenyl)-2-propenamide:- (E)-N-(4- ([amino(2-thienyl)methylidene]amino) phenethyl)-3-(4-hydroxyphenyl)-2-propenamide;- (EVN-(4-([amino(2-thienyl)methylidene]amino (phenethyl)-3-(3,4-dihydroxyphenyl)-2-propenamide;- (E)-N-(4-[ [amino(2-thienyl)methylidene]amino)phenethyl)-3-(4-hydroxy-3,5-dimethoxyphenyl)-2-propenamide;- (4R)-2-(3- {[amino(2-thienyl)methylidene]amino) -phenyl)-N-[4-(dimethylamino)phenyl]-1,3-thiazolidine-4-carboxamide;- N'-[4-(4-(2-[3,5-di(rert-b'jtyl)-4-hydroxy-phenoxy]acetyl)-l -piperazinyl)phenyl]-2-thiophenecarboximidamide;- N-(4-[4-(2-{ [3,5-di((e / -r-butyl)-4-hvdroxyphenyI]thio)acetyl)-l-piperazinyl]phenyI |-2-thiophenecarboximidamide;- N'-(4-{4-[2-(4-hydroxy-2,3.5,6-tetramethylphenoxy)-acetyl]-l-piperazinyl )phenyl)-2-thiophenecarboximidamide:- N-(4-{ [amino(2-thienyl)methylidene]amino}-phenethy])-2-[3,5-di(«rt-butyl)-4-hydroxyphenoxy]acetamide;- N-{4-[2-({2- [3,5-di(im-butyl)-4-hydroxyphenoxy]-ethyl)amino)ethyl]phenyl )-2-thiophenecarboximidamide;- rm-butyl 3-{[amino(2-thienyl)methylidene]amino| benzyl (3-[4-(diraethylamino)anilino]-3-oxopropyl (carbamate;- 3-[(3-{[amino(2-thienyl)methylidene]amino)-benzyl)amino]-N-[4-(dimethylamino)phenyl]propan amide;- 3-[(3- {[amino(2-thienyl)methylidene]amino) -benzyl)amino]-N-[3,5-dittert-butyl)-4-hydroxyphenyl]propan amide;- 3-[(3-{[amino(2-thienyl)methylidene]amino)-benzyl)amino]-N-[4-(4-methyl-l-piperazinyl)phenyl]propan amide;- 3-[(3-([amino(2-thienyl)methyhdene]amino)-benzyl)amino]-N-[4-(4-morpholinyl)pheny!]propan amide;- 3-[(3-{[arruno(2-thienyl)methylidene]arrunol-benzyl)amino]-N-(l-methyl-2,3-dihvdro-lH-indol-5-yl)propanamide;- 3-[(3-( [amino(2-thienyl)methylidene]amino}-benzyl)amino]-N-(l-benzvl-2.3-dihydro-1 H-indol-5-yl)propanamide;- 3-[(3-{[amino(2-thieny])methylidene]amino)benzyl)arnino]-W-[l-(l-naphthylmethyl)-2,3-dihydro-l / / -indol-5-yl]propanamide;- N'-[4-(2-([5-(dimethyIamino)-2-hydroxybenzyl]amino |ethyl)phenyl]-2-thiophenecarboximidamide;- N-(4-1 [(4- {[amino(2-thienyl)methylidene]amino) phenethyl)-amino]melhyl} phenyl)acetamide;- N'-[4-(2- ([(8-hydroxy-2-quinolinyl)methyl]amino) ethyl)phenyl]-2-thiophenecarboximidamide;- N'-[4-(2-([3-phenyl-2-propenyl]amino}ethyl)phenyl]-2-thiophenecarboximidamide;- N'-[4-(2-{ [3-(4-hydroxy-3-methoxyphenyl)-2-propenyl]amino)ethyl)phenyl]-2-thiophenecarboximidamide;- N'-[4-(2-([3-(4-hydroxy-3,5-dimethoxyphenyl)-2-propenyl]amino)ethyl)phenyl]-2-thiophenecarboximidamide:- N'-[4-(2-{ [5-(dimethylamino)-2-hydroxy-3-me(hoxybenzyl]amino)-ethyl)phenyl]-2-thiophenecarboxiraidamide;- N'-(4-{2-[(2-hydroxy-4,6-dimethoxybenzyl)amino]ethyl}phenyl)-2-thiophenecarboximidamide;- N'-[4-(2-{[(6-hydroxy-2,5,7,8-tetramethyl-3.4-dihydro-2H-chromen-2-yl)methyl]amino)ethyl)phenyl]-2-thiophenecarboximidamide;- N'-(4-{2-[[(E)-3-(4-hydroxy-3,5-dimethoxyphenyl)-2-propenyl](methyl )amino]ethyl) phenyl)-2-thiophenecarboximidamide ;- 4- ([(4- {[amino(2-thienyl)methylidene]amino )phenethyl)-amino]methyl} -1-pyridiniumolate;- N'-[4-(2-{[(2-hydroxy-4,6-dimethoxyphenyl)methylidene]-amino}ethyl)phenyI]-2-thiophenecarboxi midamide;- lert-butyl 4-| [amino(2-thienyl)methylidene]amino}phenethyl(2-hydroxv-4,6-dimethoxyberzyl )carbamate;- N'-{4-[4-phenyl-3,6-dihydro-l(2H)-pyridinyl)phenyl(-2-thiophenecarboximidamide;- N'-(4-|2-[4-phenyl-3,6-dihydro-l(2H)-pyridinyl]ethyl (phenyl)-2-thiophenecarboximidamide ;- N'- (4-[( 1 -benzhydryl-3-azetidinyl)oxy]phenyl) -2-thiophene-carboximidamide;- N'-[4-(2-quinolinylmethoxy)phenyl]-2-thiophene-carboximidamide;- N'-(4-(4-[2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxo-l,4-cyclohexadien-1 -yDbutanoyl]-1 -piperazinyl }phenyl)-2-thiophene-carboximidarnide:- N-|4-[2-(l,3-dimethyl-2,6-dioxo-l,2,3,6-tetrahydro-7H-purin-7-yl)ethyl]phenvl}-2-thiophenecarboximidamide;- N'-(4- {4-[2,6-di( 1 -pyrrolidinyl)-4-pyrimidinyl]-1 -piperazinyl) phenyl)-2-thiophenecarboxi midamide;- N'-{4-[2-({[4-(dimethylamino)anilino]carbonyl)amino)-ethyl]phenyl}-2-thiophenecarboxi midamide;- N-1 [ 1 -(4- ([amino(2-thienyl)methylidene]-amino) phenyl)-cyclobutyl]methyl} -6-hydroxy-2,5,7,8-tetramethyl-2-chromanecarboxamide;- N'-{4-[4-(5-methoxy-lH-indol-3-yl)-l-piperidinyl]-phenyl)-2-thiophenecarboximidamide ;- N'-(4-{2-[[5-(dimethylamino)-2-hydroxy-3-methoxybenzyl]-(methvl)amino]ethyl}phenyl)-2-thiophenecarboximidamide ;- 4-(4- ([amino(2-thienyl)methylidene]amino) phenyl)-N- \ 1 -[3-(dimethylamino Ipropyl]-2,3-dihydro- l / / -indol-5-yl} butanamide ;- 3-[(5-{ [amino(2-thienyl)methylidene]amino}-2-methoxybenzyl)amino]-A'-[l-(l-naphthylmethyl)-2,3-dihydro-1 W-indol-5-yl]propanamide ;or a salt of the latter.More preferentially, the compounds according to the invention are one of the following compounds:- 2-hydroxy-5-methoxy-N-(2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl |-benzamide;- 2,5-dihydroxy-N-(2-[4[(2-thienyl(imino)methyl)amino]phenyl]ethvl -benzamide;- 2-hydroxy-3-isopropyl-N-(2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl )-benzamide;- N-(2-hydroxy-3-tert-butyl-5-methoxy)-4-) [2-thienyl( imino)methyl]amino) benzene-butanamide;- 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-N-(2-[4-[(2-thienyl(imino)methyl)amino] phenyl]ethyl) -2H-1 -benzopyran-2-carboxamide;- 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-N-11 -[4-[(2-thienyl(imino)methyl)amino] pheny l]methyl) -2H-1 -benzopyran-2-carboxamide;- N-(2-hydroxy-5-methoxy)-4-{[2-thienyl(imino)methyl] amino )benzene-propanamide;- 5-amino-N-(4-( [amino(2-thienyl)methylidene]amino}phenethyl)-2-hydroxybenzamide;- 5-(4-([amino(2-thienyl)methylidene]amino)phenyl)-N-[4-(dimethylamino)phenyl]pentan amide;- (E)-N-(4-{[amino(2-thienyl)methylidene]amino}phenethyl)-3-(2-hydroxyphenyl)-2-propenamide;- (E)-N-(4- {[amino(2-thienyl)methylidene]amino) phenethyl)-3-(4-hydroxyphenyl)-2-propenamide;- (E)-N-(4-{[amino(2-thienyl)methylidene]amino}phenethyl)-3-(3,4-dihydroxyphenyl)-2-propenamide;- (E)-N-(4-{[amino(2-thienyl)methylidene]amino)phenethyl)-3-(4-hydroxy-3,5-dimethoxyphenyl)-2-propenamide;- N-{4-[2-({2- [3,5-di(rerr-butyl)-4-hydroxyphenoxy]-ethyl)amino)ethyl]phenyl (-2-thiophenecarboximidamide;- 3-[(3-{[amino(2-thienyl)methylidene]amino)-benzyl)amino]-N-[4-(dimethylamino)phenyl]propan amide;- 3-[(3-([amino(2-thienyl)methyhdene]amino)-benzyl )amino]-N-[3.5-di( tert-butyl)-4-hydroxyphenyljpropanamide;- 3-[(3-( [anruno(2-thienyl)methylidene]amino}-benzyl)amino]-N-[4-(4-methyl-l-piperazinyl)phenyI]propanamide:- 3-[(3-{[amino(2-thienyl)methylidene]amino]-benzyI)amino]-N-[4-(4-morpholinyl)phenyl]propan amide;- 3-[(3- ([amino(2-thienyl)methylidene]amino ] -benzyl)amino]-N-( 1 -methyl-2,3-dihydro-1 H-indol-5-yl)propanamide;- 3-[(3-{[amino(2-thienyl)methylidene]amino}-benzyl)amino]-N-(l-benzyl-2,3-dihydro-1 H-indol-5-yl )propanamide;- 3-[( 3- ([amino(2-thienyl)methylidene]amino} benzyl)amino]-A'-[ 1 -(1 -naphthylmethyl )-2,3-dihydro-lW-indol-5-yl]propanamide;- N'-[4-(2-([5-(dimethylamino)-2-hydroxybenzyl]amino)ethyl)phenyl]-2-thiophenecarboxi midamide;- N -(4- ([(4- ([amino( 2-thienyl)methylidene]amino) phenethyl )-amino]methyl) phenyl)acetamide;- N'-[4-(2-{[(8-hydroxy-2-quinolinyl)methyl]amino)ethyl)phenyl]-2-thiophenecarboxi midamide;- N'-[4-(2-{[3-phenyl-2-propenyl]amino}ethyl)phenyl]-2-thiophenecarboximidamide;- N'-[4-(2-| [3-(4-hydroxy-3-methoxyphenyl)-2-propenyl]amino|ethyl)phenyl]-2-thiophenecarboxi midamide;- N'-[4-(2-([3-(4-hydroxy-3,5-dimethoxyphenyl)-2-propenyl]amino(ethyl)phenyl]-2-thiophenecarboxi midamide;- N'-[4-(2-|[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methyl]amino|ethyl)phenyl]-2-thiophenecarboxi midamide;- N'-(4-(2-[[(E)-3-(4-hydroxy-3,5-dimethoxyphenyl)-2-propenyl](methyl)amino]ethyl} phenyl)-2-thiophenecarboximidamide;- N'-(4-12-[4-phenyl-3,6-dihydro- l(2H)-pyridinyl]ethyl (phenvl)-2-thiophenecarboximidamide;- N'- (4-[2-( {[4-(dimethylamino)anilino]carbonyl) amino)-ethyl]phenvl) -2-thiophenecarboximidamide;- N-([l-(4-{[amino(2-thienyl')methylidene]-amino}phenyl)-cyclobutyl]melhyl }-6-hydroxy-2,5,7,8-tetramethyl-2-chromanecarboxamide;or the salts of the latter.Also more preferentially, the compounds according to the invention are one of the following compounds:- 2-hydroxy-5-methoxy-N-{2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl 1-benzamide;- 2,5-dihydroxy-N-{2-[4[(2-thienyl(imino)methyl)amino]phenyl]ethyl -benzamide;- N-(2-hydroxy-5-methoxy)-4-([2-thienyl(imino)methyl] amino Ibenzene-propanamide ;- 5-amino-N-(4-( [amino(2-thienyl)methylidene]amino)phenethyl)-2-hydroxybenzamide;- 5-(4- ([amino(2-thienyl)methylidene]amino) phenyl)-N-[4-(dimethylamino)phenyl]pentan amide;- (E)-N-(4-{[amino(2-thienyl)methylidene]amino)phenethyl)-3-(2-hydroxyphenyl)-2-propenamide;- (E)-N-(4-|[amjno(2-thienyJ)methylidene]amino}phenethyl)-3-(3,4-dihydroxyphenyl)-2-propenamide;- (E)-N-(4-| [amino(2-thienyl)methylidene]amino}phenethyl)-3-(4-hydroxy-3,5-dimethoxyphenyl)-2-propenamide;- N-{4-[2-( {2-[3.5-di(rerf-butyl)-4-hydroxyphenoxy]-ethyl)amino)ethyl]phenyl}-2-thiophenecarboximidamide;- 3-[( 3- {[amino(2-thienyl)methylidene]amino }-benzyl)amino]-N-[4-(dimethylamino)phenyl]propan amide;- 3-[(3-([amino(2-thienyl)methylidene]amino)-benzyl)amino]-N-[3,5-di(tert-butyl)-4-hydroxyphenyl]propan amide;- 3-[(3- [ [amino(2-thienyl)methylidene]amino )-benzyl)amino]-N-(l -methyl-2.3-dihydro-lH-indol-5-yl)propan amide;- 3-[(3-( [amino(2-thienyl)methylidene]amino|-benzyl)amino]-N-(l-benzv!-2.3-dihydro-lH-indol-5-yl)propanamide;- 3-[(3-|[amino(2-thienyl)methylidene]amino}benzyl)amino]-A'-| l-(l-naphthylmethyl)-2,3-dihydro-lH-indol-5-yl]propanamide;- N'-[4-(2- ([5-(dimethylamino)-2-hydroxybenzyl]amino (ethyl)phenyl]-2-thiophenecarboximidamide;- N'-[4-(2-{[(8-hydroxy-2-quinolinyl)methyl]amino[ethyl)phenyl]-2-thiophenecarboximidamide;- N'-[4-(2-( [3-(4-hydroxy 3-methoxyphenyl)-2-propenyl]amino}ethyl)phenyl]-2-thiophenecarboxi midamide;- N'-[4-f2-{[3-(4-hydroxy-3,5-dimethoxyphenyl)-2-propenyl]amino)ethyl)phenyl]-2-thiophenecarboximidamide;- N'-[4-(2-{[(6-hydroxy-2,5,7,8-tetramethvl-3.4-dihydro-2H-chromen-2-yl)methyl]amino)ethyl)phenyl]-2-thiophenecarboxi midamide;- N'-(4-{2-[[(E)-3-(4-hydroxy-3,5-dimethoxvphenyl)-2-propenyl](methyl)amino]ethyl)phenyl)-2-thiophenecarboximidamide;- N'-(4-{2-[4-phenyl-3,6-dihydro-1 (2H)-pyridinyl]ethyl}phenyl)-2-thiophenecarboxi midamide;or the salts of the latter.Finally, the following compounds will be also more particularly preferred :- N-(2-hydroxy-5-methoxy)-4-{[2-thienyl(imino)methyl] amino Jbenzene-propanamide;- N-|4-[2-((2-[3.5-di(ferf-butyl)-4-hydroxyphenoxy]-ethyl}amino)ethyl]phenyl (-2-thiophenecarboxi midamide;- 3-[(3-{ [amino(2-thienyl)methylidene]amino)-benzyl)amino]-K-[4-(dimethylamino)phenyl]propan amide;- 3-[(3-{[aniino(2-thienyl lmethylidene]amino)-benzyl)amino]-N-[3,5-di(terl-butvl)-4-hydroxyphenyl]propanamide;- 3-[(3-{ [amino(2-thienyl)methyhdene]aminol-benzyl)amino]-N-(l-methyl-2.3-dihydro-lH-indol-5-yl)propanamide;- 3-[(3-| [amino(2-thienyl)methylidene]amino)-benzyl)amino]-N-(l-benzyl-2,3-dihydro-lH-indo]-5-yl)propanamide;- 3-[(3-| [amino(2-thienyl)methylidene]amino) benzyl )amino]-A'-[l-( 1 -naphthylmethyl)-2,3-dihydro-l / / -indol-5-yl]propanamide;- N'-[4-(2-j [5-(dimethylamino)-2-hydroxybenzyl]arnino}ethyl)phenyl]-2-thiophenecarboximidamide;- N'-[4-(2-{ [3-(4-hydroxy-3-methoxyphenyl)-2-propenyl]amino]ethyl)phenyl]-2-thiophenecarboximidamide;- N'-[4-(2-{ [3-(4-hydroxy-3,5-dimethoxyphenyl)-2-propenyl]amino|ethyl)phenyl]-2-thiophenecarboximidamide;- N'-[4-(2-([(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methyl]amino}ethyl)phenyl]-2-thiophenecarboxiniidamide;- N'-(4-(2-[[(E)-3-(4-hydroxy-3,5-dimethoxyphenyl)-2-propenyl](methyl)amino]ethyl)phenyl)-2-thiophenecarboximidamide:or the salts of the latter.In certain cases, the compounds according to the present invention can comprise asymmetrical carbon atoms. As a result, the compounds according to the present invention have two possible enantiomeric forms, i.e. the "R" and "S" configurations. The present invention includes the two enantiomeric forms and all combinations of these forms, including the "RS" racemic mixtures. In an effort to simplify matters, when no specific configuration is indicated in the structural formulae, it should be understood that the two enantiomeric forms and their mixtures are represented.The invention furthermore offers, as new industrial products, the compounds of general formula (IS), useful synthesis intermediates for the preparation of products of general formula (I),general formula (IS) in which A represents: either aradical in which R|, R2 and R3 represent, independently, a halogen, the OH or SR6 group or a linear or branched alkyl, alkenyl or alkoxy radical having 1 to 6 carbon atoms, or a NRtR8 radical,R4 representing a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms,R5 represents a hydrogen atom, the OH or SR(, group or a linear or branched alkyl or alkoxy radical having 1 to 6 carbon atoms,Rs representing a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms,R7 and Rg independently representing a hydrogen atom, an OH group, a linear or branched alkyl radical having 1 to 6 carbon atoms or a -CO-R9 radical in which R9 represents a linear or branched alkyl radical having 1 to 6 carbon atoms;or aradical in which R|, R; and Ri represent, independently, a hydrogen atom, the OH or SR6 group, a halogen or a linear or branched alkyl, alkenyl or alkoxy radical having I to 6 carbon atoms, or a NR7R8 radical,R4 represents a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms,R6 representing a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms,R7 and R8 independently representing a hydrogen atom, an OH group, a linear or branched alkyl radical having 1 to 6 carbon atoms or a -CO-R9 radical in which R9 represents a linear or branched alkyl radical having 1 to 6 carbon atoms:or aradical in which R|, Ri and R3 represent, independently, a hydrogen atom, a halogen, the OH or SRj group, a linear or branched alkyl, alkenyl or alkoxy radical having 1 to 6 carbon atoms, or an NR7R8 radical,R4 and R5 independently represent a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms,or R4 and R5 form together with the nitrogen atom an optionally substituted heterocycle having 4 to 7 members and 1 to 3 heteroatoms including the already present nitrogen atom, the additional heteroatoms being independently chosen from the group constituted by the O, N and S atoms,or furthermore Rj represents an alkylsulfonyl. alkylsulfoxide or alkylcarbonyl radical and then Rs represents H,Rg representing a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms,R7 and R8 independently representing a hydrogen atom, an OH group, a linear or branched alkyl radical having 1 to 6 carbon atoms or a -CO-R9 radical in which Ry represents a linear or branched alkyl radical having 1 to 6 carbon atoms;or aradical in which T represents a -(CH2)k- radical, k representing 1 or 2, and R5 represents a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atomsor aradical in which r7 and R8 represent, independently, a hydrogen atom or an OH group, or aradical in which R9 represents a hydrogen atom, the OH group or a linear or branched alkyl or alkoxy radical having 1 to 6 carbon atoms,or aradical in which T represents a -(CH2)k- radical, k representing I or 2, and R17 represents a linear or branched alkyl radical having 1 to 6 carbon atoms, or an arylalkyl, diarylalkyl, bis-arylalkvl, aminoalkyl, alkvlaminoalkyl or dialkylaminoalkyl radical, or Rj7 further represents an (heterocyclo)alkyl radical in which the heterocycle is saturated or unsaturated, has 3 to 7 members and includes at least a nitrogen atom, said nitrogen atom being optionally substituted by a hydrogen atom or an alkyl radical,or aradical in which Ru and Rj j represent, independently, a hydrogen atom or an OH group,or finally one of theradicals,B represents a linear or branched alkyl radical having 1 to 6 carbon atoms, carbocyclic or heterocyclic aryl with 5 or 6 members containing from 1 to 4 heteroatoms chosen from O, S, N and in particular the thiophene, furan, pyrrole or thiazole radicals, the aryl radical being optionally substituted by one or more groups chosen from the linear or branched alkyl, alkenyl or alkoxy radicals having 1 to 6 carbon atoms,or also B represents an NR]3Rj4 radical, in which R13 and Rw represent, independently, a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms, or Ru and R14 form together with the nitrogen atom a non aromatic heterocycle with five to six members, the elements of the chain being chosen from a group comprising -ch2-, -NH-, -O- or -S-;X represents a bond or a -(CH2)m-, -0-(CH2)m-, -S-(CH:)m-. -NR15-(CH2)m-, -CO-NRi5", -0-(CH2)m-C0-, -S-CCH-^-CO-, -NR,5-(CH2)m-CO-. -(CH2)m-C(OH)(CH3)-CO-, -CH=CH- or -CH=N- radical;Y represents a bond or a -(CH2)n- or -(CH2)r-Q-(CH2)s- radical,Q representing a piperazine, homopiperazine, 2-methylpiperazine. 2,5-dimethylpiperazine, piperidine, 1,2.3,6-tetrahydropyridine, pyrrolidine, azetidine or thiazolidine radical or a saturated carbon cycle having 3 to 7 members;O represents a bond or a -(CH2 )p-O - (C H 2)q-, -(CH2 )p-S - ( C H 2 )q-. -(CH2)p-NR16-(CH2)q-, -(CH2)p-CO-NR16-(CH2)q- or -CO-(CH2)p-NRlft-(CH2)q-radical;Z represents N02 or NH2;Ri2 represents a hydrogen atom or a linear or branched alkyl or alkoxy radical having I to 6 carbon atoms;R]5 and Rie represent, independently, a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms or a -CO-Rig radical in which R]g represents a linear or branched alkyl or alkoxy radical having 1 to 6 carbon atoms;m, n, p, q, r and s being integers from 0 to 6;it being understood that:- if A represents theradical then Y represents the piperidine radical; - if A represents theradical then Y represents a -(CH2)r-Q-(CH2)s- radical in which Q represents a saturated carbon cycle having 3 to 7 members;- and if A represents theradical with at least two of the Ri, R2, R3 and R5 radicals representing H, then X represents a -CH=CH- or -CH=N- radical and the group X-Y-O- does not represent a -CH=CH-CO-g>- radical in which (0 represents any radical.The invention further concerns the compounds of general formula (IS'), synthesis intermediates for the preparation of products of general formula (I) in which A is an indoline radical substituted as previously defined, X represents the -NR15-CO- radical, Y represents a bond and O represents a -(CH2)p-NRi(,-(CH2)q- radical,general formula (IS') in whichte represents a hydrogen atom or a protective group of carbamate type;R]5 and R]6 represent, independently, a hydrogen atom, a linear or branched alkyl radical having 1 to 6 carbon atoms or a -CO-R|g radical in which R|g represents ua linear or branched alkyl or alkoxy radical having 1 to 6 carbon atoms ;T represents a -(CH2)k- radical, k representing 1 or 2;R17 represents a linear or branched alkyl radical having 1 to 6 carbon atoms, arylalkyl, diarylalkyl, bis-arylalkyl, aminoalkyl, alkylaminoalkyl or dialkylaminoalkyl, or Rn further represents a (heterocyclo)alkyl radical in which the heterocycle is saturated or unsaturated, has 3 to 7 members and includes at least a nitrogen atom, said nitrogen atom being optionally substituted by a hydrogen atom or an alkyl radical;and p is an integer from 0 to 6.A subject of the invention is also, as medicaments, the compounds of general formula (1) described previously or their pharmaceutically acceptable salts. It also relates to pharmaceutical compositions containing these compounds or their pharmaceutically acceptable salts, and the use of these compounds or of their pharmaceutically acceptable salts for producing medicaments intended to inhibit neuronal NO synthase or the inductible NO synthase, to inhibit lipidic peroxidation or to provide the double function of NO synthase inhibition and lipidic peroxidation inhibition function.By pharmaceutically acceptable salt, is understood in particular addition salts og inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulphate, phosphate, diphosphate and nitrate or of organic acids such as acetate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulphonate, p-toluenesulphonate. pamoate, oxalate and stearate. The salts formed from bases such as sodium or potassium hydroxide also fall within the scope of the present invention, when they can be used. For other examples of pharmaceutically acceptable salts, reference can be made to "Pharmaceutical salts", J. Pharm. Sci. 66:1 (1977).The pharmaceutical composition can be in the form of a solid, for example powders, granules, tablets, gelatin capsules, liposomes or suppositories. Appropriate solid supports can be, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine and wax.The pharmaceutical compositions containing a compound of the invention can also be presented in liquid form, for example, solutions, emulsions, suspensions or syrups. Appropriate liquid supports can be, for example, water, organic solvents such as glycerol or glycols, as well as their mixtures, in varying proportions, in water.The administration of a medicament according to the invention can be carried out by topical, oral, parenteral route, by intramuscular injection, etc.The envisaged administration dose for a medicament according to the invention is comprised between 0.1 mg and 10 g according to the type of active compound used.In accordance with the invention, the compounds of general formula (I) can be prepared by the process described below.Preparation of the invention compounds:The invention compounds corresponding to the general formula (I) but not to the genera] formula (I') can be prepared following the procedures described in the examples. The products of general formula (I') are prepared as described hereafter.Preparation of compounds of general formula (!'):The compounds of general formula (I') can be prepared from intermediates of general formula (ii) according to Diagram 1 where A, B, X, Y, <E> and R12 are as defined above and Gp is a protective group of carbamate type, for example the i-butoxycarbonyl group.Diagram 1The aniline derivatives of general formula (ii) can be condensed with compounds of general formula (iii), in which L represents a leaving group (for example an alkoxy, alkylthio, aralkylthio, sulphonic acid, halide, aryl alcohol or tosyl radical), in order to produce the final compounds of general formula (I') of substituted amidine type (cf. Diagram 1). For example, for B = thiophene, the derivatives of general formula (ii) can be condensed with of S-methylthiophene thiocarboxamide hydroiodide, prepared according to a method in the literature (Ann. Chim. (1962), 7, 303-337). Condensation can be carried out by heating in an alcohol (for example in methanol or isopropanol), optionally in the presence of DMF at a temperature preferably comprised between 50 and 100 °C for a duration generally comprised between a few hours and overnight.In the particular case where A represents a pyridine-oxide, the pyridine oxidation is only carried out during the last synthesis step because of the fragility of these compounds in reducing medium. Metachloroperbenzoic acid, used as oxidizing agent, allows to obtain pyridine-oxide derivatives of general formula (i1).Salification of the compounds of general formula (I'). when carried out in the presence of a strong acid like, for example, hydrochloric acid, allows to free simultaneously the amines which have been protected in the form of rer / -butylcarbamate during the synthesis.In the case where B is an amine, the final compounds of general formula (I') are guanidines. These can be prepared, for example, by condensation of the amines of general formula (ii) with the derivatives of general formula (iv) or (iv'). The reagents of general formula (iv) in which L represents, for example, a pyrazole ring are condensed with the amines of general formula (ii) according to the conditions described in the literature (J. Org. Chem. (1992) 57, 2497-2502), similarly for the reagents of general formula (iv') in which L represents, for example, a pyrazole ring and Gp represents the tBuOCO group (Tetrahedron Leil. (1993) 34 (21), 3389-3392) or when L represents the -N-so2-cf3 group and Gp represents the tBuOCO group (J. Org. Chem. (1998) 63, 3804-3805). During the final stage of the synthesis, the deprotection of the guanidine function is carried out in the presence of a strong acid such as for example trifluoroacetic acid.Therefore, a subject of the invention is also a process for the preparation of compounds of general formula (I') as defined above, said process being characterized in that a compound of general formula (ii)in which A, B, X, Y.O and R12 are as defined above, is reacted with the intermediate of general formula (III)in which B is as defined above and L represents a leaving group, for example an alkoxy, alkylthio. aralkylthio, sulphonic acid, halide, aryl alcohol or tosyl radical.Therefore, a subject of the invention is also a process for the preparation of compounds of general formula (I') as defined above and in which B represents an amine, said process being characterized in that a compound of general formula (ii)in which A, B, X, Y,0 and R12 are as defined above, is reacted a) either with the intermediate of general formula (tv)in which L represents a leaving group, for example an alkoxy, alkylthio, aralkylthio, sulphonic acid, halide, aryl alcohol or tosyl radical,b) or with the intermediate of general formula (iv')in which L represents a leaving group, for example an alkoxy, alkylthio, aralkylthio. sulphonic acid, halide, aryl alcohol or tosyl radical, and Gp is a protective group of carbamate type, for example the t-butoxycarbonyl group,this reaction being followed, in the case where the reaction with the compound of general formula (iv') is chosen, by hydrolysis in the presence of a strong acid, for example trifluoroacetic acid.Specific case where A represents a 2,3,5 •.riMiettnl-hen / oCiUmonc:The compounds of general formula (I') in which A represents a 2,3,5-trimethyl-benzoquinone and X = -(CH2)m-C(OH)(CH3)-CO- with B, Y. ® and Rj 2 as defined above can be obtained from the compounds comprising a Trolox group. Diagram 1'. The reactivity of the Trolox with respect to the free radicals allows a chemical modification of this group to be envisaged, in fact, the action of FeCl3 in an aqueous medium (Helv. Chim. Acta (1963) 46, 333) causes a radicular opening of the benzopyranic system and leads to the compounds of general formula (I').Diagram 1'Preparation of compounds of general formula (II):The non-commercial intermediates of general formula (II). are obtained either by detachment of a protective group, or by reduction of a precursor of nitro type, as illustrated in the synthesis diagrams below.Reduction of the precursors of nitro type:The reduction of the nitro function of the intermediates of general formula (V). Diagram 2, in which A, X, Y, and R12 are as defined above, is generally carried out by catalytic hvdrogenation, in ethanol, in the presence of Pd / C, except in the case of molecules sensitive to these conditions where the nitro group is selectively reduced, for example, by heating the product in an appropriate solvent such as ethyl acetate with a little ethanol in the presence of SnCl2 (J. Heterocyclic Chem. (1987). 24, 927-930; Tetrahedron Letters (1984), 25 (8), 839-842) or using NaBH4-BiCl3 (Synth. Com. (1995) 25 (23), 3799-3803) in a solvent such as ethanol, or then by using Ni Raney with hydrazine hydrate added (Monatshefie fur Chemie, (1995), 126, 725-732), or else by using SnCl2 in the presence of Zn (Synthesis (1996), (9), 1076-1078).In the particular case of the indolic derivatives of general formula (V) (Diagram 6), the gentle reduction conditions of the nitro function (Zn in acetic acid) are inevitably accompanied by the loss of the unsaturation at the level of 1,2,3,6-tetrahydropyridine in order to produce the piperidine.Deprotection of the amino group:The intermediates of general formula (II), in which A, X, Y, O and Rj2 are as defined above, can also be prepared from the intermediates of general formula (VI), Diagram 3, which are compounds comprising an amine protected in the form, for example, of 2,5-dimethylpyrrole (N=Gp') or of reri-butyl carbamate (NH-Gp). The pyrroles, for example, are deprotected by heating in the presence of hydroxylamine hydrochloride for at least 24 hours in order to finally produce the primary amines of general formula (II). The amines protected in the form of tert-butyl carbamates are released classically in acidic medium by treatment with trifluoroacetic or hydrochloric acid.Diagram 3Preparation of compounds pf .general formula (.>'.): Synthesis of the carboxamides:The carboxamides of general formula (VJ, Diagram 4, in which X represents -CO-NRiy and A, Y, Q, O, R]2 and R15 are as defined above, are prepared by condensation of the acids of general formula (VII) with the commercial amines of general formula (VIII) under standard conditions for peptide synthesis (M. Bodanszky and A. Bodanszky. The Practice of Peptide Synthesis, 145 (Springer-Verlag, 1984)) in THF, dichloromethane or DMF in the presence of a coupling reagent such as dicyclohexylcarbodiimide (DCC), 1,l'-carbonyldiimidazole (CDI) (J. Med. Chem. (1992), 35 (23). 4464-4472) or l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC or WSCI) (John Jones, The chemical synthesis of peptides, 54 (Clarendon Press, Oxford, 1991)). The syntheses of the non-commercial acids of general formula (VII) are described in the "Preparation of the Intermediates" chapter.(A-X-CO-N series)The carboxamides of general formula (V), Diagram 5, in which X represents -0-(CH2)m-. -S-(CH2)m- or -NR|5-(CH2)m- with A, Y, O, R,2 and R,„ as defined above (Q being a heterocycle), are prepared by condensation of the acids of generalformula (IX) with the amines of general formula (X) or (XXII) under standard conditions for peptide synthesis as previously described. The syntheses of the acids of general formula (IX) and of (he amines of general formula (X), non-commercial, are described in the "Preparation of the Intermediates" chapter.Diagram 5Synthesis of the derivatives of 1,2,3,6-tetrahydropyridine:The indolic derivatives of general formula (V1), in which Q represents 1,2,3,6-tetrahydropyridine, O, R9 and R]2 being as defined above, are prepared from the substituted commercial indoles of general formula (XI), Diagram 6. The experimental protocol of the condensation reaction with the piperidone is described in Eur. J. Med. Chem. (1987) 22, 33-43. The intermediate of general formula (XII) is then condensed in a standard fashion with the halogenated derivatives of general formula (XIII) in the presence of a base such as, for example, NajCOj, in an appropriate polar solvent such as for example DMF, in order to produce the intermediates of general formula (V') (particular case of the intermediates of general formula (V)).Diagram 6The derivatives of general formula (Va) (particular case of the intermediates of general formula (V)), Diagram 7, in which Q represents 1.2,3,6-tetrahydropvridine, 0, Y and R12 being as defined above, Hal being a halogen atom, are also prepared by condensation of 4-phenyl-l,2,3,6-tetrahydropyrine with the halogenated derivatives of general formula (XIII) in the presence of a base such as, for example, K2CO3. in an appropriate polar solvent such as, for example, DMF. In an alternative manner, the compounds of general formula (Va) are accessible by Mitsonobu type condensation (Synthesis (1981), 1) between 4-phenyl-I,2,3,6-tetrahydropyrine and alcoholic derivatives of general formula (XVIII).Diagram 7 Synthesis of Theophylline derivatives:The theophylline derivatives of general formula (Vb) (particular case of the intermediates of general formula (V)), Diagram 8, in which Y, O and R12 are as defined above, are prepared by condensation of commercial Theophylline with the halogenated derivatives of general formula (XIV) in the presence of a base such as, for example, NaOH, in a hydro-alcoholic solvent.Diagram 8Synthesis of ethers of general formula (V):When O represents -(CH2)p-0-(CH2)q-, with A, Q, R12, p and q as defined above, the ethers of general formula (V), Diagram 9, can be prepared in a single stage by condensation of the alcohols of general formula (XV) with the halogenated derivatives of general formula (XVI) in the presence of a base such as for example NaH in a polar solvent such as for example THF.Diagram 9When O represents -(CH2)p-0-(CH2)q-, with A, R|2, p and q as defined above, the ethers of general formula (V) can also be prepared from the halogenated derivatives offormula (XVII) and the alcohols of general formula (XVIII), Diagram 10. in the presence of a base such as for example NaH in a polar solvent such as for example DMF.Diagram 10 Synthesis of carboxamides (A-X-N-CO- series):The carboxamides of general formula (V), Diagram 11, in which A, R|;. R15, Y and <t> are as defined above, are prepared in the same peptidic coupling conditions as the carboxamides of the A-X-CO-N- series. The preparations of the non-commercial amines of general formula (XIX) and acids of general formula (XX) are described in the "Preparation of the intermediates" chapter.Diagram 11Synthesis of the amines by reducing amination:The amines of general formula (V), Diagram 12, in which A, R12, Ri6, Y, m and O are as defined above, can be prepared by condensation of an aldehyde of general formula (XXI) with a commercial amine of general formula (XXII) in a reducing medium. The reaction takes place in an alcoholic solvent such as, for example, methanol in the presence of pulverulent 4 A molecular sieves, priorily activated, and of a reducing agent such as, for example, NaBH4 or NaBHjCN. Before addition of the reducing agent, some imines can be isolated as intermediates of general formula (V).The secondary amines of general formula (V) are then protected in the form of / er / -butyl carbamate in the presence of di-rm-butyldicarbonate, and of a base such as, for example, triethylamine, in a solvent such as, for example, dichloromethane. The syntheses of the aldehydes of general formula (XXI), non-commercial, are described in the "Preparation of the intermediates" chapter.Diagram 12.1The amines of genera] formula (V), Diagram 13, in which A, X, R|i, R](„ p and q are as defined above, can also be prepared by condensation of an amine of genera] formula (XXIII) with a commercial aldehyde of genera] formula (XXIV) in a reducing medium in the previously described conditions. The secondary amines of general formula (V) are then protected in the form ofrm-butyl carbamate, in the previously described conditions. The syntheses of the amines of general formula (XXIII) are described in the "Preparation of the intermediates" chapter. Besides, the non-commercial aldehydes of general formula (XXVI) can be prepared according to J. Org. Chem., 1993. 58. 1385-92.Diagram 13Synthesis of (he amines by reduction of the carboxamides:The amines of general formula (V), Diagram 14, in which A, X, R[i, Ri6 and q are as defined above, are accessible by reduction of the carboxamide derivatives of general formula (V), the synthesis of which is described in the "Synthesis of the carboxamides" chapter (Diagram 4). The reduction step is carried out in an anhydrous medium, by heating at 70-80 °C, in the presence of a carboxamide selective reagent such as, for example, BHj.THF, in a solvent such as, for example, THF. The secondary amines thus prepared can be protected in the form of im-butyle carbamate in the conditions described previously.Diagram 14Synthesis of the ureas:The ureas of general formula (V), Diagram 15, in which A, Y, <t>, R|2. R15 and R]6 are as defined above, are accessible by reaction of the amines of general formula (XIX) with the amines of general formula (XXII) in the presence of triphosgene and of a base such as, for example, diisopropylethylamine in an inert solvent such as dichloromethane according to an experimental protocol described in J. Org. Chem. (1994) 59 (7), 1937-1938.Diagram 15Synthesis of pyrrolidinyl-pyrimidine derivatives:The pvrimidine derivatives of general formula (V), Diagram 16, in which Q represents piperazine, <J> and R]2 being as defined above, are prepared by condensation of 4-chloro-2,6-di-pyrrolidin-l-yI-pyrimidine (J. Med. Chem. (1990) 33 (4), 1145-1151) with the piperazine derivatives of general formula (X), by heating, during 24 to 48 hours, in anhydrous pyridine at a temperature of 80-110 °C.Diagram 16.1Synthesis of the carboxamides (A-X-CO-N series):The carboxamides of general formula (VI). Diagram 17, in which A, Y, 0, Rji, Rjj. Gp and Gp' are as defined above, can be prepared from the commercial acids of general formula (VII) and the amines of general formulae (XXV) or (XXVI) in the standard conditions of peptidic synthesis as previously described. The syntheses of the amines of general formulae (XXV) and (XXVI) are described in the "Preparation of the intermediates" chapter.Diagram 17Synthesis of the carboxamides (A-X-N-CO series):The carboxamides of general formula (VI), Diagram 18, in which A, Y. 0, R]2. R15 and Gp are as defined above, can be prepared by condensation of the amines of general formula (XIX), previously described, with the acids of general formula (XXVII) in the standard conditions of peptidic synthesis as previously described. The acids of general formula (XXVII) are easily accessible by protection of the aniline function in the form, for example, of a ferf-butyl carbamate in standard conditions.Diagram 18.1Preparation of different synthesis intermediates: Synthesis of intermediates (VII):The non-commercial acids of general formula (VII) in which A is as defined above are accessible using the methods of the literature. For example, 2-hydroxy-4.5.6-trimethoxybenzoic acid is obtained in two stages from 3,4,5-trimethoxyphenol according toy. Org. Chem. (1961) 26, 1221-1223, Acta Chem. Scandinavica (1973) 27, 888-890 or Can. J. Chem. (1972) 50, 1276-1282.Some acids of general formula (VII), in which A is as defined above, include an amine (Ri substituent) that has to be protected in the form of a carbamate, of rer / -butyle in particular, before carrying out the condensation step. This protection is carried out in standard conditions described in "M. Bodanszky et A. Bodanszky, The Practice of Peptide Synthesis, 145 (Springer Verlag, 1984)".The acid derivatives of the benzofuranes are prepared using an experimental protocol described in J. Org. Chem. (1989) 54, 560-569.Synthesis of intermediates (IX):The non-commercial acids of general formula (IX) in which X represents -0-(CH2)m-with A as defined above are prepared from the hydroquinones of general formula (IX.l) obtained according to the literature (J. Chem. Snc. Perkin 1 (1981) 303-306). Condensation with commercial halogenoesters of general formula (IX.2) is carried out in the presence of a base such as, for example. k2co3, by heating in a polar solvent such as, for example, THF for at least 5 hours. The esters of general formula (IX.3) obtained intermediately are then deprotected (in an acid medium in the case of the esters of rm-butyl) in order to produce the acids of general formula (IX).Diagram 5.1The acids of general formula (IX) in which X represents -S-(ch2)m- with A as defined above, are prepared according to the literature (J. Med. Chem. (1997) 40 (12), 1906-1918).Synthesis of intermediates (X):The non-commercial amines of general formula (X), in which Q represents homopiperazine, 2-methylpiperazine, 2,5-dimethylpiperazine, 4-aminopiperidine, are synthesized in three stages from the corresponding commercial diamines. The diamines are selectively monoprotected in the form of carbamate (Synthesis (1984), (12), 1032-1033; Synth. Commun. (1990), 20, (16), 2559-2564) before reaction by nucleophilic substitution on a halogen nitrobenzene, in particular 4-fluoronitrobenzene. The amines, previously protected, are released in the last stage, according to methods described in the literature (T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, Second edition (Wiley-Interscience, 1991)), in order to produce the intermediates of general formula (X).Synthesis of intermediates (XIX):The amines of general formula (XIX), which are indoline or 1,2,3,4-tetrahydroquinoline derivatives, Diagram 11.1, in which T and Rn are as described above, can be prepared from the corresponding nitro derivatives of general formula (XIX.1). 6-nitro-l,2,3,4-tetrahydroquinoline is described in Can. J. Chem. (1952), 30, 720-722. The alkylation of the amine is classically carried out by a strong base such as, for example, NaH, in an aprotic polar solvent such as, for example, DMF in the presence of a halogenated derivative such as, for example, Mel or PhCHjBr. The nitro derivative of general formula (XIX.2) intermediately obtained is then reduced, for example, by Raney Nickel in the presence of hydrazine hydrate n order to produce the anilines of general formula (XIX).Diagram 11.1Some phenylenediamine derivatives of genera] formula (XIX), non-commercial, can be prepared according to Farmaco (1951) 6, 713-717.In the particular case where A is a phenolic derivative, the anilines of general formula (XIX) are obtained by hydrogenation, in the presence of Pd / C. of the nitrophenol precursor derivatives. The nitrated derivatives of the di-rm-butyl phenols are accessible according to a method described in J. Org. Chem. (1968) 33 (1), 223-226.Synthesis of the intermediates (XX) :The non-commercial carboxylic acids of general formula (XX) in which R|i, Y and O are as defined above are accessible by methods described in literature. The syntheses of several co-(4'-nitrophenyl)alkanoic acids are described in J. Med. Chem. (1978) 21 (5), 430-437.The synthesis of the carboxylic acids of general formula (XX), in which R^ and Y are as defined above and O = thiazolidine, is carried out following a protocol described in LiebigsAnn. Chem. (1987), 927-934.Synthesis of the intermediates (XXI) :The non-commercial aldehydes of general formula (XXI) in which A and m are as defined above are accessible from literature methods : Bull. Chem. Snc. Jpn. (1978) 51 (8), 2433-2434, Bioorg. Med. Chem. Lett. (1998) 8, 3453-3458.Synthesis of the intermediates (XXIII) :The amines of general formula (XXIII), Diagram 13.1, in which A, X, Ru,, Gp and p are as defined above, are prepared by condensation of the amines of general formula (XIX), previously described, and the protected aminoacids of general formula (XXIII.l), in the standard conditions of peptidic synthesis (see chapter Synthesis of the carboxamides (Diagram 4)). Deprotection of the amine of compounds of general formula (XXIII.2) is then carried out in acidic medium such as, for example, trifluoroacetic acid or hydrochloric acid.Diagram 13.1 Synthesis of the intermediates (XXV) :The amines of general formula (XXV), in which Y and 0 are as defined above, are prepared in several steps from commercial aniline derivatives of general formula (XXV.1), Diagram 17.1. To protect the aniline function, using a protecting group that resists to a strong basic medium, for example the 2,5-dimethylpyrrole group, is necessary. By reflux heating, in an appropriate solvent (e. g. toluene), of a mixture of the intermediate of general formula (XXV.1) with 2,5-hexanedione and paratoluenesulphonic acid, with simultaneous elimination of the water formed during the reaction, the intermediate of general formula (XXV.2) is obtained. The intermediate of general formula (XXV.3) is obtained by double alkylation of a carbone atom using two equivalents of a strong base, such as, for example, NaH in DMSO (J. Org. Chem. (1971) 36 (9), 1308-1309). in the presence of a dihalogenated derivative. The amines of general formula (XXV) are then obtained by reduction of the nitrile using, for example, LiAIHj, in a solvent such as, for example, anhydrous THF.Diagram 17.1 Synthesis of the intermediates (XXVI) :The amines of general formula (XXVI), Diagram 17.2, in which R|2 and O are as defined above, are prepared in several steps from a commercial azetidine derivative and a halogenated derivative of general formula (XIII). The condensation step is carried out classically in the presence of a strong base such as, for example, NaH in an inert anhydrous solvent such as, for example, THF. Reduction of the nitro derivative by tin chloride (J. Heterocyclic Chem. (1987), 24, 927-930 : Tetrahedron Letters (1984). 25 (8), 839-842) affords the aniline derivative of general formula (XXVI.2) which is directly protected in the form of a / er(-butyl carbamate in previously described conditions. The amine of general formula (XXVI) is obtained by hydrogenolysis of the dibenzyl group in the presence of palladium hydroxyde.Diagram 17.2Unless they are defined differently, all the technical and scientific terms used here have the same meaning as that usually understood by an ordinary specialist in the field to which this invention belongs. Similarly, all the publications, patent applications, all the patents and all other references mentioned here are incorporated by way of reference.The following examples are presented to illustrate the above procedures and should in no way be considered as restricting the scope of the invention.EXAMPLESExample 1: 2-hydroxy-5-methoxy-N-(2-[4-[i2-thienyl(imino)methyl)amino]phenyl] ethyl [-benzamide hydrochloride:1.1.) 2-hydroxy-5-methoxy-N- {2-(4-nitrophenyl)ethvl 1 -benzamide:4-nitrophenethylamine hydrochloride (1.81 g; 8.9 mmol), triethylamine (2.8 ml; 20 mmol), hydroxybenzotriazole (1.45 g; 10.7 mmol) and l-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (3.75 g; 19.62 mmol) are added to a solution of 1.5 g (8.9 mmol) of 5-methoxy-salicylic acid in dichloromethane (80 ml). The reaction medium is agitated overnight at 25 °C. The mixture is diluted with 40 ml of water and agitated for ten minutes, then the product is extracted with dichloromethane. The organic solution is dried over sodium sulphate, filtered and concentrated under vacuum and the evaporation residue is purified on a silica column (eluent = ethyl acetate / heptane; 50 / 50) in order to produce a white solid obtained with a yield of 64%. Melting point: 200 °C. NMR 'H (DMSO d6, 400 MHz. 8): 3.00 (m, 2H, CH2); 3.60 (m. 2H, CH2); 3.70 (S, 3H. -OCH3); 6.80 (d, IH, arom., J = 8.8 Hz); 7.00 (d, 1H, arom., J = 8.8 Hz); 7.35 (s, 1H, arom.); 7.50 (d, 2H, arom., J = 7.8 Hz); 8.10 (d, 2H, arom., J = 7.6 Hz); 8.90 (broad s, 1H, CO-NH); 11.90 (broad s, 1H, -OH).1.2) 2-hydroxv-5-methoxy-N-{2-(4-aminophenyl) ethyl [-benzamide:Intermediate 1.1. 2.10 g (6.64 mmol) is dissolved in a mixture of ethanol (40 ml) and dichloromethane (60 ml) and 0.3 g of palladium on carbon (10%) is added. The mixture is placed under a hydrogen atmosphere under a pressure of 4 bars. The catalyst is filtered out and the solvent evaporated off under reduced pressure. The evaporation residue is purified on a silica column (eluent = ethyl acetate / heptane; 50 / 50) in order to produce a white-cream solid. Melting point: 130°C.NMR 1H (DMSO d6, 400 MHz, 8): 2.67 (t, 2H. CH2, J = 7.4 Hz); 3.43 (m, 2H, CH2); 3.73 (S, 3H, -OCH3); 4.90 (S, 2H, NH2); 6.50 (d, 2H, arom., J = 7.8 Hz); 6.82 (d, 1H, arom., J = 8.8 Hz); 6.90 (d, 2H, arom., I = 7.8 Hz); 7.00 (d, 1H, arom., J = 8.8 Hz): 7.39 (S, 1H, arom.); 8.87 (broad s, IH, CO-NH); 12.09 (broad s, IH, -OH).1.3) 2-hydroxy-5-methoxy-N-(2-[4-[(2-thienvl(irmno)methyl)amino]phenyl]ethyl |-benzamide hydrochloride:Intermediate 1.2 (0.6 g; 2.1 mmol) is dissolved in 2-propanol (10 ml). 0.896 g of S-methyl-2-thiophenethiocarboximide hydroiodide (3.14 mmol) (Ann. Chim. (1962). 7. 303-337) is added.After heating at 50 °C for 15 hours, the reaction mixture is concentrated to dryness under vacuum. The residue is taken up in ethyl acetate and a saturated solution of sodium carbonate. After decantation, the organic phase is washed successively with 50 ml of a saturated solution of sodium carbonate, water and salt water. The organic solution is dried over sodium sulphate, filtered and evaporated under reduced pressure. The evaporation residue is purified on a silica column (eluent ethanol / dichloromethane, 5 / 95). 0.523 g of free base is obtained. The hydrochloride is prepared from 0.523 g (1.32 mmol) of the base dissolved in 20 ml of acetone and salified in the presence of 2.0 ml (2.0 mmol) of a molar solution of HCI in anhydrous diethyl ether. The crystals obtained are filtered and rinsed in diethyl ether in order to obtain after drying 0.58 g (yield of 64%) of the sought product in the form of a white solid. Melting point: 242 °C. NMR 'H (DMSO d6, 400 MHz. 8): 2.94 (t, 2H, CH2, J = 7.2 Hz); 3.58 (m, 2H, CH2); 3.73 (s, 3H, -OCH3); 6.85 (d, 1H, arom., J = 9.0 Hz); 7.01 (d, 1H, arom., J = 8.8 Hz); 7.20 - 7.70 (m, 6H, arom.); 8.16 (m, 2H, thiophene); 8.88 (broad s, 1H, NH + ); 9.11 (broad t, 1H, CO-NH, J = 5.15 Hz); 9.83 (broad s, 1H, NH+); 11.54 (broad s, 1H, NH+); 12.10 (s, 1H, -OH). IR: vc=n (amidine): 1645 cnr1; vc=o (amide): 1645 cm-1.Example 2: 2-hydroxy-5-methylthio-N-(2-[4-[(2-thienyl(imino)methyl)amino]phenyl] ethyl -benzamide hydroiodide:The experimental protocol used is the same as that described for Example 1, except that 5-methylthiosalicylic acid replaces 5-methoxysalicylic acid. The hydroiodide formed precipitates during the reaction. The crystals formed are filtered out and washed with diethyl ether. An off-white solid is obtained. Melting point: 211.4 - 212.6 °C. NMR 'H (DMSO d6, 400 MHz, 5): 2.49 (s, 3H, -SCH3); 2.94 (t, 2H, CH2, J = 7.36 Hz); 3.57 (m, 2H, CH2); 6.90 (d, 1H, arom., J = 8.64 Hz); 7.20 - 7.60 (m, 6H, arom.); 7.80 (s, 1H, arom.); 8.10 (m, 2H, thiophene); 8.87 (broad s, 1H, NH+); 9.02 (broad t, 1H, CO-NH, J = 5.12 Hz); 9.77 (broad s, 1H, NH+); 11.35 (broad s, 1H, NH+); 12.48 (s, 1H, -OH). IR: vc=N (amidine): 1639 cm-1; Vc=o (amide): 1656 cm'1.Example 3: 2,5-dihydroxy-N-{2-[4[(2-thienyl(imino)methyl)amino]phenvl]ethyl-benzamide hydrochloride:The experimental protocol used is the same as that described for Example 1, with 2,5-dihydroxybenzoic acid replacing 5-methoxysalicylic acid. A pinkish white solid is obtained. Melting point: 250 °C.NMR 'H (DMSO d6, 400 MHz, S): 2.92 (t, 2H, CH2, J = 7.20 Hz): 3.55 (m. 2H. CH2); 6.75 (d, IH, arom., J = 8.76 Hz); 6.85 (d, IH, arom., J = 8.76 Hz); 7.24 (s, IH, arom.); 7.30 - 7.50 (m, 5H, arom.); 8.16 (m, 2H. thiophene); 8.83 (m, IH, CO-NH); 8.9 (broad s, IH, NH+); 9.07 (s, 1H.-OH); 9.8 (broad s, IH, NH+); I 1.40 (s,IH, -OH); 11.70 (S, IH, NH+).IR: Vc=n (amidine): 1652 cm-1; Vc=o (amide): 1668 cm"'.Example 4: 2-hydroxy-3-isopropyl-N-)2-[4-[(2-thienyl(imino)methyl)amino]phenyl] ethyl (-benzamide hydrochloride:The experimental protocol used is the same as that described for Example 1, with 2-hydroxy-3-isopropyl-benzoic acid replacing 5-methoxysalicylic acid. A white solid is obtained. Melting point: 142.5 - 144 °C.NMR 'H (DMSO d6, 400 MHz, 5): 1.17 (d, 6H, isopropyl, J = 6.9 Hz); 2.93 (m, 2H, CH2); 3.24 (m, IH, isopropyl); 3.58 (m, 2H, CH2); 6.82 (t, IH, arom.. J = 7.8 Hz); 7,20-7.60 (m, 6H, arom.); 7.80 (d, IH, arom. J = 7.9 Hz); 8.19 (m, 2H, thiophene); 8.89 (broad s, 1 H, NH+); 9.23 (broad s, IH, CO-NH); 9.86 (broad s. 1 H, NH+);II.62 (broad s, 1 H, NH+); 13.45 (s, IH, -OH).IR: vc=n (amidine): 1637 cm-1; vc=o (amide): 1648 cm"1.Example 5: 2,6-dihydroxy-N-(2-[4-[(2-thieny](imino)methyl)amino] phenyl]ethyl]-benzamide hydrochloride:The experimental protocol used is the same as that described for Example 1, with 2,6-dihydroxybenzoic acid replacing 5-methoxysalicylic acid. A pale yellow-white solid is obtained. Melting point > 280 °C.NMR 1H (DMSO d6, 400 MHz, 5): 2.94 (t, 2H, CH2, J=7.14 Hz); 3.61 (m, 2H, CH2); 6.40 (d, 2H, arom., 1=8.32 Hz); 7.14 (t, IH, arom., J=8.28 Hz), 7,20-7.60 (m, 5H, arom.); 8.17 (m, 2H, thiophene); 8.9 (broad s, IH, NH+); 9.03 (t. IH, CO-NH, J = 5.24 Hz); 9.85 (broad s, IH, NH+); 11.55 (broad s, IH, NH+); 12.71 (broad s, 2H, -OH). IR: vc=n (amidine): 1593 cm"1; vc=o (amide): 1633 cm"1.Example 6: 2-hydroxy-4,6-dimethoxy-N-12-[4-[(2-thienyl(imino)methyl)amino] phenyl]ethyl (-benzamide hydrochloride:The experimental protocol used is the same as that described for Example 1, with -2-hydroxy-4,6-dimethoxy benzoic acid replacing 5-methoxysalicylic acid. A white solid is obtained. Melting point: 196-199 °C.NMR 'H (DMSO d6, 400 MHz, 5): 2.92 (t, 2H, CH2, J = 7.24 Hz); 3.58 (m, 2H, CH2); 3.76 (s, 3H, -OCH3); 3.85 (s, 3H, -OCH3); 6.07 (s, 1H, arom.); 6.10 (s, 1H. arom.); 7.30 - 7.60 (m, 5H, arom.); 8.17 (m, 2H, thiophene); 8.58 (broad t, 1 H. CONH, J = 5.36 Hz); 8.88 (broad s, 1H, NH+); 9.85 (broad s, 1H. NH+); 11.60 (broad s, 1H, NH+); 14.39 (s, 1H, -OH). IR: Vc=n (amidine): 1598 cm-1; vc=o (amide): 1637 cm-1.Example 7: 2-hydroxy-4.5,6-trimethoxy-N-|2-[4-[(2-thienyl (imino)methyDamino] phenyl] ethyl (-benzamide hydrochloride:The experimental protocol used is the same as that described for Example 1, with 2-hydroxy-4,5,6-trimethoxybenzoic acid (J. Org. Chem. (1961) 26, 1221-1223; Ada Chem. Scanditiavica (1973) 27, 888-890) replacing 5-methoxysalicylic acid. Melting point: 90-95 °C.NMR 'H (DMSO d6, 400 MHz, S): 2.95 (t, 2H, CH2, J =7.12 Hz); 3.61 (m, 2H, CH2); 3.66 (s, 3H, -OCH3); 3.79 (S, 3H, -OCH3); 3.80 (S, 3H, -OCH3); 6.32 (S. 1H, arom.); 7.39 - 7.48 (m, 5H, arom.); 8.16 (m, 2 H, thiophene); 8.62 (broad s, I H, CO-NH); 8.90 (broad s, 1 H, NH+), 9.80 (broad s, 1 H, NH+); 11.40 (broad s, 1 H, NH+); 13.67 (s, 1H, OH).IR: vc=n (amidine): 1591 cm"1; vc=o (amide): 1631 cm"1.Example 8: 2-hydroxy-3,5-di-tert-butyl-N-(2-[4-[(2-thienyl(imino)methyl)amino] phenyl]ethyl-benzamide hydrochloride:The experimental protocol used is the same as that described for Example 1, with 2-hydroxy-3,5-di-tert-butyl acid replacing 5-methoxy-salicylic acid. A white solid is obtained. Melting point: 172.4- 173.8 °C.NMR 'H (DMSO d6, 400 MHz. 5): 1.28 (s, 9H, t-Bu); 1.36 (s, 9H, t-Bu): 2.96 (t, 2H, CH2, J = 7.28 Hz); 3.58 (m, 2H, CH2); 7,36-7.46 (m, 6H, arom.); 7.70 (s, 1H, arom.); 8.17 (m, 2H, thiophene); 8.88 (broad s, 1 H, NH+); 9.22 (broad t, 1 H, CONH, J = 5.32 Hz); 9.82 (broad s, 1H, NH+); 11.55 (broad s, 1H, NH+); 13.60 (s, 1H, -OH).IR: Vc=n (amidine): 1585 cm-1; vc=o (amide): 1631 cm-1.Example 9: 2-hydroxy-3,5-diisopropyJ-N-(2-[4-[(2-thienyl (imino)methvDamino] phenyl]ethyl} -benzamide hydrochloride:The experimental protocol used is the same as that described in Example 1, with 2-hydroxy-3,5-diisopropylbenzoic acid replacing 5-methoxysalicylic acid. A white solid is obtained. Melting point: 212.6°-214 °C.NMR 'H (DMSO d6, 400 MHz, 8). 1.35 (m. 12H, isopropyl); 2.98 (m. IH. isopropyl); 3.12 (t, 2H, CH2, J = 7.58 Hz): 3.38 (m, IH, isopropyl); 3.72 (m, 2H. CH2); 7.37 (s, IH, arom.); 7,54-7.63 (m, 5H, arom.); 7.77 (S, IH, arom.); 8.33 (m, 2H, thiophene); 9.00 (broad s, IH, NH+); 9.30 (m, IH, CONH); 10.00 (broad s. IH, NH+).IR: vc=n (amidine): 1590 cm-1; Vc=o (amide): 1637 cm"1.Example 10: 2,4-dihydroxy-3,6-dimethyl-N-{2-[4-[(2-thienyl (imino)methyl)amino] phenyl]ethyl -benzamide hydrochloride:The experimental protocol used is the same as that described for Example 1, with 2,4-dihydroxy-4,6-dimethylbenzoic acid replacing 5-methoxysalicylic acid. A beige solid is obtained. Melting point: 150.3 - 151.9 °C.NMR 'H (DMSO d6. 400 MHz, 8): 2.08 (S, 3H, CH3); 2.38 (S, 3H, CH3); 3.09 (t, 2H, CH2, J=7.36 Hz); 3.61 (m, 2H, CH2); 6.38 (s, IH, arom.); 7,55-7.63 (m. 5H, arom.); 8.15 (broad t, IH, CONH, J = 5.28 Hz); 8.35 (m, 2H, thiophene); 9.00 (broad s, IH, NH+); 9.78 (broad s, IH, NH+); 10.00 (s, IH, -OH); 10.70 (broad s, IH, -NH+); 11.69 (broad s, IH, NH+). IR: vc=n (amidine): 1590 cm"'; v<>o (amide): 1637 cm"1.Example 11: 2,7-dihydroxy-N-{2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl}-2-naphthalenecarboxamide hydrochloride:The experimental protocol used is the same as that described for Example 1, with 3,7-dihydroxy-2-naphtoic acid replacing 5-methoxy salicylic acid. A yellow solid is obtained. Melting point: 219-219.7 °C.NMR >H (DMSO d6, 400 MHz, 5): 2.98 (t. 2H, CH2 J=7.30 Hz); 3.64 (m, 2H, CH2); 7,09-7.60 (m, 9H, arom.); 8.16 (m, 2H, thiophene); 8.32 (S, IH, arom.); 8.90 (broad s, IH, NH+); 9.16 (broad s, IH, CONH); 9.60 (s, IH, -OH); 9.80 (broad s, IH, NH+); 11.40 (broad s, IH, NH+); 11.77 (s, IH, OH). IR: Von (amidine): 1625 cm-1; vc=o (amide): 1657 cm"1Example 12: 2-hydroxv-4-methoxy-N-{2-[4-[(2-thienyl(imino)methyl)amino]phenyl] ethyl}-benzamide hydrochloride:The experimental protocol used is the same as that described for Example 1. with 2-hydroxy-4-methoxybenzoic acid replacing 5-methoxysalicylic acid. Melting point > 250 °C.NMR 'H (DMSO d6, 400 MHz, 8): 2.93 (t, 2H, CH2, J = 7.20 Hz); 3.54 (m, 2H, CH2); 3.76 (s, 3H, -OCH3); 6.44 (m, 2H. arom.); 7.40 (m, 5H. arom.): 7.87 (d, 1H, arom., J = 8.80 Hz); 8.17 (m, 2H, thiophene); 8.91 (broad s, 1H, CONH); 8.91 (broad s, 1H, NH+); 9.82 (broad s, 1H, NH+); 11.54 (broad s, 1H, NH+); 13.08 (s, 1H, -OH).IR: von (amidine): 1599 cm'1; Vc=o (amide): 1640 cm'1.Example 13: 2-hydroxv-3-isopropyl-5-methoxy-N-{2-[4-[(2-thienyl(imino)methyl) amino]phenyl]ethyl)-benzamide hydrochloride:The experimental protocol used is the same as that described for Example 1, with 2-hydroxy-3-isopropyl-5-methoxybenzoic acid (Can. J. Chem. (1972) 50. 1276-1282) replacing 5-methoxysalicylic acid. A white solid is obtained. Melting point: 170-175 °C.NMR 'H (DMSO d6, 400 MHz, 8): 1.15 (d, 6H, isopropyl, J = 6.88 Hz); 2.96 (t, 2H, CH2, J = 7.36 Hz); 3.23 (m, 1H, isopropyl); 3.57 (m, 2H, CH2); 3.75 (s, 3H, -OCH3); 6.93 (s. 1H, arom.); 7.39 (m, 6H, arom.); 8.17 (m, 2H, thiophene); 8.90 (broad s. 1H, NH+); 9.27 (broad t, 1H, CONH, J = 5.14 Hz); 9.90 (broad s, 1H, NH+): 11.60 (broad s, 1H, NH+); 13.00 (s, 1H, OH). IR: von (amidine): 1594 cm'1; Voo (amide): 1648 cm'1.Example 14: N-(2-hydroxy-3-tert-bulyl-5-methoxy)-4-([2-thienyl(imino)methyl] amino)benzene-butanamide hydrochloride14.1.) N-(2-methoxy-methoxy-3-tert-butyl-5-methoxy)-4-nitrobenzene-butanamideThe experimental protocol used is the same as that described for intermediate 1.1, with 4-(4-nitrophenyl)butanoic acid replacing 5-methoxysalicylic acid and 2-methoxymethoxy-3-rer / -buty]-5-methoxyaniline (Biorg & Med. Chem. (1998), 6, 849-868) replacing 4-nitrophenethylamine hydrochloride. A red oil is obtained with a yield of 82%. NMR 'H (DMSO d6, 400 MHz, 8): 1.32 (s, 9H, t-Butyl); 1.93 (m, 2H, CH2); 2.37 (m. 2H, CH2); 2.77 (m, 2H, CH2); 3.53 (s, 3H. OCH3); 3.68 (s, 3H, OCH3); 4.90 (s, 2H,-0CH20-); 6.57 (s, IH, arom.); 7.38 (s, IH. arom.); 7.51 (d. 2H, arom.. J = 8.50 Hz); 8.16 (d, 2H, arom., J = 8.50 Hz); 9.28 (s, IH, NHCO).14.2) N-(2-hydroxy-3-tert-butyl-5-methoxy)-4-nitro-benzenebutanamideConcentrated hydrochloric acid (0.6 ml) is added to a solution of 1.49 g (3.86 mmol) of N-(2-methoxy-methoxy-3-tert-butyl-5-methoxy)4-nitrobenzene-butanamide in methanol (30 ml). The reaction medium is agitated overnight at 25 °C. The solvents are evaporated off and the residue washed successively with 3 x 40 ml of water then 40 ml of salt water. The organic solution is dried over sodium sulphate, filtered and concentrated under reduced pressure in order to produce a brown oil, sufficiently pure to be used directly in the following stage.NMR 'H (DMSO d6, 400 MHz, 5); 1.34 (s, 9H, t-Bu); 1.76 (m, 2H, CH2); 2.44 (m. 2H, CH2); 2.78 (m, 2H, CH2); 3.65 (s, 3H, OCH3); 6.61 (s, IH, arom.); 6.66 (S, IH, arom.); 7.53 (d, 2H, arom, J = 8.62 Hz); 8.18 (d, 2H, arom., J = 8.62 Hz); 8.56 (s, IH, NH-CO); 9.94 (s, IH, -OH).14.3) N-(2-hydroxy-3-tert-butyl-5-methoxy)-4-aminobenzene-butanamideThe experimental protocol used is the same as that described for intermediate 1.2, with N-(2-hydroxy-3-tert-butyl-5-methoxy)-4-nitro-benzenebutanamide replacing 2-hydroxy-5-methoxy-N- (2-(4-nitrophenyl) ethyl [-benzamide.14.4) N-(2-hydroxy-3-tert-butyl-5-methoxy)-4-( [2-thienyl(imino) methyl]amino) benzenebutanamide hydrochloride.The experimental protocol used is the same as that described for Example 3, with N-(2-hydroxy-3-tert-butyl-5-methoxy)-4-aminobenzene-butanamide replacing 2-hydroxy-5-methoxy-N-(2-(4-aminophenyl)ethyl}-benzamide. Melting point: 146-154 °C. NMR 'H (DMSO d6, 400 MHz, 8): 1.34 (s, 9H, t-Butyl); 1.96 (m, 2H, CH2); 2.70 (m, 2H, CH2); 3.42 (m, 2H, CH2); 3.65 (s, 3H, -OCH3); 6.59 (s, IH, arom.); 6.83 (s, IH, arom.): 7,36-7.41 (m, 5H, arom.); 8.17 (m, 2H, thiophene); 8.75 (s, IH, NHCO); 8.90 (broad s, IH, NH+); 9.80 (broad s, IH, NH+); 10.35 (s, IH, -OH); 11.60 (broad s, IH, NH+).IR: von (amidine): 1596 cm1; vc=o (amide): 1698 cm"1.Example 15: 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-N-(2-[4-[(2-thienyl(imino) methyl)amino]phenyl]ethyl) -2H-1 -benzopyran-2-carboxamide hydrochloride.The experimental protocol is the same as that used for Example 1.1., with TROLOX replacing 5-methoxy-salicylic acid. A white solid is obtained. Melting point: 160-168 °C.NMR 'H (DMSO d6, 400 MHz, 5): 1.34 (s, 3H, -CH3); 1.70 (m. 1H, CH2-Trolox);1.99 (s, 3H, -CH3); 2.07 (s, 6H, CH3 x 2); 2.13 (m, 1H, CH2-Trolox); 2.40 (m, 1H, CH2-Trolox); 2.60 (m, 1H, CH2-Trolox); 2.72 (m, 2H, CH2); 3.31 (m. 2H. CH2); 4.30 (broad s, 1H, NH+); 7,20-7.23 (m, 6H, Arom); 7.57 (s, 1H, -OH); 8.17 (m, 2H. thiophene); 8.90 (broad s. 1H, NH+); 9.80 (broad s, 1H, NH+). IR Vc=n (amidine): 1599 crrr1; Vc=o (amide): 1653 cm-1.Example 16: 3,4-dihydro-6-hydroxy-2.5,7,8-tetramethyl-N-{ 1-[4-[(2-thienyl(imino)methyl)amino]phenyl]methyl }-2H-1 -benzopyran-2 -carboxamide hydrochloride:The experimental protocol used is the same as that described for Example 1. with Trolox replacing 5-methoxy-salicylic acid. A white solid is obtained. Melting point: 128-130 °C.NMR 'H (400 MHz, DMSO d6, 8): 1.45 (s, 3H, CH3); 1.95 (m, 2H, ? CH2-CH2); 2.00 (s, 3H, CH3); 2.10 (2s, 6H, 2 x CH3); 2.50 (m, 2H, 9 CH2-CH2); 4.25 (m, 2H. CH2-N); 6.35 (broad s, 2H, OH + NH+); 6.65 (d, 2H, arom.); 6.90 (d, 2H, arom.); 7.10 (m, 1H, arom.); 7.60 (m, 2H, arom.); 7.75 (broad s, 2H, NH+). IR: Vc=n (amidine): 1617 cnv1; Vc=o (amide): 1654 cnr1.Example 17: N-(4-hydroxyphenyl)-2-thiophenecarboximidamide hydroiodide:A mixture comprising 0.55 g (5 mmol) of 4-aminophenol and of 1.42 g (5 mmol) of S-methyl-2-thiophenethiocarboximide hydroiodide in solution in 20 ml of isopropanol is agitated for 2 hours at 40 °C. The precipitate formed is then filtered and rinsed twice with 25 ml of ethyl ether. After drying the expected product is obtained in the form of a white powder with a yield of 77%. Melting point: 258-259 °C.Example 18: N-(2-hydroxyphenyl)-2-thiophenecarboximidamide hydrochloride:The experimental protocol used is the same as that described for Example 17, with 2-aminophenol replacing 4-aminophenol. The reaction product is purified on a silica column (eluent: dichloromethane / methanol: 9 / 1). The free base is then salified using a 1M solution of HCI in anhydrous ethyl ether. The hydrochloride is obtained in the form of a cream powder with a yield of 20%. Melting point: 206-207 °C.Example 19: N-(3-hydroxyphenyl)-2-thiophenecarboximidamide hydroiodide:The experimental protocol used is the same as that described for Example 17. with 3-aminophenoI replacing 4-aminophenol. After drying the expected product is obtained in the form of a cream powder with a yield of 72%. Melting point: 198-200 °C.Example 20: N-(3-hydroxy-4-methoxyphenyl)-2-thiophenecarboximidamide hydrochloride:The experimental protocol used is the same as that described for Example 18, with 5-amino-2-methoxyphenol replacing 2-aminophenol. After drying the expected product is obtained in the form of a cream powder with a yield of 30%. Melting point: 253-254 °C.Example 21: N-(3-hydroxy-4-methylphenyl)-2-thiophenecarboximidamide hydrochloride:The experimental protocol used is the same as that described for Example 18, with 3-amino-o-cresol replacing 2-aminophenol. After drying the expected product is obtained in the form of a cream powder with a yield of 61%. Melting point: 245-246 °C.Example 22: N-(4-methoxyphenyl)-2-thiophenecarboximidamide hydrochloride:The experimental protocol used is the same as that described for Example 18. with p-anisidine replacing 2-aminophenol. After drying the expected product is obtained in the form of a cream powder with a yield of 40%. Melting point 78-79 °C.Example 23: N-(3,5-dimethyl-4-hydroxyphenyl)-2-thiophenecarboximidamide hydroiodide:23.1) 4-amino-2,6-dimethylphenol:A solution of 1 g (6 mmol) of 2,6-dimethyl-4-nitrophenol in 20 ml of ethanol is placed under 1.5 bar of hydrogen in the presence of 10% Pd / C for 1 hour. The Pd / C is eliminated by filtration on celite and the filtrate is concentrated under reduced pressure. The evaporation residue crystallizes spontaneously, it is washed twice with 50 ml of heptane and dried overnight under vacuum. A cream coloured solid is obtained with a yield of 86%.Melting point: 139-140 °C.23.2) N-(3,5-dimethyl-4-hydroxyphenyl)-2-thiophenecarboximidamide hydroiodideThe experimental protocol used is the same as that described for Example 17. with 4-amino-2,6-dimethylphenol replacing 4-aminophenol. After drying the expected product is obtained in the form of a white powder with a yield of 65%. Melting point: 253-254 °C.Example 24: N-(3,5-dichloro-4-hydroxyphenyl)-2-thiophenecarboximidamide hydrochloride:The experimental protocol used is the same as that described for Example 18, with 4-amino-2,6-dichlorophenol replacing 2-aminophenol. After drying the expected product is obtained in the form of a cream powder with a yield of 30%. Melting point: >260°C.Example 25: N-(3,5-bis-(l.l-dimethylethyl)-4-hydroxyphenyl)-2-thiophene carboximidamidethiophenecarboxirmdamide hydrochloride:25.1) 4-amino-2,6-bis-(l ,l-dimethylethyl)-phenol:In a 250 ml Parr bottle, 3.6 g (14 mmol) of 4-nitro-2,6-bis-(l,l-dimethylethyl)-phenol (J. Org. Chem. (1968), 33 (1), 223-226) is dissolved in 60 ml of a mixture (2 / 1) of ethanol and dichloromethane in the presence of a catalytic quantity of 10 % Pd / C. The mixture is agitated for 2 hours, at 20 °C. under 20 PSI of hydrogen. After filtration on celite, the filtrate is concentrated to dryness under reduced pressure. The reddish brown powder obtained is suspended in heptane (30 ml), filtered and rinsed with the same volume of heptane. The expected product is obtained in the form of a salmon pink powder with a yield of 50 % (1.56 g). Melting point: 123-124 °C.NMR 'H (100 MHz, CDC13, 5): 6.60 (s, 2H, Ph); 4.65 (broad s, IH, OH); 3.15 (broad s, 2H, NH2); 1.42 (s, 18H, 2x tBu).25.2) N-(2,6-bis-(l,l-dimethylethyl)-4-hydroxyphenyl)-2- thiophenecarboximidamide hydrochloride:The experimental protocol used is the same as that described for Example 18, with 4-amino-2,6-bis-(l,l-dimethylethyl)-phenol replacing 2-aminophenol. After drying the expected product is obtained in the form of a pale yellow powder with a yield of 65%. Melting point: 258-259 °C.NMR'H (400 MHz, DMSO d6, 8): 1.42 (s. 18H, 2x tBu); 7.18 (s, 2H, Ph); 7.38 (s, IH, OH); 7.39 (s, IH, thiophene); 8.18 (m, 2H, thiophene); 8.80 (broad s, IH, NH+); 9.70 (broad s, IH, NH+); 11.30 (broad s. IH, NH+).Example 26: N-(4-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H- 1-benzopyran-2-yl)methy I]-1 -piperazinyljphenyl) -2-thiophenecarboximidamide:26.1) 3,4-dihydro-2,5,7,8-tetramethyl-2-{4[(phenylmethyl)-1 -piperazinyl]-carbonyI ]-2H-l-benzopyran-6-ol;3.3 g (20.4 mmol) of l,l'-carbonyldiimidazole is added to a solution of 5 g (20 mmol) of trolox in 40 ml of THF. After agitation for 1 hour at 23 °C, 3.52 g (20 mmol) of 1-benzyl-piperazine dissolved in 20 ml of THF is added. After agitation for 15 hours, the reaction mixture is concentrated under vacuum. The evaporation residue is dissolved in 50 ml of dichloromethane and the solution is washed twice with 50 ml of water. The organic phase is dried over sodium sulphate, filtered and concentrated under vacuum. The evaporation residue is purified on a silica column (eluent: ethyl acetate / heptane: 3 / 2). 6.17 g of a white powder is obtained with a yield of 75%. Melting point: 63-65 °C.26.2) 3,4-dihydro-2,5,7,8-tetramethvl-2-(4[(phenylmethy])-l-piperazinyl]-methyl}-2H-l-benzopyran-6-ol:A solution of 4 g (9.8 mmol) of intermediate 26.1 is added dropwise to a suspension of 0.74 g (19.6 mmol) of LiAIH4 in 20ml of THF at 0 °C. After 15 minutes at 0 °C, the reaction mixture is agitated for 18 hours at 23 °C. The reaction is then cooled down using an ice bath and hydrolyzed by successively adding 4ml of ethyl acetate, 0.8 ml of water, 0.8 ml of 15% soda and finally 2.4 ml of water. The reaction mixture is then filtered on celite and the precipitate is washed 3 times with 25 ml of ethyl acetate. The filtrate is concentrated under vacuum and the residue is purified on a silica column (eluent: ethyl acetate / heptane: 1 / 1). An orange oil is obtained with a yield of 65%.26.3) 3,4-dihydro-2,5,7,8-tetramethyl-2-[(l-piperazinyl)-methyl]-2H-l-benzopyran-6-ol:0.4 g of 10% Pd / C is added to a solution of 2.52 g (6.39 mmol) of intermediate 31.2 in 15 ml of acetic acid. The mixture is agitated under 3 bars of hydrogen for 1 hour. The catalyst is eliminated by filtration and the filtrate is concentrated under vacuum. The residue is partitioned in a mixture of 80 ml of ethyl acetate and 100 ml of 2N NaOH. After decantation, the organic solution is washed twice with 150 ml of water, dried oversodium sulphate and filtered. The filtrate is concentrated under vacuum and the residue purified on a silica column (eluent: dichloromethane / methanol / NH^H (28%): 25 / 1 / 0.5). A white solid is obtained with a yield of 62%.26.4) 3,4-dihydro-2,5,7,8-tetramethyl-2-{4[(4-nitrophenyl)-1 -piperazinyl]-methyl |-2H-l-benzopyran-6-ol:0.6 g (1.97 mmol) of intermediate 31.3, 0.54 g (3.94 mmol) of potassium carbonate and 0.31 g (2.17 mmol) of l-fluoro-4-nitrobenzene are dissolved in 20 ml of DMF. The reaction mixture is heated at 100 °C for 16 hours. After returning to 23 °C, the mixture is diluted with 30 ml of water and 30 ml of ethyl acetate. The organic phase is decanted, washed twice with 20 ml of water, dried over sodium sulphate and filtered. The filtrate is concentrated under vacuum and the evaporation residue is purified on a silica column (eluent: ethyl acetate / heptane: 1 / 1). A yellow powder is obtained with a yield of 52%. Melting point: 72-75 °C.26.5) 3,4-dihydro-2,5,7.8-tetramethvl-2-{4[(4-aminophenyl)-l-piperazinyl]-methyl]-2H-1 -benzopyran-6-ol:The experimental protocol is identical to that described for intermediate 1.2, with intermediate 26.4 replacing intermediate 1.1. A yellow solid is obtained with a yield of37%.NMR 'H (100 MHz, cdci3, 5): 1.30 (s, 3H, CH3); 2.00 (m, 4H, CH2-CH2); 2.10 (s, 6H, 2 x CHj); 2.20 (s, 3H, CH3); 2.60 (s, 2H, CH2); 2.75 (m, 6H, piperazine, NH2); 3.00 (m, 4H, piperazine); 4.00 (broad s, 1H. OH); 6.70 (m, 4H, arom.).26.6) N-(4-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1 -benzopvran-2-yl)methyl]-l-piperazinyl]phenyl}-2-thiophenecarboximidamide:The experimental protocol is the same as that described for intermediate 1.3 except that the product remains in the form of a free base. A yellow powder is obtained with a yield of 55%. Melting point: 100-102 °C.NMR 'H (400 MHz, DMSO d6, 6): 1.25 (s, 3H, CH3); 1.90 (m, 2H, ? CH2-CH2); 2.14 (s, 3H, CH3); 2.15 (s, 3H, CH3); 2.20 (s, 3H, CH3); 2.60 (s, 2H, NH2); 2, 65 (broad s, 2H, ? CH2-CH2); 2.80 (m, 4H, piperazine); 3.15 (m, 4H, piperazine); 4.80 (broad s, 1H, OH); 6.90 (s, 4H, arom.); 7.05 (m, 1H, thiophene); 7.40 (m, 2H, thiophene). (MH)+: 505.3.Example 27: l-(2-hydroxy-4,6-dimethoxybenzoyl)-3-{4-[(imino(2-thienyl)methyl) aminojphenoxy} azetidine hydrochloride:27.1) l-(diphenylmethyl)-3-(4-nitrophenoxy)azetidine:0.5 g (2 mmol) of l-(diphenylmethyl)-3-hydroxyazetidine is added to a suspension of 0.06 g (2.3 mmol) of NaH in 20 ml of dry THF, under an argon atmosphere. After agitation for one hour at 23 °C, a solution of 0.29 g (2.1 mmol) of 4-fluoronitrobcnzene in 5 ml of dry THF is added dropwise to the reaction mixture. Agitation is maintained for 2 additional hours at 23 °C and the mixture is finally poured into 25 ml of water. The product is extracted twice with 25 ml of ethyl acetate, the organic phase is then washed twice with 25 ml of salt water, dried over magnesium sulphate, filtered and concentrated under vacuum. The product is purified on a silica column (eluent: 12% ethyl acetate in heptane). The pure fractions are evaporated in order to produce a colourless oil with a yield of 40%.NMR 'H (CDCli , 400 MHz, 8): 3.20 (m, 2H, azetidine); 4.50 (s, IH, CH-(Ph)2); 4.80 (m, 2H, azetidine); 4.90 (m, IH, CH-O); 6.80 (m, 2H, H arom.); 7.20-7.50 (m, 10H, H arom.); 8.20 (m, 2H, H arom.).27.2) l-(diphenylmethyl)-3-(4-aminophenoxy)azetidine :3.59 g (16 mmol) of SnCl2, 2H20 is introduced into a solution of intermediate 38.1 (1.14 g; 3.18 mmol) in 50 ml of an ethyl acetate / ethanol / acetone mixture (2 / 1 / 2). The reaction mixture is heated to reflux for 5 hours and finally after cooling down, concentrated by half under vacuum. The evaporation residue is then poured into 50 ml of a saturated solution of cold NaHCOj and extracted with 100 ml of ethyl acetate. The cloudy mixture is filtered on celite and the filtrate is decanted. The organic phase is washed successively with 50 ml of water and 50 ml of salt water. After drying on magnesium sulphate and filtration, the organic solution is concentrated under vacuum. A colourless oil is obtained with a yield of 75%.NMR 'H (CDCI3 , 400 MHz, 8): 3.10 (m, 2H, azetidine); 3 40 (broad s, 2H, NH2); 4.40 (s, IH, CH-(Ph)2); 4.70 (m, 2H, azetidine); 4.75 (m, IH, CH-O); 6.60 (s, 4H, H arom.); 7,10-7.40 (m, 10H, H arom.).27.3) I-(diphenylmethyl)-3-(4-[( 1,1-dimethylethoxy)carbonyl]-aminophenoxy) azetidine:The protection of the amine is carried out in a standard fashion using BocOBoc in the presence of triethylamine in dichloromethane. A white solid is obtained with a yield of 77%. Melting point: 149-151 °C.NMR 'H (DMSO d6, 400 MHz, 5): 1.40 (s, 9H, tBu); 2.90 (broad s, 2H, azetidine); 3.60 (broad s, 2H, azetidine); 4.50 (s, 1H, CH-(Ph)2); 4.70 (m, 1H, CH-O); 6.70 (m, 2H, H arom.); 7.10-7.60 (m, 12H, H arom.); 9.10 (s: 1H, NH).27.4) 3- {4-[( 1,1 -dimethylethoxy)carbonyl]aminophenoxy | azetidine:The experimental protocol used is the same as that described for intermediate 1.2 except for the hydrogenation catalyst which is replaced by Pd(OH)2. A white solid is obtained with a yield of 78%. Melting point: 184-186 CC.NMR 'H (DMSO d6, 400 MHz, 8): 1.50 (s, 9H, tBu); 3.50 (m, 2H, azetidine); 3.70 (m, 2H, azetidine); 4.90 (m, 1H, CH-O); 6.70 (m, 2H, H arom.); 7.30 (m, 2H, H arom.); 9.10 (s, 1H, NH).27.5) l-(2-hydroxy-4,6-dimethoxybenzoyl)-3-(4-[(l,l-dimethylethoxy)carbonyl]-aminophenoxy} azetidine:The experimental protocol used is the same as that described for Example 1, with 2-hydroxy-4,6-dimethoxybenzoic acid replacing 5-methoxysalicylic acid. A white solid is obtained. Melting point: 95 °C.NMR 'H (DMSO d6, 400 MHz, 8): 1.45 (s, 9H, Boc); 3.72 (s, 3H, -OCH3); 3.73 (s, 3H, -OCH3); 3.90 (m, 2H, CH2, azetidine); 4.20 (m, 1H, CH2, azetidine); 4.40 (m, 1H, CH2, azetidine); 5.00 (m, 1H, CH, azetidine); 6.07 (d, 2H, arom., J = 8.95 Hz); 6.76 (d, 2H, arom., J = 8.95 Hz); 7.36 (m, 2H, arom.); 9.2 (broad s, NH-Boc); 10.3 (broad s, 1H, -OH) .27.6) l-(2-hydroxy-4,6-dimethoxybenzoyl)-3-aminophenoxy-azetidine:In a flask under an argon atmosphere, intermediate 38.5 (0.8 g; 1.8 mmol) is introduced into 20 ml of dichloromethane. The solution is cooled down using an ice bath and trifluoroacetic acid (0.7 ml; 9.0 mmol) is added dropwise. Agitation is maintained while returning to ambient temperature overnight. The reaction mixture is evaporated to dryness, the residue is taken up with bisodium carbonate and then extracted with ethyl acetate. The organic phase is dried over sodium sulphate, filtered and concentrated under vacuum. Purification is then carried out on a silica column (eluent = chloroform with 3% ethanol) in order to produce a white solid with a yield of 52%. Melting point: 95 °C. NMR ]H (cdcj3, 400 MHz, 8); 3.60 (m, 2H, CH2, azetidine); 3.80 (s, 3H, -OCH,): 3.83 (s, 3H, -OCHj); 4.20 (broad s, 2H, CH2); 4.37 (m. 2H, CH2, azetidine); 4.86 (m, 1H. CH, azetidine); 5.95 (s, 1H, arom.); 6.15 (s, 1 H, arom.); 6.62 (m, 4H, arom.); 11.61 (broad s, 1H, -OH).27.7) l-(2-hydroxy-4,6-dimethoxybenzoyl)-3-(4-[(imino(2-thienyl)methyl)amino] phenoxy) azetidine hydrochloride:The experimental protocol used is the same as that described for intermediate 1.3, with intermediate 27.6 replacing 2-hydroxy-5-methoxy-N-{2-(4-aminophenyl lethyl )-benzamide. A white solid is obtained. Melting point: 185-187.7 °C. NMR 'H (DMSO d6, 400 MHz, 8); 3.71 (s, 3H, -OCH3); 3.73 (s, 3H, -OCH3): 3.85 (m, 2H, CH2, azetidine); 4.32 (m, 2H, CH2, azetidine); 5.08 (m, IH, CH. azetidine); 6.09 (m, 2H, arom.); 7.02 (m, 2H, arom.); 7.36 (m, 3H, arom.); 8.16 (m, 2H, thiophene); 8.74 (broad s, IH, NH+); 9.72 (broad s, IH, NH+); 10.33 (s, IH, -OH); 11.39 (broad s, IH, NH+). IR: von (amidine): 1590 cm"1.Example 28: N-(2-hydroxy-5-methoxy)-4-| [2-thienyl(imino)methyl]amino)benzene-butanamide hydrochloride28.1) 2-amino-4-methoxyphenolThe experimental protocol used is the same as that described for intermediate 1.2, with 4-methoxy-2-nitrophenol replacing 2-hydroxy-5-methoxy-N-12-(4-nitrophenyl)ethyl) -benzamide.28.2) N-(2-hydroxy-5-methoxy)-4-nitro-benzene-butanamideThe experimental protocol used is the same as that described for intermediate 1.1, with 4-(4-nitrophenyl Jbutanoic acid replacing 5-methoxysalicyclic and with 2-amino-4-methoxyphenol replacing 4-nitrophenethylamine acid hydrochloride.28.3) N-(2-hydroxy-5-methoxy)-4-amino-benzene-butanamide.The experimental protocol used is the same as that described for intermediate 1.2, N-(2-hydroxy-5-methoxy)-4 nitro-benzene-butanamide replacing 2-hvdroxy-5-methoxy-N-{2-(4-nitrophenyl)ethyl} -benzamide.28.4) N-(2-hydroxy-5-methoxy)-4-([2-thienyl(imino)methyl]amino}benzene-butanamide hydrochloride.The experimental protocol used is the same as that described for Example I, with N-(2-hydroxy-5-methoxy)-4-amino-benzene-butanamide replacing 2-hydroxy-5-methoxy-N-(2-(4-aminophenyl) ethyl ]-benzamide. Melting point: 199.1 - 200.7 °C.NMR 'H (DMSO d6, 400 MHz, 8): -1.9 (m, 2H, CH2); 2.45 (m. 2H, CH2); 2.70 (m, 2H, CH2); 3.64 (s, 3H, -OCH3); 6,51-6.9 (m, 2H, arom.); 7.36 (m, 6H, arom.); 8.17 (m, 2H, thiophene); 8.88 (broad s, 1H, NH + ); 9.38 (s, 2H, -OH & CONH); 9.81 (broad s, 1H, NH+); 11.52 (broad s, 1H, NH+). IR: Vc=n (amidine): 1662 cm-1; Voo (amide): 1693 cm-1.Example 29: N-(2-hydroxy-5-methoxy)-4-([2-thienyl(imino)methyl] amino)benzene-propanamide.29.1) N-(2-hydroxy-5-methoxy)-4-N-Boc-benzene-propanamide.The experimental protocol used is the same as that described for intermediate 28.2, with 3-(4-r-butoxycarbonylamino)phenylpropanoic acid replacing 4-(4-nitrophenyl)butanoic acid.29.2) N-(2-hydroxy-5-methoxy)-4-amino-benzene-propanamide.The experimental protocol used is the same as that described for intermediate 14.2, with N-(2-hydroxy-5-methoxy)-4-N-(4-(-butoxycarbonylamino)benzenepropanamide replacing N-(2-methoxymethoxy-3-tert-butyl-5-methoxy)4-nitrobenzenebutanamide.29.3) N-(2-hydroxy-5-methoxy)-4-{[2-thienyl (imino) methyl amino)-benzene-propanamide hydrochloride.The experimental protocol used is the same as that described for Example 28, with N-(2-hydroxy-5-methoxy)-4-amino-benzene-propanamide replacing N-(2-hydroxy-5-methoxy)-4-amino-benzene-butanamide. Melting point: 197.6-197.8 °C.NMR 'H (DMSO d6, 400 MHz, 8): 2.49 (in, 2H, CH2l; 2.70 (m. 2H, CH2); 3.61 (s, 3H, -OCH3); 6,50-7.00 (m, 2H, arom.); 7.40 (m, 6H, arom.); 8.90 (broad s, 1H, NH+); 9.40 (s, 2H. -OH and -CONH); 9.90 (broad s, 1 H, NH+); 11.60 (broad s, 1H, NH+).IR: Von (amidine): 1660 cm-1; Voo (amide): 1685 cm-1.Example 30: / er / -butyl 2-([(4-{[amino(2-thienyl)methylidene]amino)phenethyl) amino]-carbonyl) -4-methoxyphenylcarbamate:The experimental protocol used is the same as that described for Example 1, with 2-[(rm-butoxycarbonyl)amino]-5-methoxy benzoic acid (prepared in a standard fashion from commercial 2-amino-5-methoxy benzoic acid) replacing 5-methoxy salicylic acid. White solid. Melting point: 190-192°C.Example 31: 2-amino-N-(4-{[amino(2-thienyl)methylidene]amino)phenethyl)-5-methoxybenzamide:Compound 31 is prepared from compound 30 which is treated in a standard fashion with hydrochloric acid in an organic solution, the product of the reaction is then purified on a silica column (eluent CH2C12 / Me0H / NH40H: 80 / 20 / 0.5). White solid. Melting point >200°C.Example 32: 5-amino-N-(4-| [amino(2-thienyl)methylidene]amino |phenethyl)-2-hydroxybenzamide:The experimental protocol used is identical to that described for Example 31, with 5-[(ferf-butoxycarbonyl)amino]2-hydroxybenzoic acid replacing 2-amino-5-methoxy benzoic acid in the first stage. Yellowish white solid. Melting point >260°C.Example 33: N-(4-{[amino(2-thienyl)methylidene]amino}phenethyl)-2-hydroxy-5-methoxy-3-methylbenzamide: The experimental protocol used is the same as that described for Example 1, with 2-hydroxy-5-methoxy-3-methyl-benzoic acid [Can. J. Chem. (1972) 50, 1276-1282) replacing 5-methoxy salicylic acid. Pale yellow solid. Melting point: 175.2-175.8°C.Example 34: N-|2-(4-{ [amino(2-thienyl)methylidene]amino)anilino)-2-oxoethyl]-3,5-di(tert-butyl)-4-hydroxybenzamide: The experimental protocol used is the same as that described for Example 1, starting with 3,5-di( / ert-butyl)-4-hydroxybenzoic acid and glycine-p-nitroanilide. White solid. Melting point >250°C.Example 35: N'-{4-[4-( 1,2,3,4-tetrahydro-2-naphthalenylcarbonyl)-1 -piperazinyl]phenyl}-2-thiophenecarboximidamide hydrochloride: The experimental protocol used is the same as that described for Example 1, starting with l,2,3,4-tetrahydro-2-naphthoic acid and 4-nitrophenylpiperazine. Pale yellow solid. Melting point: I91-194°C.Example 36: 4-(4- ([amino(2-thienyl)methyl idene]amino} phenyl)-N-14-[(methylsulphonyl)amino]phenyllbutanamide: The experimental protocol used is the same as that described for Example 1. starting with 4-nitrophenylbutanoic acid and N-(4-aminophenyl)methanesulphonamide (Farmaco (1951) 6, 713-717).Pale yellow solid. Melting point: 187.3-187.5°C.Example 37: 4-(4- ([amino(2-thienyl)methyl idene]amino} pheriyl)-N-[4-(dimethyIarnino)phenyl]butanamide hydrochloride: The experimental protocol used is the same as that described for Example 1, starting with 4-nitrophenylbutanoic acid and N,N-dimethyl-p-phenylenediamine. Pink solid. Melting point: 175-179°C.Example 38: 5-(4- ([amino(2-thienyl)methyl idene]amino} phenyl)-N-[4-(dimethylamino)phenyl]pentanatnide hydrochloride: The experimental protocol used is the same as that described for Example 1. starting with 4-nitrophenylpentanoic acid (J. Med. Chem. (1978) 21 (5), 430-437) and N,N-dimethyl-p-phenylenediamine. White solid. Melting point: 166-168°C.Examples 39 to 43 are synthesized according to the same strategy as that used for Example I, except the nitro derivative reduction stage which is not carried out with hydrogen and Pd / C hut in the presence of SnCl2,2HiO as indicated in the synthesis of intermediate 27.2.Example 39: (E)-N-(4-{[amino(2-thienyl)methylidene]amino}phenethyl)-3-(2-hydroxyphenyl)-2-propenamide: White solid. Melting point: 145-155°C.Example 40: (E)-N-(4-{[amino(2-thienyl)methylidene]amino)phenethyl)-3-(4-hydroxyphenyl)-2-propenamide: Beige solid. MH+: 392.12.Example 41: (E)-N-(4-{[amino(2-thienyl)methylidene]amino)phenethyl)-3-(3,4-dihydroxyphenyl)-2-propenamide: Yellow oil. MH+: 408.08.Example 42: (E)-N-(4-( [amino(2-thienyl)methylidene]amino)phenethyl)-3-(4-hydroxy-3,5-dimethoxyphenyl)-2-propenamide: Pale yellow solid. Melting point: 196.4-197.6°C.Example 43: (4fi)-2-(3-| [amino(2-thienyl)methylidene]amino(-phenyl)-N-[4-(dimethylamino)phenvl]-l,3-thiazolidine-4-carboxamide hydrochloride: Compound 43 is prepared from (4 / ?)-2-(4-nilrophenyl)-thiazolidine-4-carboxylic acid (Liehigs Ann. Chem. (1987), 927-934). White solid. Melting point: 195-197°C.Example 44: N'-[4-(4-[2-[3,5-di(f£rf-butyl)-4-hydroxy-phenoxy]acetyl |-1-piperazinyl)pheny l]-2-thiophenecarboximidamide dihydrochloride:44.1) 2-[3.5-di(tert-butyl)-4-hydroxyphenoxy] acetic acid:3.6 ml (46 mmol) of trifluoroacetic acid is added to a solution of 1.56 g (4.64 mmol) of lerl-butyl 2-[3,5-di( / m-butyl)-4-hydroxyphenoxy] acetate (prepared according to J. Heterocycl. Chem. (1994) 31, 1439-1443) in 20 ml of dichloromethane. The reaction mixture is agitated for 1 hour, concentrated under vacuum and the residue is dissolved in 50 ml of Et20. The organic solution is extracted twice with 25 ml of a saturated solution of NaHC03, the aqueous phase is then washed with 25 ml of Et20. The basic aqueous solution is then acidified, at 0°C, with a saturated solution of KHS04 and finally the expected product is extracted using twice 25 ml of Et20. The organic solution is dried over sodium sulphate, filtered and concentrated under vacuum in order to produce a white powder with a yield of 70%. Melting point: 172-173°C.44.2) N'-[4-(4-(2-[3,5-di(ter / -butyl)-4-hydroxyphenoxy]acetylj-1-piperazinyl)phenyl]-2-thiophenecarboximidamide dihydrochloride:The experimental protocol used is the same as that described for Example 1, starting with intermediate 44.1 and 4-nitrophenylpiperazine. Yellow solid. Melting point: 187-188°C.Example 45: N-{4-[4-(2-( [3,5-di(ter / -butyl)-4-hydroxyphenyl |thio}acetyl)-1-piperazinyl]phenyl )-2-thiophenecarboxi midamide The experimental protocol used is the same as that described for Example I, starting with 2-([3,5-di( / erf-butyl)-4-hydroxyphenyl]thio)acetic acid (prepared according to J. Med. Chem. (1997)40 (12), 1906-1918) and 4-nitrophenylpiperazine. Yellow solid. Melting point: 67-69°C.Example 46: N'-(4-{4-[2-(4-hydroxy-2.3,5,6-tetramethylphenoxy)-acetyl]-1-piperazinyl]phenyl)-2-thiophenecarboximidamide hydrochloride: The experimental protocol used is the same as that described for Example I, starting with 2-(4-hydroxy-2,3,5,6-tetramethylphenoxy)acetic acid and 4-nitrophenylpiperazine. Pale yellow solid. Melting point: 210-212°C.Example 47: N-(4-([amino(2-thienyl)methylidene]amino)-phenethyl)-2-[3,5-di( / i'rt-butyl)^l-hydroxyphenoxy]acetamide hydroiodide: The experimental protocol used is the same as that described for Example 1, starting with intermediate 44.1 and 4-nitrophenethylamine. Yellow solid. Melting point: 158-159X.Example 48: N-(4-[2-({2- [3,5-di(rerf-butyl)-4-hydroxyphenoxy]-ethyl)amino)ethyl]phenyl )-2- thiophenecarboximidamide hydrochloride:48.1) 2,6-di(fm-butyl)-4- {2-[(4-nitrophenetyl^amino]ethoxy} phenol:In a flask, under an argon atmosphere, 1.92 g (4.5 mmol) of 2-[3,5-di((erf-butyl)-4-hydroxyphenoxy]-N-(4-nitrophenetyl)acetamide (synthesis intermediate of compound 47) is introduced into 80 ml of anhydrous THF. A solution of 13.45 ml (13.45 mmol) of BH3 in THF is added to the reaction mixture and the mixture is agitated while heating at reflux for 4 hours 30 minutes. At the end of the reaction, 10 ml of MeOH is added and the heating is maintained for a further 30 minutes. The reaction mixture is then concentrated under vacuum, the residue is taken up with 30 ml of a MeOH / HCl 3N mixture (2 / 1) and the mixture is taken to reflux for an additional hour. The reaction mixture is returned to 22°C, diluted with 50 ml of CH2C12 and 2M aqueous soda is added until a basic pH is obtained. After decantation, the organic phase is washed successively with 20 ml of water and 20 ml of salt water, dried over sodium sulphate, filtered and concentrated under vacuum. The expected product is purified by chromatography on a silica column (eluent: CH2CI2 / EtOH: 25 / 1). Pale yellow solid.48.2) tert-butyl 2-[3,5-di(ter / -butyI)-4-hydroxyphenoxy]ethyl(4-nitrophenethyl) carbamate:1.27 g (3 mmol) of intermediate 48.1 is dissolved in a mixture of 15 ml of CH2CI2 and 0.53 ml (3 mmol) of N,N-diisopropylethylamine. The mixture is cooled down using an ice bath before the addition in one portion of 0.67 g (3 mmol) of (Boc)20. The reaction mixture is agitated at 23°C for 5 hours. After concentration under vacuum, the residue is taken up in 50 ml of ethyl acetate and poured into a water-ice mixture. The organic phase is decanted, washed successively with 20 ml of water and 20 ml of salt water. After drying over sodium sulphate, filtration and concentration under vacuum, a yellow solid is obtained with a quantitative yield.48.3) tert-butyl 4-aminophenethyl {2-[3,5-di(terr-butyl)-4-hydroxyphenoxy]-ethyl) carbamate:1.7 g (3 mmol) of intermediate 48.2 and 0.8 ml (15 mmol) of hydrazine hydrate are dissolved in 50 ml of absolute ethanol before the addition of 0.2 g of Raney Nickel. The reaction mixture is then heated to reflux until the starting product totally disappears (4 hours 30 minutes). After cooling down, a small quantity of silica is added to the flask and the solvent is finally eliminated under vacuum. The powder thus obtained is placed directly at the top of a chromatography column. The product is eluted using a AcOEt / Heptane mixture 1 / 2. The expected product is obtained in the form of an orange oil with a yield of 83%.48.4) tert-butyl 4-( [amino(2-thienyl)methylidene]amino}phenethyl(2-[3,5-di(wr / -butyl)-4-hydroxyphenoxy]ethyl (carbamate:0.93 g (1.9 mmol) of intermediate 48.3 and 0.60 g (2.1 mmol) of S-methyl-2-thiophenethiocarboximide hydroiodide (Ann. Chim. (1962) 7, 303-337) are dissolved in 50 ml of isopropanol. The reaction mixture is agitated for 15 hours al 60°C. After evaporation of the solvent under vacuum, the residue is taken up in 60 ml of AcOEt and 40 ml of a saturated solution of Na2C03. The mixture is vigorously agitated and finally decanted. The organic phase is washed successively with 20 ml of water, 20 ml of salt water, dried over sodium sulphate, filtered and concentrated under vacuum. The product is used directly in the following stage without additional purification.48.5) N-{4-[2-({2- [3,5-di( / m-butyl)-4-hydroxyphenoxy]-ethyl)amino)ethyl]phenyl)-2-thiophenecarboxi midamide:0.8 g (1.3 mmol) of intermediate 48.4 is dissolved in 20 ml of ethanol and 7 ml of a 3N solution of hydrochloric acid is added. The mixture is agitated for 1 hour at 23°C. After cooling down using an ice bath, the solution is rendered basic by adding Na2C03 in powder form and the mixture is finally diluted with 50 ml of AcOEt. After vigorous agitation and decantation, the organic phase is washed with 20 ml of salt water, dried over sodium sulphate, filtered and concentrated to dryness. The residue is purified on a silica column (eluent: Ac0Et / Heptane / NH40H: 12.5 / 12.5 / 0.5).48.6) N-(4-[2-((2- [3,5-di(fert-butyl)-4-hydro\yphenoxy]-ethyl }-amino)ethyl]phenyl)-2- thiophenecarboximidamide hydrochloride:Intermediate 48.5 (0.29 g, 0.6 mmol) is dissolved in 30 ml of absolute ethanol, the mixture is cooled down using an ice bath before the addition of 2.4 ml (2.4 mmol) of a IN solution of HCI in anhydrous ether. After agitation for 30 minutes at 23°C, the solvent is evaporated off under vacuum in order to produce a pink solid. Melting point: I51-153°C.Example 49: rm-butyl 3-{[amino(2-thienyl)methylidene]amino (benzyl (3-[4-(dimethylamino)anilino]-3-oxopropyl (carbamate: 49.1) ;m-butyl 3-[4-(dimethylamino)anilino]-3-oxopropyl carbamate: The experimental protocol used is the same as that described for intermediate 1.1, starting with N-Boc-fS-alanine and N,N-dimethyl-p-phenylenediamine. White solid. Melting point: 166-168°C.49.2) 3-arruno-N-[4-(dimethylamino)phenyl]propanamide:35 ml of a 6N solution of HCI is added to a solution of 3.46 g (1 1.3 mmol) of intermediate 49.1 in 85 ml of AcOEt. The reaction mixture is agitated for 15 minutes at 23°C. After decantation, the aqueous phase is collected, rendered basic by adding 2N NaOH at 0°C. The product is then extracted using twice 100 ml of CH2CI2. The organic solution is then washed with 25 ml of salt water, dried over sodium sulphate, filtered and concentrated under vacuum. A beige solid (73%) is obtained which is used as it is in the following stage.49.3) N-[4-(dimethylamino)pheny]]-3-[(3-nitrobenzyl)amino]propanamide1.15 g (5.5 mmol) of intermediate 49.2, 0.92 g (6 mmol) of 3-nitrobenzaldehyde and 3 g of a previously activated pulverulent 4 A molecular sieve are added successively to a flask containing 100 ml of anhydrous MeOH, under an inert atmosphere. The reaction mixture is agitated vigorously for 15 hours before the addition, by portions, of 0.24 g (6 mmol) of NaBH4. The agitation is maintained for 4 additional hours before the addition of 10 ml of water. After a quarter of an hour, the sieve is filtered out and the reaction mixture is extracted twice with 100 ml of CH2CI2. The organic phase is washed successively with 50 ml of water, 50 ml of salt water, dried over sodium sulphate, filtered and concentrated under vacuum. The residue is purified on a silica column (eluent: CH2Cl2 / EtOH: 20 / 1). A beige solid is obtained with a yield of 86%.49.4) rert-butyl 3-{[amino(2-thienyl)methylidene]amino|benzyl|3-[4-(dimethylamino) anilino]-3-oxopropyl }carbamate:The experimental protocol used is identical to that described for the synthesis of intermediates 48.2 to 48.4. A white solid is obtained. Melting point: 70-72°C.Example 50: 3-[(3-( [amino(2-thienyl)methylidene]amino)-benzyl)amino]-N-[4-(dimethylamino)phenyl]propanamide hydrochloride: This compound is obtained by conversion of compound 49 according to an experimental protocol described for intermediates 48.5 and 48.6. A beige solid is obtained. Melting point: 142-144°C.Example 51: 3-[(3-{[amino(2-thienyl)methylidene]amino)-benzyl)amino]-N-[3,5-di(tert-butyl)-4-hydroxyphenyl]propanamide hydrochloride: The experimental protocol used is the same as that described for compound 50, with 4-amino-2,6-di((er / -butyl)phenol (intermediate 25.1) replacing N,N-dimethyl-p-phenylenediamine. A light beige solid is obtained. Melting point: 166-169°C.Example 52: 3-[(3-{[amino(2-thienyl)methyhdene]amino)-benzyl)amino]-N-[4-(4-methyl-l-piperazinyl)phenyl]propanamide hydrochloride: The experimental protocol used is the same as that described for compound 50, with 4-(4-methyl-l-piperazinyl)aniline replacing N,N-dimethyl-p-phenylenediamine. A light beige solid is obtained. Melting point: 195-197°C.Example 53: 3-[(3-| [amino(2-thienyl)methylidene]amino)-benzyl)amino]-N-[4-(4-morpholinyl)phenyl]propanamide hydrochloride: The experimental protocol used is the same as that described for compound 50, with 4-(4-morpholinyl)aniline replacing N,N-dimeth>l-p-phenyIenediamine. A light beige solid is obtained. Melting point: 190-192°C.Example 54: 3-[(3-{[amino(2-thienyl)methylidene]aminol-benzyl)amino]-N-(l-methyl-2,3-dihydro-1 H-indol-5-yl)propanamide hydrochloride:54.1) l-methyl-5-nitroindoline:25 ml of anhydrous DMF is introduced into a 150 ml three-necked flask, under an inert atmosphere, followed by 0.84 g (21 mmol) of 60% NaH. The reaction mixture is cooled down using an ice bath before the dropwise addition of a solution of 3.28 g (20 mmol) of 5-nitroindoline in 5 ml of anhydrous DMF. Once this addition is complete, agitation is maintained for 1 hour at 23°C, before the dropwise introduction of a solution of 1.31 ml (21 mmol) of Mel in 5 ml of anhydrous DMF. Agitation is maintained for 15 hours at 23°C. The reaction is finally neutralized, at 0°C, with 20 ml of a saturated solution of NH4C1. The reaction mixture is then diluted with 20 ml of water and 50 ml of AcOEt. After decantation, the organic phase is washed successively with 20 ml of water, 20 ml of salt water, dried over magnesium sulphate, filtered and concentrated under vacuum. A dark yellow powder is obtained.54.2) l-methyl-5-aminoindoline:Approximately 400 mg of Raney nickel is added to a mixture of 2.84 g (15.9 mmol) of 1-methyl-5-nitroindoline and 4 ml (80 mmol) of hydrazine hydrate in 60 ml of absolute ethanol. The reaction mixture is heated to reflux for 5 hours. After returning to 23°C, a little silica is added to the flask and the solvent is evaporated off under vacuum. The evaporation residue is placed directly at the top of a chromatography column. The expected product is eluted using a Heptane / AcOEt mixture (3 / 7). A violet powder is obtained (65%) which is used directly in the following stage.54.3) 3-[(3-{ [amino(2-thienyl)methylidene]amino)-benzyl)amino]-N-(l -methyl-2,3-dihydro-lH-indol-5-yl)propanamide hydrochloride:The experimental protocol used is the same as that described for compound 49, with I-methyl-5-aminoindoline replacing N,N-dimethyl-p-phenylenediamine. Deprotection and salification are carried out according to the experimental protocol described for intermediate 48.5. A light beige solid is obtained. Melting point: 134-136°C.Example 55: 3-[(3-| [amino(2-thienyl)methylidene]amino}-benzyl)amino]-N-(l-benzyl-2,3-dihydro-lH-indol-5-yl)propanamide hydrochloride: The experimental protocol used is the same as that described for compound 54, with benzyl bromide replacing iodomethane. A white solid is obtained. Melting point: 193-195°C.Example 56: 3-[(3-{ [amino(2-thienyl)methylidene]amino)benzyl)amino]-jY-[l-( 1-naphthylmethyl)-2,3-dihydro-lW-indol-5-yl]propanamide: The experimental protocol used is the same as that described for compound 54, with l-(chloromethyI)-naphhtalene replacing iodomethane. A beige solid is obtained. Melting point: 185-187°C.Example 57: N'-[4-(2-{ [5-(dimethylamino)-2-hydroxybenzyl]amino )ethyl)phenyl]-2-thiophenecarboximidamide: The experimental protocol used is the same as that described for intermediates 49.3 and 48.2 to 48.5 starting with 4-nitrophenetylamine and 5-(dimethylamino)-2-hydroxybenzaldehyde (Bull. Chem. Soc. Jpn. (1978) 51 (8), 2433-2434). White solid. Melting point: 182.3-182.6°C.Examples 58 to 65 are synthesized according to the same strategy as that used for Example 57.Example 58: N-(4-{[(4-| [amino(2-thienyl)methylidene]amino[phenethyl)-amino]methyl (phenyl)acetamide: White solid. Melting point: 237.8-239°CExample 59: N'-[4-(2-{ [(8-hydroxy-2-quinolinyl)methyl]aminolethyl)phenyl]-2-thiophenecarboximidamide: Pale yellow solid. Melting point >230°C.Example 60: N'-[4-(2-| [3-phenyl-2-propenyl]amino)ethyl)phenyl]-2-thiophenecarboximidamide hydroiodide: White solid. Melting point: 151-153°C.Example 61: N'-[4-(2-([3-(4-hydroxy-3-methoxyphenyl)-2-propenyl]amino)ethyl)phenyl]-2-thiophenecarboximidamide difumarate: White solid. Melting point: 174-176°C.Example 62: N'-[4-(2-{[3-(4-hydroxy-3,5-dimethoxyphenyl)-2-propenyl]aminolethyl)phenyl]-2-thiophenecarboxi midamide dihydrochloride: Beige solid. Melting point: 182-184°C.Example 63: N'-[4-(2-{ [5-(dimethylamino)-2-hydroxy-3-methoxybenzyl]amino}-ethyl)phenyl]-2-thiophenecarboximidamide: 5-(dimethylamino)-2-hydroxy-3-methoxybenzaldehyde is prepared according to Bull. Chem. Snc. Jpn. (1978) 51 (8), 2433-2434). Brown foam.Example 64: N'-(4-{2-[(2-hydroxy-4,6-dimethoxybenzyl)amino]ethyl)phenyl)-2-thiophenecarboximidamide: White solid. Melting point >230°C.Example 65: N'-[4-(2-| [(6-hydroxv-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methyl]amino}ethyl)phenyl]-2-thiophenecarboximidamide: This compound is prepared from 6-hydroxy-2,5,7.8-tetramethyl-2-chromanecarbaldehyde (Bioorg. Med. Chem. Lett. (1998) 8. 3453-3458). White solid. Melting point >230°C.Example 66: N'-(4-(2-[[(E)-3-(4-hydroxy-3,5-dimethoxyphenyl)-2-propenyl](methyl)amino]ethyl)phenyl)-2-thiophenecarboximidamide: This compound is prepared from N-methyl-2-(4-nitrophenyl)-ethylamine hydrochloride and (£)-3-(4-hydroxy-3,5-dimethoxyphenyl)-2-propenal according to the experimental protocols described successively for intermediates 49.3, 27.2 and 1.3 (the product remaining in the form of the free base). Pinkish white solid. Melting point: 153.2-154°C.Example 67: 4-{ [(4-{ [amino(2-thienyl)methylidene]amino) phenethyl)-amino]methyl J -1-pyridiniumolate:67.1) N'-(4-{2-[(4-pyridinylmethyl)araino]ethyl Jphenyl)-2-thiophenecarboximidamide: The experimental protocol used is the same as that described for compound 50 starting with isonicotinic aldehyde and 4-nitrophenethylamine.67.2) 4-{[(4-{[amino(2-thienyl)methylidene]amino}phenethyl)-amino]methy 1)-1 -pyridiniumolate:Under an argon atmosphere, 0.1 g (0.23 mmol) of intermediate 67.2 is dissolved in 10 ml of chloroform. The solution is cooled down to 0°C before the dropwise addition of 0.052 g (0.3 mmol) of metachloroperbenzoic acid in 10 ml of chloroform. The reaction mixture is agitated for 30 minutes at 0°C before being poured into a water + ice mixture. The product is extracted using twice 20 ml of CH2C12, the organic solution is washed with 20 ml of salt water, dried over magnesium sulphate, filtered and concentrated under vacuum. The residue is purified on a silica column (eluent: CH2C12 / Et0H / NH40H: 0.5 / 9.5 / 0.5) in order to produce a yellow oil with a yield of 20%. MH+ = 453.18.Example 68: N'-[4-(2-{ [(2-hydroxy-4,6-dimethoxyphenyl)methylidene]-amino}ethyl)phenyl]-2-thiophenecarboximidamide: The formation of the imine between the 2-hydroxy-4,6-dimethoxybenzaldehyde and 4-nitrophenethylamine is carried out according to the experimental protocol used for the synthesis of intermediate 49.3, except for the addition of NaBH4. The other stages are identical to those described for the syntheses of intermediates 27.2 and 1.3 (the product remaining in the form of a free base). Bright yellow oil which partially crystallizes.Example 69: tert-butyl 4-{ [amino(2-thienyl)methylidene]amino )phenethyl(2-hydroxy-4,6-dimethoxybenzyl)carbamate: The experimental protocol used is the same as that described for the synthesis of intermediates 49.3 and 49.4, starting with 2-hydroxy-4,6-dimethoxybenzaldehyde and 4-nitrophenetylamine. A pale yellow foam is obtained. MH+ = 512.23.Example 70: N'-{4-[4-phenyl-3,6-dihydro-l(2H)-pyridinyl]phenyl}-2-thiophenecarboximidamide:70.1) 1 -(4-nitrophenyl)-4-phenyl-1,2,3,6-tetrahydropyridine:A mixture of 0.5 g (2.5 mmol) of 4-phenyl-1,2,3,6-tetrahydropyridine, 0.51 ml (2.8 mmol) of diisopropylethylamine, 0.71 g (5 mmol) of K2C03, 0.40 g ((2.8 mmol)of 4-fluoronitrobenzene in 10 ml of DMF is heated at 100°C, for 24 hours. At the end of the reaction, the mixture is poured into 25 ml of a saturated solution of NaHC03 and the product is extracted using 25 ml of AcOEt. After decantation, the organic solution is washed twice with 20 ml of water followed by 20 ml of salt water, drying over magnesium sulphate, filtration and evaporation of the solvent under vacuum lead to a yellow solid with a yield of 42%. Melting point: 185-192°C (decomposition).70.2) N'-{4-[4-phenyl-3,6-dihydro-1 (2H)-pyridinyl]phenyl}-2-thiophene-carboximidamide:The experimental protocol used is the same as that described for intermediates 27.2 and 1.3 (the product remaining in the form of a free base).Example 71: N'-(4-{2-[4-phenyl-3,6-dihydro-1 (2H)-pyridinylJethyl}phenyl)-2-thiophenecarboximidamide dihydrochloride:71.1) 1 -(4-nitrophenethyl)-4-phenyl-1,2,3,6-tetrahydropyridine:1.29 g (6.6 mmol) of 4-phenyl-l,2,3,6-tetrahydropyridine, 0.92 ml (6.6 mmol) of Et3N and 1.62 ml (6.6 mmol) of tributylphosphine are added to a solution of 1.0 g (5.98 mmol) of 4-nitrophenethyl alcohol in 25 ml of CH2C12. The reaction mixture is agitated vigorously at 23°C and 1.04 ml (6.6 mmol) of diethylazodicarboxylate is added dropwise. After 4 hours, the reaction is stopped by adding 5 ml of a saturated solution of NH4C1. After decantation, the aqueous phase, is extracted twice with 5 ml of CH2CI2, the organic phases are combined and washed twice with 5 ml of water, twice with 5 ml of salt water, dried over magnesium sulphate, filtered and concentrated under vacuum. The residue is purified on a silica column (eluent Heptane / AcOEt: 9 / 1 to 7 / 3) in order to produce 1.20 g of the expected product.71.2) N'-(4-{ 2-[4-phenyl-3,6-dihydro-l(2H)-pyridinyl Jethyl }phenyl)-2-thiophenecarboximidamide dihydrochloride:The experimental protocol used is the same as that described for intermediates 27.2 and 1.3.Pale yellow solid. Melting point: 185°C (decoinp.)Example 72: N'-{4-[(l-benzhydryl-3-azetidinyl)oxy]phenyl}-2-thiophene-carboximidamide:The experimental protocol used is the same as that described for intermediate 1.3 (the product being isolated in the form of a free base), intermediate 27.2 replacing intermediate 1.2.White solid. Melting point: 210-211°C.Example 73: NH4-(2-quinolinyhnethoxy)phenyl]-2-thiophene-carboximidamide hydroiodide:73.1) 2-[(4-nitrophenoxy)methyl]quinoline:Under an argon atmosphere, 0.4 g (11 mmol) of 60% NaH is introduced into a flask containing 25 ml of anhydrous DMF. A solution of 1.38 g (10 mmol) of 4-nitrophenol in 5 ml of anhydrous DMF is added dropwise, under agitation al 23°C. After 30 minutes a solution of 1.77 g (10 mmol) of 2-(chloromethyl)-quinoline in 5 ml of anhydrous DMF is added dropwise and agitation is continued for 15 hours while heating the mixture at 90°C. At the end of the reaction, the mixture is poured onto ice and an abundant precipitate forms. The suspension is filtered, rinsed twice with 25 ml of water followed by 20 ml of ethyl ether. A white solid is thus obtained with a yield of 75%. Melting point: I54-155°C.73.2) N'-[4-(2-quinolinylmethoxy)phenyl]-2-thiophenecarboximidamide hydroiodide: The experimental protocol used is the same as that described for intermediates 1.2 and 1.3, except that the hydroiodide precipitates spontaneously in the reaction, it is therefore isolated pure during simple filtration.Example 74: N'-(4-{4-[2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxo-l,4-cyclohexadien- l-yl)butanoyl]-1 -piperazinyl) phenyl )-2-thiophene-carboximidamide:The experimental protocol used is the same as that described in the literature (Helv. Chim. Acta (1963) 46, 333), starting with W-[4-(4-| [(25)-6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2W-chromen-2-yl]carbonyl]-l-piperazinyl)phenyl]-2-thiophenecarboximidamide dihydrochloride (W09842696, Example 27). A brown crystalline foam is obtained. MH+ = 534.20.Example 75: N-{4-[2-(l,3-dimethyl-2,6-dioxo-l,2,3,6-tetrahydro-7H-purin-7-yl)ethyl]phenyl }-2-thiophenecarboximidamide fumarate:75.1) l,3-dimethyl-7-(4-nitrophenetyl)-3,7-dihydro-lW-purine-2,6-dione: A mixture of 0.59 g (3.26 mmol) of theophylline, 1.5 g (6.52 mmol) of 2-(4-nitrophenyl)ethyl bromide, 0.13 g (3.26 mmol) of NaOH pellets in 4 ml of water and 8 ml of isopropanol is heated to reflux for 24 hours. After returning to 23°C, the insoluble portion is filtered and the filtrate is extracted with 25 ml of CH2C12. The organic phase is washed with 10 ml of water followed by 10 ml of salt water. After drying over sodium sulphate, filtration and concentration to dryness, the residue is purified on a silica column (eluent: CH2CI2 / Me0H: 95 / 5). A white solid is obtained with a yield of 50%.75.2) N-{4-|2-( l,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)ethyl]phenyl}-2-thiophenecarboximidamide fumarate:The experimental protocol used is the same as that described for intermediates 1.2 and 1.3 except that the free base is salified in ethanol in the presence of fumaric acid. White solid. Melting point: 225-227°C.Example 76: N'-(4-{4-[2,6-di(l-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl 1 phenyl)-2-thiophenecarboximidamide:76.1) 4-[4-(4-nitrophenyl)-l-piperazinyl]-2,6-di(l-pyrrohdinyl)pyrimidine:2.52 g (10 mmol) of 4-chloro-2,6-di-pyrrolidin-l-yl-pyrimidine {J. Med. Chem. (1990) 33 (4), 1145-1151) and 2.07 g (10 mmol) of 4-nitrophenylpiperazine are dissolved in a 250 ml flask containing 20 ml of anhydrous pyridine, under an argon atmosphere. The reaction mixture is heated at 100°C for 48 hours. After cooling down, the contents of the flask are poured into 250 ml of water and the product is extracted using twice 50 ml of CH2C12. The organic phase is then washed with 50 ml of salt water, dried over magnesium sulphate, filtered and concentrated under vacuum. The residue is purified on a silica column (eluent: Heptane / AcOEt: 2 / 1). An orange solid is obtained with a yield of 49%. Melting point: 200-201°C.76.2) N'-(4-(4-[2,6-di(l-pyrrolidinyl)-4-pyrimidinyl]-l-piperazinyl)phenyl)-2-thiophenecarboximidamide:The experimental protocol used is the same as that described for intermediates 1.2 and 1.3 except that the product is isolated in the form of a free base. Yellow solid. Melting point: 215-217°C.Example 77: N'-{4-[2-() [4-(dimethylamino)anilino]carbonyl )amino)-ethyl]phenyl )-2-thiophenecarboximidamide hydroiodide:77.1) Ar-[4-(dimethylamino)phenyl]- / V'-(4-nitrophenethyl)urea:0.9 g (3.3 mmol) of triphosgene is dissolved in 5 ml of anhydrous CH2C12 in a 100 ml three-necked flask, under an argon atmosphere, and the solution is agitated at 23°C. Using a motorized syringe, a solution of 2.09 g (10 mmol) of N,N-dimethyl-p-phenylenediamine dihydrochloride and 5.2 ml (30 mmol) of diisopropylethylamine in 20 ml of anhydrous CH2C12 is added dropwise over 1 hour. Ten minutes after the addition is completed, a solution of 1.36 g (10 mmol) of 2-(4-aminophenyl)ethylamine and 1.8 ml of diisopropylethylamine in 5 ml of anhydrous CH2C12 is added in one portion. After agitation for 2 hours at 23°C, the precipitate formed is eliminated by filtration, the filtrate is washed with 10 ml of water followed by 10 ml of salt water. The organic solution isdried over sodium sulphate, filtered and concentrated under vacuum. The residue obtained is purified by being rapidly passed through a silica column (eluent: AcOEt). White solid.77.2) N'-(4-[2-(| [4-(dimethylamino)anilino]carbonyl}amino)-ethyl]phenyl |-2-thiophenecarboximidamide hydroiodide:The experimental protocol used is the same as that described for the synthesis of intermediates 1.2 and 1.3 except that the hydroiodide precipitates spontaneously during the reaction, it is therefore isolated pure during a simple filtration. Yellow solid. MH+ = 408.2.Example 78: N-| [l-(4-j [amino(2-thienyl)methylidene]-amino)phenyD-cyclobutyl]methyl [-6-hydroxy-2,5,7,8-tetramethy 1-2-chromanecarboxamide hydrochloride:78.1) 2-[4-(2,5-dimethyl-l / / -pyrrol-l-yl)phenyl]acetonitrile:20 g (0.15 mol) of p-aminobenzyl cyanide, 19 ml (0.17 mol) of 2,5-dicetohexane and 2.88 g (0.015 mol) of hydrated p-toluene sulphonic acid are dissolved in a 500 ml flask. This mixture is heated to reflux, the water formed is trapped using a Dean Stark apparatus. At the end of the reaction, the solvent is evaporated off under vacuum and the residue is taken up in 300 ml of AcOEt. The. organic solution is washed successively with twice 200 ml of water, 200 ml of a saturated solution of Na2C03, 200 ml of water, 200 ml of a saturated solution of KHS04 and finally 200 ml of water and 200 ml of salt water. After drying over sodium sulphate, filtration and concentration under vacuum, the residue is purified rapidly on a silica column. A light beige solid is obtained with a yield of 34%. Melting point: 112-113°C.78.2) 1 -[4-(2,5-dimethyl-l / / -pyrrol- l-yl)phenyl]cyclopentanecaibonitrile:0.88 g (22 mmol) of 60% NaH is introduced into a 100 ml three-necked flask containing 20 ml of anhydrous DMSO, under an argon atmosphere. A solution of 2.1 g (10 mmol) of intermediate 78.2 and 2.23 ml (11 mmol) of 1,3-dibromopropane in 10 ml of anhydrous DMSO is added as rapidly as possible to this suspension, under agitation. The addition speed is adjusted according to the temperature of the reaction medium which must remain in the region of 25-35°C. At the end of the reaction (1 hour 30 minutes), the contents of the flask are poured into 100 ml of a water + ice mixture. The product is extracted with 50 ml of AcOEt and the organic solution is washed successively with 5 times 20 ml of water, 20 ml of salt water, dried over sodium sulphate, filtered and concentrated under vacuum. The residue is purified on a silica column(eluent: Heptane / AcOEt: 9 / 1). A white solid is obtained with a yield of 55%. Melting point: 117-120°C.78.3) | l-[4-(2,5-dimethyl-lf / -pyrrol-l-yl)phenyl]cyclopentyl}methanamine:A solution of 2.03 g (8.1 mmol) of intermediate 78.2 in 20 ml of anhydrous THF is introduced dropwise at 0°C into a 100 ml three-necked flask, under an argon atmosphere, containing 20 ml (20 mmol) of a 1M solution of LiALH4 in anhydrous THF. At the end of the addition, the reaction mixture is agitated for 3 hours at 23°C. The reaction mixture is then cooled down using an ice bath and the excess LiAlH4 is destroyed by slowly adding 20 ml of AcOEt followed by 10 ml of a 1M aqueous solution of NaOH. After vigorous agitation for 30 minutes at 23°C, the contents of the three-necked flask are filtered through celite. The filtrate is diluted with 40 ml of AcOEt and 20 ml of water. After decantation, the organic solution is washed with 20 ml of a 1M solution of NaOH, 20 ml of salt water, dried over sodium sulphate, filtered and concentrated under vacuum. The residue is purified on a silica column (eluent: CH2C12 / EtOH: 9 / 1 to 8 / 2). A yellow oil is obtained with a yield of 64%.78.4) jY-(( l-[4-(2,5-dimethyl-l / / -pyrrol-l-yl)phenyl]cyclopentyl)methyl)-6-hydroxy-2,5,7,8-tetramethyl-2-chromanecarboxamide:The experimental protocol used is the same as that described for intermediate 26.1, with intermediate 78.3 replacing 1-benzyl piperazine. A white solid is obtained with a yield of 79%. Melting point: 90-94°C.78.5) A'-{[l-(4-aminophenyl)cyclopentyl]methyl|-6-hydroxy-2,5,7,8-tetramethyl-2-chromanecarboxamide:A solution of 0.49 g (1 mmol) of intermediate 78.4 and 1.05 g (15 mmol) of hydroxylamine hydrochloride in a mixture of 13 ml of isopropanol and 1 ml of water is heated at 100°C for 72 hours. After cooling down, the solvent is evaporated off under vacuum and the residue is taken up in 20 ml of AcOEt and 20 ml of water. The organic phase is decanted and washed with 20 ml of water followed by 20 ml of salt water, dried over sodium sulphate, filtered and concentrated under vacuum. The evaporation residue is purified on a silica column (eluent: Heptane / AcOEt: 6 / 4). The expected product is obtained in the form of a yellow oil with a yield of 50%.78.6) N-{ [l-(4-j [amino(2-thienyl)methylidene]amino|phenyl)-cyclobutyl]methyl |-6-hydroxy-2,5,7,8-letramethyl-2-chromanecarboxamide hydrochloride:The experimental protocol used is the same as that described for intermediate 1.3, with intermediate 78.5 replacing intermediate 1.2. Beige solid. Melting point: 185-187°C.Example 79 : N'-(4-[4-(5-methoxy-lH-indol-3-yl)-l-piperidinyl]-phenyl )-2-thiophenecarboximidamide chlorhydride:79.1) 5-methoxy-3-( 1,2,3,6-tetrahydro-4-pyridinyl)-1 tf-indole:The experimental protocol used is described in literature (Eur. J. Med. Chem. (1987) 22, 33-43), starting from 5-methoxy-l / / -indole and from 4,4-piperidinediol.79.2) 5-methoxy-3-[l-(4-nitrophenyl)-1,2,3,6-tetrahydro-4-pyridinyl]-ltf-indole :The experimental protocol used is the same as the one described for intermediate 26.4, starting from intermediate 79.1.79.3) 4-[4-(5-melhoxy-lH-indol-3-yl)-l-piperidinyl]phenylamine:9.2 g Zinc are added, by small portions, to a solution, cooled by an ice bath, of 0.7 g (2 mmol) of the intermediate 79.2 in 35 mL acetic acid. This mixture is agitated 18 hours at 20°C before being filtrated. The filtrate is concentrated under vacuum and the traces of acetic acid are eliminated by coevaporation in the presence of toluene. The residue of evaporation is finally dissolved in 100 mL CH2CI2. The organic solution obtained is then washed successively with 50 mL water and 50 mL brine. After drying over MgSOi, filtration and evaporation of the solvent under vacuum, the residue is used as is in the following step.79.4) N'-{4-[4-(5-methoxy-lH-indol-3-yl)-l-piperidinyl]-phenyl}-2-thiophenecarboximidamide chlorhydride :The experimental protocol used is the same as the one described for intermediate 1.3, the intermediate 79.3 replacing the intermediate 1.2. Orange solid. Melting point : 209-213°C.Example 80 N'-(4-| 2-[[5-(dimethylamino)-2-hydroxy-3-methoxybenzvl]-(methyl)amino]ethyl}phenyl)-2-thiophenecarboximidamide :The experimental protocol used is the same as the one described for Example 57, starting from 5-(dimethylamino)-2-hydroxv-3-methoxybenzaldehyde (prepared according to Bull. Chem. Soc. Jpn. (1978) 51 (8), 2433-2434) and N-methyl-2-(4-nitrophenyl)ethylamine hydrochloride. Dark yellow foam. MS : MH+ : 439.2.Example 81 : 4-(4-{[amino(2-thienyI)methy]idene]amino)phenyl)- / V-( l-[3-(dimethylamino)propyl]-2,3-dihydro-l / / -indol-5-yllbutan amide81.1) AyV-dimethyl-3-(5-nitro-2,3-dihydro-1 / / -indol-1 -yl)- 1-propanamine :In a 250 mL double-necked flask, under argon atmosphere, containing a suspension of 2.4 g (60 mmol) of NaH (60%) in 60 mL DMF, are introduced by portions 4.92 g (30 mmol) of 5-nitroindoline. The vigorous hydrogene release is accompanied by formation of a red suspension. Agitation is maintained 30 minutes at 23°C before addition, by portions, of 4.74 g (30 mmoles) of 3-dimethylaminopropylchloride hydrochloride. The reaction mixture is agitated and heated at 60°C during 18 hours. The whole is finally poured on 200 mL of a water / ice mixture. The product is then extracted by 2 times 100 mL AcOEt. The organic solution is washed successively with 100 mL water and 100 mL brine. After drying over MgS04 and concentration under vacuum, the residue of evaporation is purified by flash chromatography an a silica column (eluent : AcOEt / MeOH : 100 / 0 to 0 / 100). A dark yellow oil is obtained with a yield of 48%.81.2) l-[3-(dimethylamino)propyl]-5-indolinamine :The experimental protocol used is the same as the one described for intermediate 54.2, the intermediate 81.1 replacing the intermediate 54.1. Violet oil.81.3) 4-(4-([amino(2-thienyl)methylidene]amino}phenyl)- / V-{ l-[3-(dimethylamino)propyl]-2,3-dihydro-lH-indol-5-yl)butanamide :The experimental protocol used is the same as the one described for Example 1, starling from the intermediate 81.2 and 4-nitrophenylbutanoic acid.Example 82 : 3-[(5-j [amino(2-thienyl)methylidene]amino)-2-methoxybenzyl)amino]-N-[l-( l-naphthylmethyl)-2,3-dihydro-l / / -indol-5-yl]propanamideThe experimental protocol used is the same as the one described for Example 56,2-methoxy-5-nitrobenzaldehyde (J. Org. Chem. (1993) 58. 1385-1392) replacing3-nitrobenzaldehyde.Pharmacological study of the products of the inventionStudy of the effects on neuronal constitutive NO synthase of a rat's cerebellumThe inhibitory activity of the products of the invention is determined by measuring their effects on the conversion by NO synthase of [3H]L-arginine into [3H]L-citrull ine according to the modified method of Bredt and Snyder (Proc. Natl. Acad. Sci. USA, (1990) 87: 682-685). The cerebellums of Sprague-Dawley rats (300g - Charles River) are rapidly removed, dissected at 4°C and homogenized in a volume of extraction buffer (HEPES 50 mM, EDTA 1 mM, pH 7.4, pepstatin A 10 mg / ml, leupeptin 10 mg / ml). The homogenates are then centrifuged at 21000 g for 15 min at 4°C. Dosage is carried out in glass test tubes in which 100 nl of incubation buffer containing 100 mM of HEPES (pH 7.4), 2 mM of EDTA, 2.5 mM of CaCl2, 2 mM of dithiotreitol, 2 mM of reduced NADPH and 10 Hg / ml of calmodulin are distributed. 25 (il of a solution containing 100 nM of [3H]L-arginine (Specific activity: 56.4 Ci / mmole, Amersham) and 40 (iM of non-radioactive L-arginine is added. The reaction is initiated by adding 50 of homogenate, the final volume being 200 (J.L (the missing 25 are either water or the tested product). After 15 min, the reaction is stopped with 2 ml of stopping buffer (20 mM of HEPES, pH 5.5, 2 mM of EDTA). After passing the samples through a 1 ml column of DOWEX resin, the radioactivity is quantified by a liquid scintillation spectrometer. The compounds of examples 1 to 7, 10 to 12, 19, 21, 22, 26 to 28, 31, 32, 38 to 42, 48. 50 to 62, 65, 66, 68, 71 and 73 described above show an IC5U lower than 3.5 p.M.Study of the effects on lipidic peroxidation of the cerebral cortex of a ratThe inhibitory activity of the products of the invention is determined by measuring their effects on the degree of lipidic peroxidation, determined by the concentration of malondialdehyde (MDA). The MDA produced by peroxidation of unsaturated fatty acids is a good indication of lipidic peroxidation (H Esterbauer and KH Cheeseman, Metk. Enzymol. (1990) 186: 407-421). Male Sprague Dawley rats of 200 to 250 g (Charles River) were sacrificed by decapitation. The cerebral cortex is removed, then homogenized using a Thomas potter in a 20 mM Tris-HCI buffer, pH = 7.4. The homogenate was centrifuged twice at 50000 g for 10 minutes at 4°C. The pellet is maintained at -80°C. On the day of the experiment, the pellet is replaced in suspension at a concentration of 1 g / 15 ml and centrifuged at 515 g for 10 minutes at 4°C. The supernatant is used immediately to determine the lipidic peroxidation. The homogenate of rat's cerebral cortex (500 |il) is incubated at 37°C for 15 minutes in the presence of the compounds to be tested or of solvent (10 )j.l). The lipidic peroxidation reaction is initiatedby adding 50 of FeCl;> at 1 mM, EDTA at 1 mM and ascorbic acid at 4 mM. After incubation for 30 minutes at 37°C, the reaction is stopped by adding 50 (il of a solution of hydroxylated di tertio butyl toluene (BHT, 0.2 %). The MDA is quantified using a colorimetric test, by reacting a chromogenic reagent (R), N-methyl-2-phenylindol (650 (il) with 200 of the homogenate for 1 hour at 45°C. The condensation of an MDA molecule with two molecules of reagent R produce a stable chromophore the maximum absorbence wavelength of which is equal to 586 nm. (Caldwell et al. European J. Pharmacol. (1995) 285, 203-206). The compounds of Examples 1,3, 14 to 16, 25, 29, 32 to 34, 37 to 39, 41, 42, 44 to 48, 50, 51,54 to 57, 61, 62, 70, 71, 74 and 76 to 78 described above all show an IC50 lower than 30 |lM.
Claims
Claims 1. Product of general formula (I) characterized in that it comprises the compounds of general formula (Γ) A-X-Y—Φ (Γ) NH, in which A represents: either a radical in which R|, R2 and R3 represent, independently, a halogen, the OH or SRf) lu group or a linear or branched alkyl, alkenyl or alkoxy radical having I to 6 carbon atoms, or a NR7R8 radical, R4 representing a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms, R5 represents a hydrogen atom, the OH or SRj group or a linear or branched alkyl or 15 alkoxy radical having 1 to 6 carbon atoms. Re representing a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms, R7 and Rg independently representing a hydrogen atom, an OH group, a linear or branched alkyl radical having 1 to 6 carbon atoms or a -CO-R9 radical in which R9 20 represents a linear or branched alkyl radical having 1 to 6 carbon atoms; - 88 or a radical in which R,, R2 and R3 represent, independently, a hydrogen atom, the OH or SRfl group, a halogen or a linear or branched alkyl, alkenyl or alkoxy radical having I to 6 carbon atoms, or a NR7R8 radical, 5 R4 represents a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms, Rs representing a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms, R7 and Rg independently representing a hydrogen atom, an OH group, a linear or 10 branched alkyl radical having 1 to 6 carbon atoms or a -CO-R9 radical in which Ry represents a linear or branched alkyl radical having 1 to 6 carbon atoms; or a radical in which Rj, R2 and R3 represent, independently, a hydrogen atom, a halogen, the OH or SRf, group, a linear or branched alkyl, alkenyl or alkoxy radical having I to 6 15 carbon atoms, or an NR7R8 radical, R4 and R5 independently represent a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms, or R4 and R5 form together with the nitrogen atom an optionally substituted heterocycle having 4 to 7 members and 1 to 3 heteroatoms including the already present nitrogen2u atom, the additional heteroatoms being independently chosen from the group constituted by the Ο, N and S atoms, or furthermore Ra represents an alkylsulfonyl, alkylsulfoxide or alkylcarbonyl radical and then Rj represents H, Rg representing a hydrogen atom or a linear or branched alkyl radical having 1 to 6 25 carbon atoms, R7 and Rg independently representing a hydrogen atom, an OH group, a linear or branched alkyl radical having 1 to 6 carbon atoms or a -CO-R9 radical in which Rg represents a linear or branched alkyl radical having 1 to 6 carbon atoms; or a 5 radical in which T represents a -(CH2)k- radical, k representing 1 or 2, and R5 represents a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms or a radical in which R7 and Rs represent, independently, a hydrogen atom or an OH group, or a R, •N H 10 radical in which Rg represents a hydrogen atom, the OH group or a linear or branched alkyl or alkoxy radical having 1 to 6 carbon atoms. or a T N I R.7 radical in which T represents a -(CHj)k- radical, k representing 1 or 2, and R17 represents a linear or branched alkyl radical having 1 to 6 carbon atoms, or an arylalkyl, diarylalkyl, bis-arylalkyl, aminoalkyl, alkylaminoalkyl or dialkylaminoalkyl radical, or - 90 R17 further represents a (heterocyclo)alkyl radical in which the heterocycle is saturated or unsaturated, has 3 to 7 members and includes at least a nitrogen atom, said nitrogen atom being optionally substituted by a hydrogen atom or an alkyl radical, or a radical in which R,o and R, | represent, independently, a hydrogen atom or an OH group. or finally one of the N Jl Ν' 'N radicals, B represents a linear or branched alkyl radical having 1 to 6 carbon atoms, carbocyclic or 10 heterocyclic aryl with 5 or 6 members containing from 1 to 4 heteroatoms chosen from O, S, N and in particular the thiophene, furan, pyrrole or thiazole radicals, the aryl radical being optionally substituted by one or more groups chosen from the linear or branched alkyl, alkenyl or alkoxy radicals having 1 to 6 carbon atoms, or also B represents an NR13R14 radical, in which R|3 and R14 represent, independently, 15 a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms, or R|3 and R]4 form together with the nitrogen atom a non aromatic hcterocycle with five to six - 91 members, the elements of the chain being chosen from a group comprising -CH2-, -NH-, -O- or -S-; X represents a bond or a -(CH2)m-, -(CH2)m-CO, -O-(CH?)m-, -S-iClL·),,,-, -NRl5-(CH2)nl-, -CO-NR15-, -O-(CH2)m-CO-, -S-(CH2)m-CO-, -NR,5-(CH2)m-CO-. 5 -(CH2)ln-C(OH)(CH3)-CO-, -CH=CH- or -CH=N- radical; Y represents a bond or a -(CH2)n- or -(CH2)r-Q-(CH2)s- radical. Q representing a piperazine, homopiperazine, 2-methylpiperazine, 2,5-dimethylpiperazine, piperidine, 1,2,3,6-tetrahydropyridine, pyrrolidine, azetidine or thiazolidine radical or a saturated carbon cycle having 3 to 7 members; in Φ represents a bond or a -(CH2)p-O - (C H 2)q-, -(CH2)P-S - (C H 2)q-, -(CH2)p-NR|6-(CH2)q-, -(CH2)p-CO-NRl6-(CH2)q- or -CO-(CH2)p-NRl6-(CH2)qradical; R|2 represents a hydrogen atom or a linear or branched alkyl or alkoxy radical having 1 to 6 carbon atoms; 15 R]5 and R|g represent, independently, a hydrogen atom or a linear or branched alkvl radical having 1 to 6 carbon atoms or a -CO-Rig radical in which R|g represents a linear or branched alkyl or alkoxy radical having 1 to 6 carbon atoms; m, n, p, q, r and s being integers from 0 to 6; it being understood that: 20 - if A represents the R9· •N H radical then Y represents the piperidine radical; - if A represents the CH3 -92 radical then Y represents a -(CH2)r-Q-(CH2)s- radical in which Q represents a saturated carbon cycle having 3 to 7 members; - and if A represents the radical with at least two of the R|, R2, Rj and R5 radicals representing H, then X 5 represents a -CH=CH- or -CH=N- radical and the group X-Y-Φ- does not represent a -CH=CH-CO-co- radical in which ω represents any radical; said general formula (I) also comprising the following compounds: - 2-hydroxy-5-methoxy-N-j2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl)benzamide; 10 - 2,5-dihydroxy-N-)2-[4[(2-thienyl(imino)methyl)amino]phenyl]ethyl -benzamide; - 2-hydroxy-3-isopropyl-N-(2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl )benzamide; - 2,6-dihydroxy-N-(2-[4-[(2-thienyl(imino)methyl)amino]pfienyl]ethyI [-benzamide; - 2-hydroxy-4,6-dimethoxy-N-{2-[4-[(2-thieny](imino)methyl)amino]phenyl]ethyl |15 benzamide; - 2-hydroxy-3,5-di-tert-butyl-N-j2-[4-[(2-tfiienyl(imino)metfiyl)amino]phenyl]ethylbenzamide; - 2-hydroxy-3,5-diisopropyl-N-(2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl |benzamide; 20 - 2-hydroxy-4-methoxy-N-)2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl )benzamide; - 2-hydroxy-3-isopropyl-5-methoxy-N-{2-[4-[(2-thienyl(imino)methyl)amino] phenyl]ethyl} -benzamide; - N-(2-hydroxy-3-tert-butyl-5-methoxy)-4-{ [2-thienyl(imino)methyl]amino) benzene25 butanamide; - 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyI-N-(2-[4-[(2-thienyl(imino)methyl)amino] phenyl]ethyl} -2H-1 -benzopyran-2-carboxamide; - 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-N-( l-[4-[(2-thienyl(imino)methyl)amino] phenyl ]methy 1) -2H-1 -benzopyran-2-carboxamide; 5 - N-(2-hydroxyphenyl)-2-thiophenecarboximidamide; - N-(3-hydroxyphenyl)-2-thiophenecarboximidamide; - N-(3-hydroxy-4-methoxyphenyl)-2-thiophenecarboximidamide; - N-(3-hydroxy-4-methy]phenyl)-2-thiophenecarboximidamide; - N-(4-methoxyphenyl)-2-thiophenecarboximidamide; 10 - N-(3,5-dimethyl-4-hydroxyphenyl)-2-thiophenecarboximidamide; - N-(3,5-dichloro-4-hydroxyphenyl)-2-thiophenecarboximidamide; - N-(2,6-bis-(l,l-dimethy]ethyl)-4-hydroxyphenyl)-2-thiophenecarboximidamide; - N-{4-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yI (methyl) 1-piperazinyljpheny I)-2-thiophenecarboxi midamide; 15 - l-(2-hydroxy-4,6-dimethoxybenzoyI)-3-(4-[iimino(2-thienyl)methyl)amino]phenoxy) azetidine; - N-(2-hydroxy-5-methoxy)-4-{[2-thienyI(imino)methyl]amino|benzene-butanumide; - N-(2-hydroxy-5-methoxy)-4-| [2-thienyl(imino)methyl] amino)benzene-propanamide; - N-(4-{[amino(2-thienyl)methylidene]amino (phenethyl)-2-hydroxy-5-methoxy-3 20 methylbenzamide; (E)-N-(4-([amino(2-thienyl)methylidene]umino|phenelhyl)3-(2-hydroxyphenyl)-2-propenamide; (E)-N-(4-)[amino(2-thienyl)methylidene]amino)phenethyl) 3-(4-hydroxyphenyl)-2-propenamide; 25 - (E)-N-(4-)[amino(2-thienyl)methylidene]amino(phenethyl) 3-(3,4-dihydroxyphenyl)-2-propenamide; - 94 - (Ε)-N-(4-( [ami no(2-thienyl )methylidene]amino (phenethyl)-3-(4-hydroxy-3,5dimethoxyphenyl)-2-propenamide; - 3-((3-{[aminot2-thienyl)methylidene]amino)-benzyl)amino]-N-[3,5-di(tert-butyl)-4hydroxyphenyl]propanamide; 5 - N'-(4-(2-[(2-hydroxy-4,6-dimethoxybenzyl)amino]ethyl)phenyl)-2thiophenecarboxi midamide; Ν'-[4-(2 -([(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2yl)methyl]amino|ethyl)phenyl]-2-thiophenecarboxi midamide; or also the salts of the products of general formula (I). 10 2. Product according to claim 1, characterized in that it corresponds to general formula (I1) and that moreover: A represents: either a radical in which R|, R2 and R3 represent, independently, the OH or SRf, group or a 15 linear or branched alkyl or alkoxy radical having 1 to 6 carbon atoms, R4 representing a hydrogen atom or a linear or branched alkyl radical having I to 6 carbon atoms, R5 represents a hydrogen atom, the OH or SR6 group or a linear or branched alkyl or alkoxy radical having 1 to 6 carbon atoms, 20 Ro representing a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms, or a radical in which R,, R2 and R3 represent, independently, a hydrogen atom, the OH group, a linear or branched alkyl or alkoxy radical having 1 to 6 carbon atoms, R4 and R5 represent independently a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms, 5 or R4 and R5 form together with the nitrogen atom an optionally substituted heterocycle having 4 to 7 members and 1 to 3 heteroatoms including the already present nitrogen atom, the additional heteroatoms being independently chosen from the group constituted by the Ο, N and S atoms, or furthermore R4 represents an alkylsulfonyl or alkylcarbonyl radical and then R5 10 represents H, or a radical in which R], R2 and R3 represent, independently, a hydrogen atom, the OH or SR6 group, a halogen or linear or branched alkyl, alkenyl or alkoxy radical having 1 to 6 carbon atoms, 15 R4 represents a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms, Rg representing a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms, or a 20 radical in which T represents a -(CH2)k- radical, k representing 1 or 2, and Rs represents a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms or a Ri radical in which R7 and R« represent, independently, a hydrogen atom or an OH group, or a R, -N H radical in which Rg represents a hydrogen atom, the OH group or a linear or branched alkyl or alkoxy radical having 1 to 6 carbon atoms, or a T > N 1(1 1(1 radical in which T represents a -(CH2)k- radical, k representing I or 2, and R17 represents a linear or branched alkyl radical having 1 to 6 carbon atoms, or an arylalkyl, diarylalkyl, bis-arylalkyl, aminoalkyl, alkylaminoalkyl or dialkylaminoalkyl radical, or R17 further represents a (heterocyclo)alkyl radical in which the heterocycle is saturated or unsaturated, has 3 to 7 members and includes at least a nitrogen atom, said nitrogen atom being optionally substituted by a hydrogen atom or an alkyl radical, or a radical in which Rio and R, represent, independently, a hydrogen atom or an OH 15 group, radicals B represents a linear or branched alkyl radical having 1 to 6 carbon atoms, carbocyclic or heterocyclic aryl with 5 or 6 members containing from 1 to 4 heteroatoms chosen from 5 O, S, N and in particular the thiophene, furan, pyrrole or thiazole radicals, the aryl radical being optionally substituted by one or more groups chosen from the linear or branched alkyl, alkenyl or alkoxy radicals having 1 to 6 carbon atoms, X represents a bond or a -(CH2)m-CO, -O-(CH2)m-· -S-(CH2)m-, -NR15-(CH2)m-, -CO-NRi;-, -O-(CH2)m-CO-, -S-(CH2)m-CO-, -NR15-(CH3)m-CO1() or -(CH2)m-C(OH)(CH3)-CO- radical; Y represents a bond or a -(CH2)n- or -(CH2)r-Q-(CH2)s- radical. Q representing a piperazine, piperidine, 1,2.3,6-tetrahydropyridine, azetidine or thiazolidine radical or a saturated carbon cycle having 3 to 7 members; Φ represents a bond or a -(CH2)p-O-(CH2)q- radical; 15 R12 represents a hydrogen atom or a linear or branched alkyl or alkoxy radical having 1 to 6 carbon atoms; Ris and R,6 represent, independently, a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms or a -CO-R|g radical in which R,« represents a linear or branched alkyl or alkoxy radical having 1 to 6 carbon atoms; 20 m, n, p, q, r and s being integers from 0 to 6; or a salt of such product.
3. Product according to claim 1, characterized in that it is one of the following compounds: - 2-hydroxy-5-methoxy-N-j2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl(benzamide; 5 - 2-hydroxy-5-methylthio-N-{2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl}benzamide; - 2,5-dihydroxy-N-| 2-[4[(2-thienyI(imino)methyl)amino]phenyl]ethyl -benzamide: - 2-hydroxy-3-isopropyl-N-{2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl(benzamide; 10 - 2,6-dihydroxy-N- {2-[4-[(2-thienyl< imino)methyl)amino]phenyljethyl) -benzamide; - 2-hydroxy-4,6-dimethoxy-N-(2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl(benzamide; - 2-hydroxy-4,5,6-trimethoxy-N-(2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl )benzamide; 15 - 2-hydroxy-3,5-di-tert-butyl-N-(2-[4-[(2-thienyl(imino)methyl)amino]phenyl(ethylbenzamide; - 2-hydroxy-3,5-diisopropyl-N-(2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl )benzamide; - 2,4-dihydroxy-3,6-dimethyl-N-{2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl2d benzamide; - 2,7-dihydroxy-N-(2-[4-[(2-thienyl(imino)methyI)amino]phenyl]ethyl)-2naphthalenecarboxamide; - 2-hydroxy-4-mcthoxy-N-(2-[4-[(2-thienyl(inhno)methyl)amino]phenyl]ethyl(benzamide; 25 - 2-hydroxy-3-isopropyl-5-methoxy-N-{2-[4-[(2-thienyl(imino)methyl)amino] phenyljethyl) -benzamide; - N-(2-hydroxy-3-tert-butyl-5-methoxy)-4-([2-thienyl(imino)methyl]amino(benzenebutanamide; -99- 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-N-(2-[4-[(2-thienyl(imino)methyl)amino] phenyl]ethyl(-2H-l-benzopyran-2-carboxamide; - 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-N-( l-[4-[(2-thienyI(imino)methyl)amino] phenyl]methyl}-2H-l-benzopyran-2-carboxamide; 5 - N-(4-hydroxyphenyl)-2-thiophenecarboximidamide; - N-(2-hydroxyphenyl)-2-thiophenecarboximidamide; - N-(3-hydroxyphenyl)-2-thiophenecarboximidamide; - N-(3-hydroxy^1-methoxyphenyl)-2-thiophenecarboximidamide; - N-(3-hydroxy-4-methylphenyl)-2-thiophenecarboximidamide; 10 - N-(4-methoxyphenyl)-2-thiophenecarboximidamide; - N-(3,5-dimethyl-4-hydroxyphenyI)-2-thiophenecarboximidamide; - N-(3,5-dichloro-4-hydroxyphenyl)-2-thiophenecarboximidamide; - N-(2,6-bis-( 1,1 -dimethylethyl)-4-hydroxyphenyl)-2-thiophenecarboxi midamide; - N-{ 4-(4-((3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)methyl] 15 l-piperazinyl]phenyl(-2-thiophenecarboximidamide; - 1 -(2-hydroxy-4,6-dimethoxybenzoy 1 )-3-{4-[(imino(2-thienyl)methyl)amino] phenoxy (azetidine; - N-(2-hydroxy-5-methoxy)-4-{[2-thienyl(imino)methyl]aminolbenzene-butanamide; - N-(2-hydroxy-5-methoxy)-4-( [2-thieny](imino)methyl] aminolbenzene-propanamide; 20 - reri-butyl 2-([(4-) [amino(2-thienyl)methylidene]amino)phenelhyl)amino]-carbonyl |4-methoxyphenylcarbamate ; - 2-amino-N-(4-([amino(2-thienyl)methy]idene]amino(phenethyl)-5-methoxybenzamide; - 5-amino-N-(4-{[amino(2-thienyl)methylidene]amino}phenethyl)-2-hydroxybenzamide; - N-(4-{[amino(2-thienyl)methylidene]amino)phenethyl)-2-hydroxy-5-methoxy-325 methylbenzamide; - loo - N-[2-(4-([amino(2-thienyl)methylidene]amino)anilino)-2-oxoethyl]-3,5-di(i£,ri-butyl)4-hydroxybenzamide; - Ν'-(4-(4-( 1,2,3.4-tetrahydro-2-naphthaIenylcarbonyl)-1 -piperazinyl]phenyI}-2thiophenecarboxi midamide; 5 - 4-(4-{[amino(2-thienyl)methylidene]amino)phenyl)-N-(4[(methylsulfonyl)amino]phenyl) butanamide; - 4-(4-( [amino(2-thienyl)methylidene]amino |phenyl)-N-[4(dimethylamino)phenyl]butan amide; - 5-(4- ([amino( 2-thienyl)methylidene]amino (phenyl)-N-[410 (dimethylamino)phenyl(pentanamide; - (E)-N-(4-([amino(2-thienyl)methylidene]amino}phenethyl)3-(2-hydroxyphenyl)-2-propenamide; - (E)-N-(4-( (amino(2-thienyl)methylidene]amino)phenethyl)3-(4-hydroxyphenyl)-2-propenamide; 15 - (E)-N-(4-([amino(2-thienyl)methylidene]amino)phenethyl)3-(3,4-dihydroxyphenyl)-2-propenamide; - (E)-N-(4-([amino(2-thienyl)methylidene]amino)phenethyl)-3-(4-hydroxy-3,5dimethoxyphenyl)-2-propenamide; - (4R)-2-(3-{ [amino(2-thienyl)methylidene]amino)-phenyl)-N-[420 (dimethylamino)phenyl]-1,3-thiazolidine-4-carboxamide; - N'-[4-(4-{2-[3,5-di(Zert-butyl)-4-hydroxy-phenoxy]acetyl)-1-piperazinyl)pheny 11-2thiophenecarboximidamide; - N-{4-(4-(2-([3,5-di(teri-butyl)-4-hydroxyphenyl]thio} acetyl)-l-piperazinyl]phenyl 1-2 thiophenecarboximidamide; 25 - N'-(4-(4-[2-(4-hydroxy-2,3,5,6-tetramethylphenoxy)-acetyl]-1-piperazinyI Ipheny 1)-2 thiophenecarboximidamide; - N-(4-([amino(2-thienyl)methylidene]amino)-phenethyl)-2-[3,5-di(fert-butyl)-4hydroxyphenoxy]acetamide; - ΙΟΙ - Ν-(4-(2-( (2- [3,5-di(iert-butyl)^)-hydroxyphenoxy]-ethyl (amino)ethyl(phenyl (-2thiophenecarboximidamide; - ferr-butyl 3-([amino(2-thienyl)methylidene]ainino)benzyl)3-[4(dimethylamino)anilino]-3-oxopropyl) carbamate; 5 - 3-((3-([amino(2-thienyl)methylidene]amino}-benzyl)amino]-N-[4(dimethylamino)phenyl]propanamide; - 3-((3-([amino(2-thienyI)methylidene]amino(-benzyl)amino]-N-[3,5-di(tcrt-butyl)-4hydroxyphenyl]propanamide; - 3-((3-{[amino(2-thienyl)methylidene]amino} -benzyl)amino]-N-[4-(4-methyl-110 piperazinyl)phenyl]propanamide; - 3-((3-([amino(2-thienyl)methylidene]amino (-benzyl)amino]-N-[4-(4morpholinyl)phenyl]propan amide; - 3-((3-{[amino(2-thieny])methylidene]amino(-benzyl)amino]-N-(l-methyl-2,3-dihydro 1 H-indol-5-yl)propanamide; 15 - 3-((3-( [amino(2-thienyl)methylidene]amino)-benzyl)amino]-N-(l-benzyl-2,3-dihydro lH-indol-5-yl)propanamide; - 3-(( 3-( [amino(2-thienyl)methylidene(amino}benzyl)amino]-(V-[ 1-(1-naphthyl methyl)2,3-dihydro-li / -indol-5-yl]propanamide; - N'-[4-(2-( [5-(dimethylamino)-2-hydroxybenzyl]amino) ethyl )phenyl]-220 thiophenecarboximidamide; - N-(4-{[(4- ([amino(2-thienyl)methylidene]amino} phenethyl)amino]methyl (phenyl)acetamide; - N'-[4-(2-j [(8-hydroxy-2-quinolinyl)methyl]amino(ethyl)phenyl]-2thiophenecarboximidamide; 25 - N'-[4-(2-([3-phenyl-2-propenyl]amino)ethyl)phenyl]-2-thiophenecarboximidamide; - N'-[4-(2-( [3-(4-hydroxy-3-mcthoxyphenyl)-2-propenyl]amino)ethyl)phenyl]-2thiophenecarboximidamide; - N'-[4-(2-{ [3-(4-hydroxy-3,5-dimethoxyphenyl)-2-propenyl]amino)ethyl)pheny 1(-2thiophenecarboximidamide; - 102 - N'-[4-(2-([5-(dimethylamino)-2-hydroxy-3-methoxybenzyl]amino(-ethyl)phenyl]-2thiophenecarboxi midamide; - N'-(4-j2-[(2-hydroxy-4,6-dimethoxybenzyl)amino]ethyl)phenyl)-2thiophenecarboximidamide; 5 - N’-[4-(2-( [(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2yl)methyl]amino}ethyl)phenyl]-2-thiophenecarboximidamide; - N'-(4-{2-[[(E)-3-(4-hydroxy-3,5-dimethoxyphenyl)2-propenyl](methyl)amino]ethyl}phenyl)-2-thiophenecarboximidamide ; - 4- {[(4- ([amino(2-thienyl)methylidene]amino | phenethyl)-amino]methyl} 10 1-pyridiniumolate; - N'-[4-(2-([(2-hydroxy-4,6-dimethoxyphenyl)methylidene]-amino)ethyl)phenyl]2-thiophenecar bo\i midamide; - tert-butyl 4-| [amino(2-thienyl)methylidene]amino)phenethyl(2-hydroxy4,6-dimethoxybenzyl )carbamate; 15 - Ν'-(4-[4-phenyl-3,6-dihydro-l(2H)-pyridinyl]phenyl)-2-thiophenecarboximidamide; - N'-(4-{2-[4-phenyl-3,6-di hydro-l(2H)-pyridinyl]ethy] )pheny 1)2-thiophenecarboximidamide ; - N'-(4-[(l-benzhydryl-3-azetidinyl)oxy]phenyl}-2-thiophene-carboximidamide; - N'-[4-(2-quinolinylmethoxy)phenyl]-2-thiophene-carboximidainide; 20 - N'-(4-{4-[2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxo-1.4-cyclohcxadien1 -ybbutanoyl]-1 -piperazinyl) phenyl )-2-thiophene-carboximidamide; - N-{4-[2-( l,3-dimethyl-2,6-dioxo-l,2,3,6-tetrahydro-7H-purin-7-yl)ethyl]phenyl}2-thiophenecarboximidamide; - N'-(4-{4-[2,6-di(l-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl Iphenyl)25 2-thiophenecarboximidamide; - N'-{4-[2-() [4-(dimethylamino)anilino]carbonyl(amino)-ethyl]phenyl}2-thiophenecarboximidamide; - 103 - N- ([ 1 -(4- ([amino(2-thienyl)methylidene]-amino} phenyl)-cyclobutyl]methyl (6-hydroxy-2,5,7,8-tetramethyl-2-chromanecarboxamide; - N'-{4-[4-(5-melhoxy-lH-indol-3-yl)-l-piperidinyl]-phenyl (-2thiophenecarboxi midamide; 5 - N'-(4-(2-[[5-(dimethyJamino)-2-hydroxy-3-methoxybenzyl](methyl)amino]ethyl|phenyl)-2-thiophenecarboximidamide; - 4-(4-( [amino(2-thienyl)methylidene]amino [phenyl )-N-{ l-[3-(dimethylamino)propyl(2,3-dihydro-1H- indol-5-y 1} butanamide; - 3-((5-{[amino(2-thienyl)methylidene]amino)-2-methoxybenzyl)amino(10 7V-[l-( 1 -naphthyl methyl )-2,3-dihydro- l / / -indol-5-yl]propanamide; or a salt of the latter.
4. Product according to claim 3, characterized in that it is one of the following compounds; - 2-hydroxy-5-methoxy-N-{2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl |15 benzamide; - 2,5-dihydroxy-N-(2-[4[(2-thienyl(imino)mcthyl)amino]phenyl]ethyl -benzamide; - 2-hydroxy-3-isopropyl-N-(2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl (benzamide; - N-(2-hydroxy-3-tert-butyl-5-methoxy)-4-( [2-thienyl(imino)methyl]amino( benzene20 butanamide; - 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-N-{2-[4-[(2-thienyl(imino)methyl)amino] phenyijethyl} -2H-1 -benzopyran-2-carboxamide; - 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-N-(1 -[4-[(2-thienyl(imino)methyl)amino] phenyl]methyl)-2H-l-benzopyran-2-carboxamide; 25 - N-(2-hydroxy-5-methoxy)-4-| [2-thienyl(imino)methyl] aminojbenzene-propanamide; - 5-amino-N-(4-( [amino(2-thienyl)methylidene]amino(phenethyl)-2-hydroxybenzamide; - 5-(4-([amino(2-thienyl)methylidene]amino 1 phenyl)-N-[4(dimethylamino)phenyl(pentanamide; - 104 - (E)-N-(4-) )amino(2-thienyl)methylidene]amino}phenethyl)3-(2-hydroxyphenyl)-2-propenamide; - (E)-N-(4-( [amino(2-thienyl)methylidene]amino}phenethyb3-(4-hydroxyphenyl)-2-propenamide;5 - (E)-N-(4-{[amino(2-thienyl)methylidene]amino)phenethyl·)3-(3,4-dihydroxyphenyl)-2-propenamide; - (E)-N-(4-([amino(2-thienyl)methylidene]amino)phenethyl)-3-(4-hydroxy-3,5dimethoxyphenyl)-2-propenamide; - N-{4-(2-({2- [3,5-di(tert-butyl)-4-hydroxyphenoxy]-ethyllamino)ethyl]phenyl )-210 thiophenecarboximidamide; - 3-)( 3-) )amino(2-thienyl)methylidene]amino)-benzyl)amino]-N-[4(dimethylamino)phenyl]propanamide; - 3-)(3-) [amino(2-thienyl)methylidene]amino}-benzyl)amino]-N-[3,5-di(tert-butyl)-4hydroxyphenyljpropan amide; 15 - 3-((3-) [amino(2-thienyl)methylidene]amino}-benzyl)amino]-N-[4-(4-methyl-1 piperazinyl)phenyl]propanamide; - 3-)(3-) [amino(2-thienyl)methylidene|amino}-benzyl)amino]-N-[4-(4morpholinyl)phenyl]propanamide; - 3-[(3-)[amino(2-thienyl)methylidene]amino|-benzyl)amino]-N-(l-methyl-2,3-dihydro 20 lH-indol-5-yl)propanamide; - 3-)(3-([amino(2-thienyl)methylidene]amino)-benzyl)amino]-N-(l-benzyl-2,3-dihydro lH-indol-5-yl)propan amide; - 3-)(3-)[amino(2-thienyl)methylidene]amino}benzyl)amino]-A,-[l-(1-naphthyl methy I)2,3-dihydro-l / / -indol-5-yl]propan amide; 25 - N'-[4-(2-{[5-(dimethylamino)-2-hydroxybenzyl]amino}ethyl)phenyl]-2thiophenecarboximidamide; - N-(4-([(4-) [amino(2-thienyl)methylidene]amino) phenethyl)amino Irnethyl) phenyl)acetamide; - 105 - N'-[4-(2-([(8-hydroxy-2-quinolinyl)methyl]amino (ethyl)phenyl]-2thiophenecarboximidamide; - N'-[4-(2-([3-phenyl-2-propenyl]amino)ethyl)phenyl]-2-thiophenecarboximidamide; - N'-[4-(2-([3-(4-hydroxy-3-methoxyphenyl)-2-propenyl]amino)ethyl)phenyl]-25 thiophenecarboximidamide; - N’-[4-(2-([3-(4-hydroxy-3,5-dimethoxyphenyl)-2-propenyl]amino)ethyl)phenyl]-2thiophenecarboximidamide; - N'-[4-(2-( [(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2yl)methyl]amino)ethyl)phenyI]-2-thiophenecarboximidamide; 10 - N'-(4-(2-[[(E)-3-(4-hydroxy-3,5-dimethoxyphenyl)2-propenyl](methyl)amino]ethyl)phenyl)-2-thiophenecarboximidamide; - N'-(4-(2-[4-phenyl-3,6-dihydro-l(2H)-pyridinyl]ethyl Ipheny 1)2-thiophenecarboxi midamide; - Ν'-(4-(2-(( [4-(dimethylamino)anilino]carbonyl)amino)-ethyl]phenyl)15 2-thiophenecarboximidamide; - N- ([ 1 -(4- ([amino(2-thienyl)methylidene]-amino) phenyl )-cyclobutyl]methyl) 6-hydroxy-2,5,7,8-tetramethyl-2-chromanecarboxainide; or a salt of the latter.
5. Product according to claim 4, characterized in that it is one of the following 20 compounds: - 2-hydroxy-5-methoxy-N-(2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl )benzamide; - 2,5-dihydroxy-N-(2-[4[(2-thienyl(imino)methyl)amino]phenyl]ethyl -benzamide; - N-(2-hydroxy-5-methoxy)-4-( [2-thienyl(imino)methyl] amino)benzene-propanamide ; 25 - 5-amino-N-(4-{[amino(2-thienyl)methylidene]amino)phenethyl)-2-hydroxybenzamide; - 5-(4-([amino(2-thienyl)methylidene]amino)phenyl)-N-[4(dimethylamino)phenyl]pentanamide; - 106 - (E)-N-(4- ([amino(2-thienyl )methylidene]amino) phenethyl )3-(2-hydroxyphenyl)-2-propenamide; - (E)-N-(4-{[amino(2-thieny])methylidene]amino) phenethyl)3- (3,4-dihydroxyphenyl)-2-propenamide; 5 - (E)-N-(4-{[amino(2-thienyl)methylidene]amino)phenethyl)-3-(4-hydroxy3,5-dimethoxyphenyl )-2-propenamide; - N-{4-(2-((2-[3,5-di(rert-butyl)-4-hydroxyphenoxy]-ethyl)amino)ethyl]phenyl )-2thiophenecarboxiinidamide; - 3-((3-) [amino(2-thienyl)methylidene|amino) -benzyl )amino]-N-[410 (dimethylamino)phenyl]propanamide; - 3-((3-( [amino(2-thienyl)methylidene]amino)-benzyl)amino]-N-[3,5-di(tert-butyl)4- hydroxyphenyl|propanamide; - 3-[(3-([amino(2-thienyl)methyIidene)arruno)-benzyl)amino]-N-(l-methyl-2,3-dihydro 1 H-indol-5-yl)propanamide; 15 - 3-[(3-{[amino(2-thienyl)methylidenelamino(-benzyl)amino]-N-(l-benzyl-2,3-dihydro lH-indol-5-yl)propanamide; - 3-[(3-([amino(2-thienyl)methylidene]amino}benzyl)amino]-jV-[l-(l-naphthylmethyl)2,3-dihydro-l / Y-indol-5-yl]propanamide; - N’-[4-(2-1 [5-(dimethylamino)-2-hydroxybenzyl]amino(ethyl)phenyl]-220 thiophenecarboximidamide; - N’-[4-(2-{[(8-hydroxy-2-quinolinyl)methyl]amino )ethyl)phenvl]-2thiophenecarboximidamide; - N'-[4-(2-([3-(4-hydroxy-3-methoxyphenyl)-2-propenyl]amino (ethyl)phenyl]-2thiophenecarboximidamide; 25 - N'-[4-(2-([3-(4-hydroxy-3,5-dimethoxyphenyl)-2-propenyI]amino}ethyl)pheny 1]-2thiophenecarboximidamide; - N'-[4-(2-{[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2yl)methyl]amino(ethyl)phenyl]-2-thiophenecarboximidamide; - 107 - N'-(4-(2-[[(E)-3-(4-hydroxy-3,5-dimethoxyphenyl)2-propenyl](methyl)amino]ethyl)phenyl)-2-thiophenecarboximidamide; - N'-(4-{2-[4-phenyl-3,6-dihydro-1( 2H)-pyridinyljethyl) pheny 1)2-thiophenecarboximidamide; 5 or a salt of the latter.
6. Product according to claim 5, characterized in that it is one of the following compounds: - N-(2-hydroxy-5-methoxy)-4-([2-thienyl(imino)methyl] amino)benzene-propanamide; - N-(4-(2-( (2-[3,5-di(iert-butyl)-4-hydroxyphenoxy(-ethyl )amino)ethyl]phenyl )-210 thiophenecarboximidamide; - 3-((3-([amino(2-thienyl)methylidene]amino (-benzyl)amino]-N-[4(dimethylamino)phenyl]propanamide; - 3-((3-((amino(2-thienyl)methylidene]amino)-benzyl)amino]-N-[3,5-di(tert-buty 1)4-hydroxyphenyl|propanamide; 15 - 3-((3-( [amino(2-thienyl)methylidene]amino 1 -benzyl)amino]-N-( l-methyl-2,3-dihydrolH-indol-5-yl)propanamide; - 3-((3-( [amino(2-thienyl)methylidene]amino (-benzyl)amino]-N-(l-benzyl-2,3-dihydro1 H-indol-5-yl)propanamide; - 3-((3- ([amino(2-thienyl)methylidene]amino (benzyl )amino]- / V-[ 1-( 1 -naphthy lmethyl ΙΙΟ 2,3-dihydro-l / / -indol-5-yl]propanamide; - N'-[4-(2-{[5-(dimethylamino)-2-hydroxybenzyI]amino)ethyl)phenyl]-2thiophenecarboximidamide; - N'-[4-(2-([3-(4-hydroxy-3-methoxyphenyl)-2-propenyl]amino)ethyl)phenyl]-2thiophenecarboximidamide; 25 - N'-[4-(2-{[3-(4-hydroxy-3,5-dimethoxyphenyl)-2-propenyl]amino}ethyl)phenyl(-2thiophenecarboximidamide; - N'-[4-(2-{[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2yl)methyl]amino)ethyl)phenyl]-2-thiophenecarboximidamide; - 108 - N'-(4-{2-[[(E)-3-(4-hydroxy-3,5-dimethoxyphenyl)2-propenyl](methyl)amino]ethyl}phenyl)-2-thiophenecarboximidamide; or a salt of the latter.
7. As new industrial products, the compouinds of general formula (IS), useful 5 synthesis intermediates for the preparation of products of general formula (I) according to claim 1, general formula (IS) in which A represents: either a 10 radical in which R,, Ri and R, represent, independently, a halogen, the OH or SR(, group or a linear or branched alkyl, alkenyl or alkoxy radical having 1 to 6 carbon atoms, or a NRrRg radical, Ra representing a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms, 15 R5 represents a hydrogen atom, the OH or SR(, group or a linear or branched alkyl or alkoxy radical having 1 to 6 carbon atoms, Rg representing a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms, R7 and Rg independently representing a hydrogen atom, an OH group, a linear or 20 branched alkyl radical having 1 to 6 carbon atoms or a -CO-Rg radical in which Rg represents a linear or branched alky] radical having 1 to 6 carbon atoms; - 109 10 or a radical in which R, R2 and R3 represent, independently, a hydrogen atom, the OH or SRg group, a halogen or a linear or branched alkyl, alkenyl or alkoxy radical having 1 to 6 carbon atoms, or a NR7R8 radical, R4 represents a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms, Rg representing a hydrogen atom or a linear or branched alkyl radical having I to 6 carbon atoms, R7 and Rg independently representing a hydrogen atom, an OH group, a linear or branched alkyl radical having 1 to 6 carbon atoms or a -CO-R9 radical in which RM represents a linear or branched alkyl radical having 1 to 6 carbon atoms; radical in which R|, R2 and R3 represent, independently, a hydrogen atom, a halogen, the OH or SR9 group, a linear or branched alkyl, alkenyl or alkoxy radical having 1 to 6 carbon atoms, or an NR7R8 radical, R4 and R5 independently represent a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms, or R4 and R5 form together with the nitrogen atom an optionally substituted heterocycle having 4 to 7 members and 1 to 3 heteroatoms including the already present nitrogen atom, the additional heteroatoms being independently chosen from the group constituted by the Ο, N and S atoms, or furthermore R4 represents an alkylsulfonyl, alkylsulfoxide or alkylcarbonyl radical and then R5 represents H, Rg representing a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms, - 110R7 and Rs independently representing a hydrogen atom, an OH group, a linear or branched alkyl radical having 1 to 6 carbon atoms or a -CO-R9 radical in which R9 represents a linear or branched alkyl radical having 1 to 6 carbon atoms; or a 5 radical in which T represents a -(CH2)k- radical, k representing 1 or 2, and R5 represents a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms or a radical in which R7 and Rs represent, independently, a hydrogen atom or an OH group, or a H 10 radical in which R9 represents a hydrogen atom, the OH group or a linear or branched alkyl or alkoxy radical having 1 to 6 carbon atoms, or a R|7 radical in which T represents a -(CH2)k- radical, k representing 1 or 2, and Rj7 represents a linear or branched alkyl radical having 1 to 6 carbon atoms, or an arylalkyl, 15 diarylalky 1, bis-arylalkyl, aminoalkyl, alkylaminoalkyl or dialkylaminoalkyl radical, or - Ill R17 further represents an (heterocyclo)alkyl radical in which the heterocycle is saturated or unsaturated, has 3 to 7 members and includes at least a nitrogen atom, said nitrogen atom being optionally substituted by a hydrogen atom or an alkyl radical, or a 5 radical in which R,o and R|, represent, independently, a hydrogen atom or an OH group, radicals, B represents a linear or branched alkyl radical having 1 to 6 carbon atoms, carbocyclic or 10 heterocyclic aryl with 5 or 6 members containing from 1 to 4 heteroatoms chosen from O, S, N and in particular the thiophene, furan, pyrrole or thiazole radicals, the aryl radical being optionally substituted by one or more groups chosen from the linear or branched alkyl, alkenyl or alkoxy radicals having 1 to 6 carbon atoms, or also B represents an NR13R14 radical, in which R13 and R,4 represent, independently, 15 a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms, or Rn and R,4 form together with the nitrogen atom a non aromatic heterocycle with five to six -112members, the elements of the chain being chosen from a group comprising -CH2-, -NH-. -O- or -S-; X represents a bond or a -(CH2)m-, -O-(CH2)m-, -S-(CH2)m-, -NRi5-(CH2)m-, -CO-NR15-, -O-(CH2)m-CC)-, -S-(CH2)m-CO-, -NR|s-(CH2)m-CO-, 5 -(CH2)m-C(OH)(CH3)-CO-, -CH=CH- or -CH=N- radical; Y represents a bond or a -(CH2)„- or -(CH2)r-Q-(CH2)s- radical, Q representing a piperazine, homopiperazine, 2-methylpiperazinc, 2,5-dimethylpiperazine, piperidine, 1,2,3,6-tetrahydropyridine, pyrrolidine, azetidine or thiazolidine radical or a saturated carbon cycle having 3 to 7 members; 10 Φ represents a bond or a -(CH2)p-O-(CH2)q-, -(CH2)P-S -(C H 2)q-, -(CH2)p-NR|6-(CH2)q-, -(CH2)p-CO-NR16-(CH2)q- or -CO-(CH2)p-NRl6-(CH2)qradical; Z represents NO2 or NH2; R12 represents a hydrogen atom or a linear or branched alkyl or alkoxy radical having 1 15 lo 6 carbon atoms; R15 and R,g represent, independently, a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms or a -CO-R|g radical in which R,g represents a linear or branched alkyl or alkoxy radical having 1 to 6 carbon atoms; m, n, p, q, r and s being integers from 0 to 6; 20 it being understood that: - if A represents the Ri •N H radical then Y represents the piperidine radical; - 113 - if A represents the radical then Y represents a -(CH2)r-Q-(CH2)s- radical in which Q represents a saturated carbon cycle having 3 to 7 members; - and if A represents the 5 radical with at least two of the R[, R2, R3 and R5 radicals representing H, then X represents a -CH=CH- or -CH=N- radical and the group X-Y-Φ- does not represent a -CH=CH-CO-0)- radical in which ω represents any radical.
8. As new industrial products, the compounds of general formula (IS1) in which: 10 π represents a hydrogen atom or a protective group of carbamate type; R15 and R]6 represent, independently, a hydrogen atom, a linear or branched alkyl radical having 1 to 6 carbon atoms or a -CO-R|g radical in which R18 represents ua linear or branched alkyl or alkoxy radical having 1 to 6 carbon atoms; T represents a -(CH2)k- radical, k representing I or 2; - 114 R17 represents a linear or branched alkyl radical having 1 to 6 carbon atoms, arylalkyl, diarylalkyl, bis-arylalkyl, aminoalkyl, alkylaminoalkyl or dialkylaminoalkyl. or R|7 further represents a (heterocyclo)alkyl radical in which the heterocycle is saturated or unsaturated, has 3 to 7 members and includes at least a nitrogen atom, said nitrogen atom 5 being optionally substituted by a hydrogen atom or an alkyl radical; and p is an integer from 0 to 6.9 . As a medicament, a product of general formula (I) according to one of claims 1 to 6. or a pharmaceutically acceptable salt of said product.10-Pharmaceutical composition containing as active ingredient at least one product 10 according to one of claims 1 to 6, or a pharmaceutically acceptable salt of said product.11, Use of a product of general formula (I) according to any one of claims 1 to 6, or a pharmaceutically acceptable salt of said product, in order to produce a medicament intended to inhibit NO synthase.12 . Use of a product of general formula (I) according to any one of claims 1 to 6, or a 15 pharmaceutically acceptable salt of said product, in order to produce a medicament intended to inhibit lipidic peroxidation.
13. Use of a product of general formula (I) according to any one of claims 1 to 6, or a pharmaceutically acceptable salt of said product, in order to produce a medicament having both an NO synthase inhibitory activity and a lipidic peroxidation inhibitory activity.
